Document:

<PAGE>
                                                                  EXECUTION COPY

                                                                    EXHIBIT 4.33

                          TRANSITIONAL SUPPLY AGREEMENT

         This Transitional Supply Agreement (this "AGREEMENT") is entered into
this 27th day of March, 2003 between Galen (Chemicals) Limited, an Irish
corporation ("PURCHASER"), and Pfizer Inc., a Delaware corporation ("PFIZER").

                                    RECITALS

         WHEREAS, Pfizer, Purchaser and Galen Holdings plc, a public limited
company organized under the Laws of Northern Ireland, have entered into the
Purchase and Sale Agreement (OCs), dated as of March 5, 2003 (the "PURCHASE
AGREEMENT"), pursuant to which certain Affiliates of Pfizer are selling the
Purchased Assets (as defined in the Purchase Agreement) to Purchaser;

         WHEREAS, pursuant to the terms of the Purchase Agreement, Pfizer has
agreed to supply to Purchaser for a limited time the Products; and

         WHEREAS, Pfizer and Purchaser desire to define their respective rights
and obligations with regard to the supply of the Products in this Agreement.

         NOW, THEREFORE, for good and valuable consideration, the sufficiency
and receipt of which are hereby acknowledged, the Parties hereby agree as
follows:

                                   ARTICLE 1

                                   DEFINITIONS

         1.1      Definitions. As used in this Agreement, the following terms
shall have the meanings set forth or as referenced below:

         "ACTION" shall mean any action, suit, proceeding, arbitration or
Governmental Authority action, notification, investigation or audit.

         "AFFILIATE" shall mean, with respect to any Person, any other Person
that directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with, such Person at any time during
the period for which the determination of affiliation is being made.

         "AGREEMENT" shall mean this Agreement, as the same may be amended or
supplemented from time to time in accordance with the terms hereof.

         "BUSINESS DAY" shall mean any day other than a Saturday, a Sunday or a
day on which banks in New York, New York, United States of America are
authorized or obligated by Law or executive order to close.

<PAGE>

         "CERTIFICATE OF ANALYSIS" shall mean a written certification,
substantially in the form attached as Schedule F, delivered by Pfizer to
Purchaser with each shipment of Ordered Products.

         "cGMPs" shall mean the current Good Manufacturing Practices applicable
to pharmaceutical products for human use in the United States of America and
similar regulations applicable to pharmaceutical products for human use in other
countries where a material amount of any of the Products are sold.

         "CONFIDENTIAL PFIZER INFORMATION" shall have the meaning set forth in
Section 10.2.

         "CONFIDENTIAL PURCHASER INFORMATION" shall have the meaning set forth
in Section 10.1.

         "ESTROSTEP TARGET SHELF LIFE" shall have the meaning set forth in
Section 3.6(a).

         "FAJARDO PLANT" shall mean the manufacturing and packaging facility and
equipment located in Fajardo, Puerto Rico used to manufacture the Products.

         "FCA" shall mean FCA as defined in the International Chamber of
Commerce Incoterms 2000.

         "FDA" shall mean the United States Food and Drug Administration.

         "FIRM ORDER" shall mean a written irrevocable firm purchase order for
the Products, which order shall include a delivery schedule specifying the
delivery date for each Product ordered and the location to which shipment of the
Product is to be delivered.

         "GOVERNMENTAL AUTHORITY" shall mean any supranational, national,
federal, state, provincial or local judicial, legislative, executive or
regulatory authority.

         "INDEMNIFIABLE CLAIM" shall have the meaning set forth in Section 9.4.

         "INDEMNIFIED PARTY" shall have the meaning set forth in Section 9.3.

         "INDEMNIFYING PARTY" shall have the meaning set forth in Section 9.3.

         "INDEPENDENT LABORATORY" shall have the meaning set forth in Section
5.1(c).

         "LABELING" shall mean any and all printed labels, labeling and package
inserts for the Products.

         "LAWS" shall mean all laws, statutes, rules, regulations, ordinances
and other pronouncements having the effect of law of any Governmental Authority.

         "LESS THAN TARGET SHELF LIFE PRODUCTS" shall have the meaning set forth
in Section 3.6(b).

                                       2
<PAGE>

         "LOESTRIN TARGET SHELF LIFE" shall have the meaning set forth in
Section 3.6(a).

         "LOSS" or "LOSSES" shall mean any and all damages, fines, fees,
penalties, deficiencies, losses and expenses (including interest, court costs,
reasonable fees of attorneys, accountants and other experts or other expenses of
litigation or other proceedings or of any claim, default or assessment).

         "NDA" shall mean a New Drug Application filed with the FDA relating
solely to any of the Products requesting permission to place a drug on the
market in accordance with 21 C.F.R. Part 314 and all supplements filed pursuant
to the requirements of the FDA, including all documents, data and other
information concerning any such Product that are necessary for FDA approval to
market any such Product in the United States of America.

         "NEGOTIATION PERIOD" shall have the meaning set forth in the Purchase
Agreement.

         "NON-SERIOUS ADVERSE EVENT" for the Products shall mean an untoward
medical occurrence at any dose for any of the Products that is not a Serious
Adverse Event.

         "ORDERED PRODUCTS" shall mean the Products ordered pursuant to a Firm
Order.

         "PARTY" shall mean Pfizer or Purchaser and, when used in the plural,
means Pfizer and Purchaser.

         "PERSON" shall mean any individual, firm, corporation, partnership,
limited liability company, trust, joint venture or other entity or organization.

         "PPI" shall have the meaning set forth in Section 4.2(a).

         "PRODUCT CLAIM" shall mean a claim from a Third Party for money or
other compensation (beyond the cost of a particular Product) in respect of
potential or actual injury or harm allegedly due and owing as a result of the
use, application or defect of any of the Products or labeling of any of the
Products, in each case irrespective of the legal theory of liability.

         "PRODUCT QUALITY COMPLAINT" shall have the meaning set forth in Section
6.1(a).

         "PRODUCT REGISTRATION" shall mean the licenses, permits, certificates,
approvals, registrations or other authorizations for each Product under the
applicable Laws of any Governmental Authority, including any NDAs.

         "PRODUCTS" shall mean the certain products set forth on Schedule A.

         "PROCEEDING" shall have the meaning set forth in Section 11.5.

         "PURCHASE AGREEMENT" shall have the meaning set forth in the Recitals
above.

         "RECALL" shall have the meaning set forth in Section 6.2.

                                       3
<PAGE>

         "SERIOUS ADVERSE EVENT" for the Products shall have the meaning set
forth in 21 C.F.R. Section 314.80(a), as amended, or the ICH guidelines, as
applicable.

         "SPECIFICATIONS" shall mean the specifications for each of the Products
as set forth on Schedule B.

         "STANDARD COST" shall mean, in respect of the period commencing on the
date hereof and ending on December 31, 2003, Pfizer's standard cost for calendar
year 2002 as set forth on Schedule C and, in respect of subsequent calendar
years, shall mean the standard cost in effect for the preceding calendar year,
as adjusted pursuant to Section 4.2.

         "TARGET SHELF LIFE" shall have the meaning set forth in Section 3.6(a).

         "TERM" shall have the meaning set forth in Section 8.1.

         "THIRD PARTY" shall mean any Person who or which is neither a Party nor
an Affiliate of a Party.

         1.2      Other Definitional Provisions.

         (a) The words "HEREOF", "HEREIN", "HERETO" and "HEREUNDER" and words of
similar import, when used in this Agreement, shall refer to this Agreement as a
whole and not to any particular provision of this Agreement.

         (b) The terms defined in the singular shall have a comparable meaning
when used in the plural, and vice versa.

         (c) The term "INCLUDING" shall mean "INCLUDING, WITHOUT LIMITATION".

         (d) When a reference is made in this Agreement to an Article, a Section
or Schedule, such reference shall be to an Article of, a Section of or a
Schedule to, this Agreement unless otherwise indicated.

                                   ARTICLE 2

                SUPPLY OF PRODUCTS; FORECASTS AND PURCHASE ORDERS

         2.1      Products to be Supplied. Purchaser agrees to purchase from
Pfizer, and Pfizer agrees to sell to Purchaser, except as otherwise provided
herein, all of Purchaser's requirements for the Products, ordered during the
Term as provided herein. Pfizer shall solely and exclusively supply the Products
to Purchaser and its designees, and neither Pfizer nor any of its Affiliates
shall have the right to manufacture or supply any Product or any generic version
thereof for or to any other Person.

                                       4
<PAGE>

         2.2      Forecasts.

         (a)      Purchaser shall provide Pfizer with a Firm Order for the
period from the date hereof up to and including June 30, 2003, which Firm Order
shall be attached as Schedule E. Pfizer shall supply the quantities set forth on
Schedule E for each Product in accordance with the delivery schedule set forth
therein, and to the extent such Firm Order is not sufficient to meet Purchaser's
actual requirements for any Product for such period, Pfizer shall use its
commercially reasonable efforts to supply Purchaser with its requirements beyond
the amounts set forth on Schedule E. For periods after June 30, 2003, Firm
Orders shall be filled by Pfizer in accordance with the Firm Orders placed by
Purchaser pursuant to Section 2.2(b).

         (b)      Except as provided in Section 2.2(a), within 10 days after the
beginning of each calendar quarter, Purchaser shall give to Pfizer a forecast of
Purchaser's estimated quarterly requirements of the Products for the 24 month
period commencing with the next succeeding calendar quarter. The 24 month
forecast delivered to Pfizer pursuant to the preceding sentence shall represent
Purchaser's reasonable estimates of the quantity of the Products that Purchaser
will require during such 24 month period to which such forecast applies, and the
forecast of its requirements of the Products during the first quarter of such 24
month period shall be reflected in a Firm Order accompanying such forecast.

         (c)      Notwithstanding the foregoing, any Firm Order for any Product
placed for a calendar quarter in accordance with Section 2.2(b) shall be between
75% and 125% of the most recent forecast estimated quantity for such Product for
such calendar quarter provided by Purchaser to Pfizer in accordance with this
Section 2.2 prior to the Firm Order being placed by Purchaser. If requested by
Purchaser, Pfizer shall use its commercially reasonable efforts to supply an
amount over 125% of the most recent forecast estimated quantity for a Product.

         (d)      Pfizer shall promptly notify Purchaser in writing if at any
time Pfizer has reason to believe that Pfizer will not be able to fill a Firm
Order for any Product in all material respects in accordance with the delivery
schedule specified therein by Purchaser and pursuant to the terms and conditions
of this Agreement.

         (e)      All forecasts to be provided or delivered by Purchaser to
Pfizer pursuant to this Section 2.2 shall be in writing.

         2.3      Capacity. Any forecasts delivered by Purchaser to Pfizer
pursuant to Section 2.2 and the aggregate of all Firm Orders must be within
Pfizer's capacity as set forth on Schedule D.

         2.4      Acceptance of Firm Order. Pfizer agrees to accept all Firm
Orders submitted in accordance with and on the terms set forth in this
Agreement. No terms and conditions contained in any Firm Order, acknowledgment,
invoice, bill of lading, acceptance or other preprinted form issued by either
Party shall be effective to the extent they are inconsistent with or modify the
terms and conditions contained herein.

                                       5
<PAGE>

         2.5      Delivery. All Products sold pursuant to this Agreement shall
be delivered FCA FAJARDO (Pfizer's place of manufacture). Purchaser shall bear
the cost of shipping and insurance.

                                   ARTICLE 3

                          SUPPLY AND SERVICES CRITERIA

         3.1      General. Subject to the terms of this Agreement, Pfizer shall
produce the Products following the same practices and procedures in effect as of
the date of this Agreement.

         3.2      Compliance with Specifications. All Products supplied
hereunder shall be in finished dosage form, filled, labeled and packaged for
commercial sale or distribution as samples, as the case may be, by Pfizer in
accordance with the terms and conditions of this Agreement, the Specifications
and applicable Laws. Pfizer shall be responsible for the purchase of all raw
materials in accordance with the NDAs and other regulatory filings for the
Products as necessary to supply finished Products to Purchaser under this
Agreement. Purchaser shall promptly notify Pfizer of any changes to the
Specifications that are required by changes in applicable Laws or are otherwise
desired by Purchaser, including changes to the packaging or Labeling of the
Products. Any such changes shall be subject to the prior approval of Pfizer
(which approval shall not be unreasonably withheld), and Pfizer shall use its
commercially reasonable efforts to accommodate such changes. If any such change
would cause an increase or decrease in the Standard Costs of the Products,
Pfizer shall promptly notify Purchaser of the change in the Standard Costs of
the Products, and Purchaser shall bear the cost of such change. Purchaser shall
also bear any one-time costs required to implement any such change. With respect
to any regulatory filings and approvals made or sought by Purchaser under this
Section 3.2, Pfizer shall, and shall cause its relevant Affiliates to, provide
reasonable cooperation to Purchaser in connection therewith. If a change
proposed to be made to the Specifications or the manufacture of the Products
under this Section 3.2 requires prior approval by any applicable Governmental
Authority before implementation, such change shall not be implemented in respect
of a Product until such change has been so approved.

         3.3      Practices. Pfizer shall adhere in all material respects to
cGMPs as they apply to the manufacturing, handling and control of the Products.

         3.4      Labeling. For up to 180 days after the date hereof, Pfizer
shall continue to use Pfizer's Labeling on the Products manufactured for
Purchaser. After such time, each such Product shall be manufactured with
Labeling and packaging identifying Purchaser (or Purchaser's designee) as the
distributor thereof and, only if required by applicable Law, Pfizer or its
applicable Affiliate as the manufacturer thereof. Purchaser shall provide Pfizer
with its Labeling as soon as practicable from the date Purchaser completes the
related registration process, but in no event later than 90 days thereafter. In
the event that inventories of Pfizer's Labeling have been depleted and Purchaser
has not provided Pfizer with Purchaser's Labeling, Pfizer shall procure
additional Pfizer's Labeling until such time

                                       6
<PAGE>

Purchaser provides Pfizer with Purchaser's Labeling in accordance with this
Section 3.4. Should Purchaser wish to substitute its Labeling prior to the date
that is 180 days after the date hereof, Purchaser shall reimburse Pfizer for its
out-of-pocket cost for the unused Labeling that would otherwise have been used
through the end of such 180 day period. As between Pfizer and Purchaser, with
respect to the Products sold after the date hereof, Purchaser shall be solely
responsible for ensuring that the Labeling and other printed materials, if any,
comply with all applicable Laws; provided, however, that Pfizer warrants to
Purchaser that the Products supplied hereunder prior to the conversion of the
Labeling from Pfizer's Labeling to Purchaser's Labeling in accordance with this
Section 3.4 shall comply with the FDA-approved Labeling as it exists on the date
hereof.

         3.5      Capital Investments. Pfizer shall not be required to make any
capital investment for the purpose of expanding the capacity or modification of
the manufacturing facility for the Products. Pfizer shall seek to minimize any
investment required for compliance with changes in Law during the Term, but if
any such investments are required, the cost of these capital investments shall
be borne by Purchaser. Pfizer agrees to review such investments with Purchaser
and to obtain its approval prior to initiating the investments, such approval
not to be unreasonably withheld. If Purchaser does not approve of these
investments, Pfizer may immediately terminate the manufacture of all Products
from the manufacturing facility requiring these investments if it is unable to
obtain the required approvals of the relevant Governmental Authority to continue
to operate the facility without investment and without penalty.

         3.6      Shelf Life.

         (a)      Pfizer shall have as its objective to deliver to Purchaser (i)
Ordered Products, which correspond to the Products set forth on Schedule A with
the Estrostep(R) trademark, with a shelf life of not less than 12 months from
the date of delivery to Purchaser ("ESTROSTEP TARGET SHELF LIFE") and (ii)
Ordered Products, which correspond to the Products set forth on Schedule A with
the Loestrin(R) trademark, with a shelf life of not less than 18 months from the
date of delivery to Purchaser ("LOESTRIN TARGET SHELF LIFE" and, together with
the Estrostep Target Shelf Life, the "TARGET SHELF LIFE").

         (b)      If any Ordered Products are delivered to Purchaser with a
shelf life of less than the applicable Target Shelf Life (the "LESS THAN TARGET
SHELF LIFE PRODUCTS"), and any Less than Target Shelf Life Products are returned
to Purchaser by any Third Party customer as a result of such Less than Target
Shelf Life Products having been delivered to Purchaser with less than the
applicable Target Shelf Life, then Pfizer shall provide replacement Products to
Purchaser, at no cost to Purchaser, and shall make arrangements for the return,
reworking or disposal, at Pfizer's option and expense, of such returned Less
than Target Shelf Life Products.

         (c)      Notwithstanding anything herein to the contrary, Pfizer's sole
liability and obligation to Purchaser in respect of any failures by Pfizer to
deliver Ordered Products to Purchaser with the applicable Target Shelf Life
shall be as provided in Section 3.6(b).

                                       7
<PAGE>

                                   ARTICLE 4

                                  CONSIDERATION

         4.1      Pricing. Subject to Section 4.2, the Parties agree that the
price for each of the Products during the Term shall be the Standard Cost of
such Product in effect at the time of delivery of the applicable Firm Order in
accordance with Sections 2.2(a) and (b) to Pfizer.

         4.2      Standard Cost Adjustments.

         (a)      The Standard Cost of each Product shall be adjusted effective
as of each January 1st during the Term by such percentage increase in the
Producer Price Index as published by the United State Department of Labor,
Bureau of Labor Statistics (the "PPI") over the immediately preceding 12 month
period, except to the extent that Pfizer has elected to adjust the Standard Cost
as set forth in Section 4.2(c) for such year. The Standard Cost adjustment under
this Section 4.2(a) shall be notified to Purchaser not later than June 30th of
each year and shall be retroactively effective to January 1st of that same year
and shall apply to all Firm Orders received on or after said January 1st. In the
event that Pfizer fails to provide notice of any PPI increase by June 30th of a
given year, any such increase shall only be effective as of the date such notice
is actually given and shall only apply to Firm Orders received on or after such
date. If the PPI is not available for any period, the most similar available
index shall be used.

         (b)      In the event that Purchaser's Firm Orders for all Products in
the aggregate for three consecutive quarters in a calendar year are at least 20%
lower than aggregate quantities estimated in the forecast for the corresponding
periods provided 12 months prior to the submission of such Firm Orders, Pfizer
may elect in its sole discretion to adjust that portion of the Standard Cost of
the Products that represent Pfizer's allocation of overhead solely relating to
the dedicated hormone facility at the Fajardo Plant by the change in the
allocation for such overhead to be incurred by Pfizer in the following year.
Schedule G sets forth the applicable overhead allocations for the dedicated
hormone facility for each Product as of the date hereof. All other components of
the Standard Cost of such Product for such year shall be adjusted by the index
set forth in Section 4.2(a) or the change in cost set forth in Section 4.2(c),
as the case may be. Pfizer shall act in good faith in connection with the
Standard Cost adjustment set forth in this Section 4.2(b). Any Standard Cost
adjustment made pursuant to this Section 4.2(b) shall be notified to Purchaser
not later than June 30th of each year and shall be retroactively effective to
January 1st of that same year and shall apply to all Firm Orders received on or
after said January 1st. In the event that Pfizer fails to provide notice of any
overhead allocation increase by June 30th of a given year, any such increase
shall only be effective as of the date such notice is actually given and shall
only apply to Firm Orders received on or after such date.

         (c)      In the event that during any given calendar year during the
Term, a change of more than 20% (above or below the amount included in the
applicable Standard Cost of a Product) in the price to Pfizer of any material,
service or utility used in the manufacture of a Product results in an increase
or decrease in the total Standard Cost of such Product of 5% or

                                       8
<PAGE>

more, Pfizer may elect in its sole discretion to adjust the Standard Cost for
such Product for the following calendar year to reflect the increase or decrease
in cost above or below that included in the then prevailing Standard Cost for
such Product. Pfizer shall act in good faith in connection with the Standard
Cost adjustment set forth in this Section 4.2(c). Any Standard Cost adjustment
made pursuant to this Section 4.2(c) shall be notified to Purchaser not later
than June 30th of each year and shall be retroactively effective to January 1st
of that same year and shall apply to all Firm Orders received on or after said
January 1st. In the event that Pfizer fails to provide notice of any such
increase or decrease by June 30th of a given year, any such increase or decrease
shall only be effective as of the date such notice is actually given and shall
only apply to Firm Orders received on or after such date.

         4.3      Payment of Obligations. Invoices for Firm Orders shall be
submitted to Purchaser upon delivery by Pfizer of the Ordered Products and such
invoices shall be payable in full within 30 days from the date of receipt of the
invoice. Payment shall be made by Purchaser by check delivered to Pfizer's
address as designated in such invoice or by wire transfer to an account
designated by Pfizer. Any required payment hereunder not made by Purchaser on or
before the date specified in this Section 4.3 shall bear interest from the date
such payment is due until the date it is actually received by Pfizer at an
annual rate equal to 12%.

         4.4      Audit Right. Purchaser shall have the right to have a
nationally recognized independent public accounting firm audit, within 60 days
of delivery by Pfizer to Purchaser of a notice of Standard Cost adjustment
pursuant to Section 4.2(b) or (c), Pfizer's books and records relating to the
manufacture of the Products, for the sole purpose of verifying Pfizer's
determination of the adjustment to the Standard Cost undertaken pursuant to
Section 4.2(b) or (c). Such audit shall be at reasonable times during normal
business hours and upon reasonable notice to Pfizer. A copy of such auditing
firm's conclusions of its audit shall be furnished to Pfizer at least ten
Business Days prior to disclosure to Purchaser to allow Pfizer an opportunity to
review the accuracy of the auditing firm's conclusions. The conclusions of such
audit firm shall be final and binding on the Parties. Purchaser shall bear the
full cost of such audit (including reimbursement to Pfizer for administrative
costs it incurs in connection with the audit), unless such audit discloses a
variance of more than 5% from the increase in Standard Cost imposed by Pfizer,
in which event, Pfizer shall bear the full cost of such audit. Any amounts that
are determined to be due and owing by Pfizer to Purchaser following such audit
shall be paid within 30 Business Days thereafter, together with any interest due
thereon from the date of overpayment by Purchaser at the rate of 12% per annum.
The payment of such interest shall not limit Purchaser from exercising any other
legal rights it may have as a consequence of the lateness of any payment.

                                       9
<PAGE>

                                   ARTICLE 5

                       ACCEPTANCE OF PRODUCTS BY PURCHASER

         5.1      Receipt of Product; Acceptance; Product Returns.

         (a)      Purchaser shall be entitled to reject any portion or all of
any shipment of Products that does not conform to the Certificate of Analysis or
otherwise fails to comply with the warranties set forth in Article 7 (unless
such non-conformity was attributable to an act or omission of Purchaser or the
common carrier once the Product was delivered by Pfizer to such common carrier),
provided that (i) Purchaser shall notify Pfizer within 30 days after receipt of
such shipment if it is rejecting a shipment due to obvious physical damage,
obvious packaging defect or quantity discrepancies that are evident upon visual
inspection of the packaged Products as shipped by Pfizer and (ii) in the case of
Products having defects other than those obvious defects, Purchaser shall notify
Pfizer within 90 days after receipt of such Product. Notwithstanding anything
contained herein, Purchaser shall have no obligation to inspect the Products
beyond a visual inspection of each shipment for obvious physical damage or
quantity discrepancies that are evident upon visual inspection of the packaged
Products as shipped by Pfizer. Without in any way limiting Pfizer's indemnity
obligation as set forth in Section 9.1, if no notice is provided by Purchaser
within such time periods, then Purchaser shall be deemed to have accepted the
shipment. Any notice of rejection by Purchaser shall be accompanied by a
reasonably detailed statement of its reasons for rejection and a report of any
pertinent analysis performed by Purchaser on the allegedly nonconforming
Product, together with the methods and procedures used. Pfizer shall notify
Purchaser as promptly as reasonably possible, but in any event within ten
Business Days after receipt of such notice of rejection, whether it accepts
Purchaser's assertions of nonconformity.

         (b)      Whether or not Pfizer accepts Purchaser's assertion of
nonconformity, promptly upon receipt of a notice of rejection, unless otherwise
specified by Purchaser, Pfizer shall use its commercially reasonable efforts to
provide replacement Products for those rejected by Purchaser in the original
shipment. If the Product rejected by Purchaser from such original shipment
ultimately is found to be nonconforming (whether pursuant to Section 5.1(c) or
if Pfizer so acknowledges in writing), Pfizer shall bear all expenses for such
replacement Product (including all transportation and/or disposal charges and
cost of manufacture for such nonconforming Product) to the extent Purchaser
previously paid for any corresponding nonconforming Product. If it is determined
subsequently that such Product was in fact conforming (whether pursuant to
Section 5.1(c) or if Purchaser so acknowledges in writing), then Purchaser shall
be responsible not only for the purchase price of the allegedly nonconforming
Product (including all transportation charges), but also, upon receipt and
acceptance by Purchaser in accordance with the procedures (and at the same price
charged in the original shipment) set forth above, the replacement Product.
Replacement shipments shall also be subject to the procedures contained in
Section 5.1(a).

         (c)      If Pfizer disagrees with any alleged nonconformity, then an
independent laboratory (or other expert) of recognized repute reasonably
acceptable to both Parties (the

                                       10
<PAGE>

"INDEPENDENT LABORATORY") shall analyze an aliquot sample or such other portions
of a shipment, furnished by Purchaser from the shipment received by Purchaser,
as may be necessary to substantiate whether the shipment rejected by Purchaser
conformed in all material respects to the Certificate of Analysis and any other
pertinent Specifications or otherwise failed to comply with the warranties set
forth in Article 7 at the time of delivery to the common carrier. At the same
time Purchaser furnishes to the Independent Laboratory an aliquot sample or such
other portion of such shipment, Purchaser shall also furnish to Pfizer a split
sample of such aliquot sample or such other portion of such shipment. In
conducting its analysis hereunder, the Independent Laboratory shall use the same
analytical methodology used by Pfizer. Pfizer shall provide a reasonably
detailed description of such analytical methodology to the Independent
Laboratory. Both Parties agree to cooperate with the Independent Laboratory's
reasonable requests for assistance in connection with its analysis hereunder.
Both Parties shall be bound by the Independent Laboratory's results of analysis,
which, absent manifest error, shall be deemed final as to any dispute over
compliance of the Product in all material respects with the Certificate of
Analysis and/or any other pertinent Specifications and/or the warranties set
forth in Article 7. If the analysis of the Independent Laboratory shows that the
Products do not conform in all material respects to the Certificate of Analysis
or any other pertinent Specifications or the warranties set forth in Article 7
at the time of delivery to the common carrier, the costs of such analysis shall
be paid by Pfizer. If the analysis of the Independent Laboratory shows that the
Products do conform in all material respects to the Certificate of Analysis and
any other pertinent Specifications and the warranties set forth in Article 7 at
the time of delivery to the common carrier, the costs of such analysis shall be
paid by Purchaser.

         (d)      If Pfizer acknowledges an alleged nonconformity (or if the
Independent Laboratory concludes that the Product was nonconforming in
accordance with Section 5.1(c)), Pfizer promptly (and in any case within 30 days
thereafter) shall make arrangements for the return, reworking or disposal, at
Pfizer's option, of the nonconforming Product. If Pfizer requests that Purchaser
dispose of such nonconforming Product, Pfizer shall give Purchaser written
instructions as to how Purchaser or its agent shall, at Pfizer's expense and
liability, lawfully dispose of any non-conforming Products, and Purchaser shall
provide Pfizer with written certification of such destruction. Pfizer shall pay,
or reimburse Purchaser, for any reasonable return shipping charges or
out-of-pocket costs incurred by Purchaser for such return shipment or lawful
disposal of such nonconforming Product in accordance with Pfizer's instructions.

         5.2      Quality Control. Pfizer shall conduct all quality control
testing of the Products prior to shipment in accordance with the applicable
Product Registrations and Laws. Pfizer shall retain records and samples of
Products relating to such testing as required by applicable Law. If Purchaser
conducts quality control testing of Products after delivery thereof to
Purchaser, Purchaser shall use the same analytical methodology as used by
Pfizer. Upon written request from Purchaser, Pfizer shall provide a reasonably
detailed description of the analytical methodology used by Pfizer for quality
control testing of the Products.

         5.3      Inspections. Pfizer shall afford Purchaser or Purchaser's
representatives reasonable access, but no more than two times per year, to
inspect, review and audit the

                                       11
<PAGE>

premises where the Products are being tested and/or manufactured for the sole
purpose of confirming that all Products tested and/or manufactured at such
facility are tested and/or manufactured in accordance with cGMPs, the applicable
Product Registration and other requirements of this Agreement and of applicable
Law. In connection with such inspection, review or audit, Pfizer shall allow
Purchaser to review and inspect the applicable testing and/or manufacturing
facility and records, to meet with Pfizer's personnel and to obtain copies from
Pfizer of any such records solely for the purpose of confirming that Pfizer's
manufacturing and record-keeping is compliant with the applicable Product
Registration, this Agreement and applicable Laws. Such inspections, reviews and
audits shall occur upon not less than ten days' prior written notice to Pfizer,
such inspections, reviews and audits shall only be conducted during normal
business hours and such inspections, reviews and audits shall not unreasonably
disrupt the normal operations of Pfizer. Purchaser's exercise of its inspection
rights hereunder shall in no way waive, modify or diminish Pfizer's obligations
under this Agreement.

         5.4      Notification, Etc. of Certain Matters. In the event that
representatives of any relevant Governmental Authority inspect or notify Pfizer
of their intention to inspect the Fajardo Plant in connection with the
manufacturing or supply of the Products, Pfizer shall notify Purchaser promptly
upon learning of such inspection, and shall supply Purchaser with copies of all
correspondence and other documentation received from the Governmental Authority
relating thereto. Pfizer shall provide promptly to Purchaser copies of any
letter, comments or inquiry from any relevant Governmental Authority in
connection with the manufacturing or supply of the Products that requires a
response or action by Pfizer including, but not limited to, an FDA Form 483 or a
Warning Letter. Pfizer shall permit Purchaser to review and comment on the
content of any written response relating to an inspection of the Fajardo Plant
that relates in any way to the Products before Pfizer submits that response to
the Governmental Authority. If such comments are provided promptly (within one
week unless the circumstances require greater expedition), Pfizer shall consider
the comments before submission of the response.

         5.5      Restart Matters. In the event that any relevant Governmental
Authority determines that Pfizer must cease manufacturing the Products as well
as other products in the Fajardo Plant due to Pfizer's failure to adhere to
cGMPs relating to manufacturing, handling or controlling of any product made in
the Fajardo Plant, Pfizer shall use reasonable best efforts to obtain approval
from the relevant Governmental Authority to begin manufacturing the Products as
soon as practicable thereafter. In the event of a Fajardo Plant shutdown
described herein, should the relevant Governmental Authority allow Pfizer to
begin manufacturing products in the Fajardo Plant on an incremental
product-by-product basis, Pfizer shall not discriminate against the Products
during Pfizer's efforts to obtain approval to restart manufacturing.

                                       12
<PAGE>

                                   ARTICLE 6

           PRODUCT QUALITY COMPLAINTS; PRODUCT RECALLS; ADVERSE EVENTS

         6.1      Product Quality Complaints.

         (a)      Subject to Sections 6.1(b) through (d), Purchaser shall be
responsible for responding to all Product Quality Complaints with respect to the
Products. Both Parties shall cooperate to effect any resolutions with respect to
any Product Quality Complaint. "PRODUCT QUALITY COMPLAINT" shall mean any
complaint that questions the purity, identity, potency or quality of any
Product, its packaging or labeling, any complaint that concerns any incident
that causes any Product or its labeling to be mistaken for, or applied to,
another article, any bacteriological contamination, any significant chemical,
physical or other change or deterioration in any distributed Product or any
failure of any Product to meet its applicable Specifications. Where the subject
matter of the Product Quality Complaint relates in any way to the
responsibilities of a Party under this Agreement or the duties performed by a
Party hereunder, such Party shall, within three Business Days but not more than
five days from receipt of written notice by such Party from the other Party or
receipt by such Party of any other information from a Third Party constituting a
Product Quality Complaint, initiate a complaint investigation at such Party's
expense. Such Party shall conduct such investigation expeditiously. The
investigating Party shall report its findings to the other Party's contact
listed below in Section 6.1(b) or (c), as the case may be.

         (b)      Pfizer shall inform Purchaser's contact of any Product Quality
Complaint received by it within three Business Days but no more than five days
from the receipt date by Pfizer. Such information shall be sent to the contact
set forth below:

                           Warner Chilcott Inc.
                           100 Enterprise Drive
                           Rockaway, New Jersey  07866
                           Attention:     Vice President - Regulatory Affairs
                           Facsimile No.: (973) 442-3280
                           Telephone No.: (973) 442-3233

         (c)      Purchaser shall inform Pfizer's contact of any Product Quality
Complaint received by it within three Business Days but no more than five days
from the receipt date by Purchaser. Such information shall be sent to Pfizer as
set forth below:

                           Pfizer Inc.
                           Product Complaints
                           182 Tabor Road
                           Morris Plains, New Jersey  07950-2614
                           Attention:     Director of Product Complaints
                           Facsimile No.: (973) 385-5404
                           Telephone No.: (973) 385-2132

                                       13
<PAGE>

         (d)      Nothing in this Section 6.1 is intended to limit, alter or
restrict a Party's reporting obligations under applicable Law.

         6.2      Product Recalls.

         (a)      In the event that either Party obtains information that a
Product or any portion thereof should be alleged or proven not to meet the
Specifications, the Labeling or the Product Registration for such Product or to
be otherwise defective, such Party shall notify the other Party immediately and
both Parties shall cooperate fully regarding the investigation and disposition
of any such matter. Pfizer and Purchaser shall each maintain such traceability
records as are sufficient and as may be necessary to permit a recall, product
withdrawal or field correction of any of the Products. In the event (i) any
applicable Governmental Authority should issue a request, directive or order
that a Product be recalled or withdrawn or (ii) Purchaser determines that any
Product already in interstate or international commerce presents a risk of
injury or gross deception or is otherwise defective and that a recall of such
Product is appropriate (each of (i) and (ii), a "RECALL"), each Party shall give
telephonic notice (to be confirmed in writing) to the other within 24 hours of
the occurrence of such event.

         (b)      Purchaser shall have sole responsibility for carrying out any
Recalls. Pfizer shall provide full cooperation and assistance to Purchaser in
connection therewith as may be reasonably requested by Purchaser. Purchaser
shall be responsible for all expenses of effecting any such Recall (including
any out-of-pocket expenses incurred by Pfizer in connection with such
cooperation), except to the extent such Recall is attributable to a breach by
Pfizer of its obligations hereunder (in which case Pfizer shall be responsible
for the expenses associated with any such Recall attributable to such breach).

         6.3      Adverse Events.

         (a)      Within one month after the date hereof, the Parties shall
discuss and develop mutually acceptable guidelines and procedures for the
surveillance, receipt, evaluation, reporting and communication (as between the
Parties), exchange of Serious Adverse Event and Non-Serious Adverse Event
information, and the migration of such data, in accordance with the terms of
this Agreement in order to permit both Parties to comply with their respective
obligations under all applicable Laws until such time as all Product
Registrations and other Governmental Authorizations, including clinical trial
applications, are transferred to Purchaser or its designee. The Parties shall
bear their respective costs incurred in connection with receiving, recording,
reviewing, reporting, communicating and exchanging with each other regarding
and, as applicable, reporting and responding to any Serious Adverse Events or
Non-Serious Adverse Events.

         (b)      Until the earlier of (i) nine months after the Closing and
(ii) the date upon which all Product Registrations are transferred to Purchaser,
Pfizer shall maintain systems for global pharmacovigilance for the Products.
Until such time as guidelines and procedures are developed in accordance with
Section 6.3(a), each Party shall promptly notify the other Party of any
significant adverse event(s) that affect the marketing of such Products or are
required

                                       14
<PAGE>

to be reported in accordance with FDA regulations, including adverse drug
experiences and governmental inquiries. Purchaser shall have the reporting
responsibility for such events as provided under applicable Law to applicable
Governmental Authorities. Each of Pfizer and Purchaser shall cooperate with the
other Party in connection therewith as reasonably requested by the other Party
and as follows:

                  (i)      Serious Adverse Events for the Products of which one
         Party becomes aware shall be submitted to the other Party within the
         time frames specified in the applicable regulations or guidelines.
         Non-Serious Adverse Events for the Products that are reported to one
         Party shall be submitted to the other Party no more than one month from
         the date received by the first-mentioned Party; provided, however, that
         medical and scientific judgment should be exercised in deciding whether
         expedited reporting is appropriate in other situations, such as
         important medical events that may not be immediately life-threatening
         or result in death or hospitalization, but may jeopardize the patient
         or may require intervention to prevent a Serious Adverse Event outcome.

                  (ii)     All Serious Adverse Events and Non-Serious Adverse
         Events shall be submitted by one Party to the other Party pursuant to
         this Section 6.3 in accordance with the current contact information for
         the non-reporting Party. Each Party shall provide the other with
         current contact information in writing promptly after the date hereof,
         but in no event later than 15 Business Days after such date, and, in
         the event of any changes, promptly shall update such information in
         writing to the other Party.

         6.4      Medical Inquiries. Purchaser shall have sole responsibility,
at its expense, for handling all medical inquiries concerning the Products.
Pfizer shall, and shall cause its relevant Affiliate to, refer all routine
medical information requests in writing to Purchaser as set forth in Section
6.3(b)(ii). Urgent medical information requests shall be referred by Pfizer to
Purchaser by telephone.

                                   ARTICLE 7

                          WARRANTIES; CERTAIN COVENANTS

         7.1      Pfizer hereby warrants to Purchaser, for the benefit of
Purchaser, that (a) Ordered Products supplied pursuant to this Agreement shall
in all material respects be (i) in compliance with the Specifications, cGMPs and
all other requirements and conditions contained in this Agreement and (ii)
warranted to be free of defects in material and workmanship and (b) Pfizer shall
either (i) at its option, repair or replace, within a reasonable period of time,
or (ii) if Pfizer is unable after using its commercially reasonable efforts to
effectively perform such repair or replacement within a reasonable amount of
time, refund the price of any Ordered Products that fail to conform with the
warranties in this Section 7.1.

         7.2      To the extent permissible by Law, the warranties contained in
Section 7.1(a) are exclusive and in lieu of all other warranties, express or
implied, and Pfizer expressly

                                       15
<PAGE>

disclaims and excludes any implied warranty of merchantability or implied
warranty of fitness for a particular purpose.

         7.3      Except as provided in Section 9.1(b) in respect of Pfizer's
maximum annual indemnification liability in respect of third party claims, in
the event of any breach of this Agreement, the parties hereto shall be entitled
to all remedies available at Law or equity.

                                    ARTICLE 8

                              TERM AND TERMINATION

         8.1      Term. Subject to the other provisions of this Article 8, this
Agreement shall have a term ("TERM") beginning on the date hereof and ending on
the later of (a) five years from the date hereof and (b) four years from the
expiration of the Negotiation Period and shall not be renewable. Notwithstanding
the foregoing, this Agreement shall terminate on the date on which Pfizer
completes the sale of the Fajardo Plant to Purchaser.

         8.2      Termination Upon Obtainment of Alternate Source of Supply.
Purchaser agrees to proceed as promptly as practicable after the date of this
Agreement to obtain an alternate source of supply for the Products. As soon as
Purchaser shall obtain an alternate source of supply for the Products, Purchaser
shall promptly notify Pfizer, and Pfizer may, at its sole discretion and at any
time during the remaining Term, terminate the supply of the Products under this
Agreement upon 30 days prior written notice to Purchaser. Pfizer shall provide
Purchaser (or Purchaser's designee) with the assistance of its employees and
access to its other internal resources to provide Purchaser with a reasonable
level of technical assistance and consultation in connection with the regulatory
qualification of an alternate supplier for the Products, provided that Purchaser
shall reimburse Pfizer for the fully-burdened cost of such technical assistance
and consultation to the extent that Pfizer provides in excess of 120 man-hours
of such assistance and consultation, provided further that Purchaser shall
reimburse Pfizer for all reasonable out-of-pocket costs incurred in connection
with such assistance and consultation.

         8.3      Termination by Pfizer.

         (a)      This Agreement may be terminated by Pfizer, at its option,
upon the commencement against Purchaser of a voluntary or involuntary proceeding
under any bankruptcy, insolvency, liquidation or similar Law, or upon the
appointment with respect to Purchaser of a successor, trustee, custodian,
sequestrator or similar official.

         (b)      This Agreement may be terminated by Pfizer in the event of a
material breach by Purchaser of Purchaser's obligations of performance under
this Agreement if such breach is not cured within 60 days following receipt of
notice of such material breach from Pfizer.

                                       16
<PAGE>

         8.4      Termination by Purchaser.

         (a)      This Agreement may be terminated by Purchaser, at its option,
upon the commencement against Pfizer of a voluntary or involuntary proceeding
under any bankruptcy, insolvency, liquidation or similar Law, or upon the
appointment with respect to Pfizer of a successor, trustee, custodian,
sequestrator or similar official.

         (b)      This Agreement may be terminated by Purchaser in the event of
a material breach by Pfizer of Pfizer's obligations of performance under this
Agreement if such breach is not cured within 60 days following receipt of notice
of such material breach from Purchaser.

         8.5      Effect of Termination or Expiration. Indemnification and
confidentiality obligations that accrue prior to the effective date of such
termination or the expiration of this Agreement shall survive the termination or
expiration of this Agreement. If this Agreement is terminated by Pfizer pursuant
to Section 8.3(b), then Purchaser shall purchase all merchantable inventory,
including work in process, raw materials and packaging materials, at Pfizer's
full cost. This Section 8.5 shall survive the termination or expiration of this
Agreement.

                                   ARTICLE 9

                                 INDEMNIFICATION

         9.1      Indemnification by Pfizer.

         (a)      Pfizer agrees to indemnify, protect, defend and hold Purchaser
and its directors, officers, employees and agents harmless from and against any
Losses that they may incur at any time by reason of any Action brought by any
Governmental Authority or other Third Party arising out of (i) Pfizer's breach
of this Agreement or of any warranty made by Pfizer to Purchaser under this
Agreement or (ii) Pfizer's supply of damaged or defective Product that does not
meet the Specifications.

         (b)      In no event shall Pfizer's liability pursuant to Section
9.1(a) for any and all Losses to Purchaser, other than any Losses arising out of
any Product Claims (but only if such Product Claims are indemnifiable pursuant
to Section 9.1(a)), exceed $10,000,000 in the aggregate for any given calendar
year during the Term.

         9.2      Indemnification by Purchaser. Purchaser agrees to indemnify,
protect, defend and hold Pfizer and its directors, officers, employees and
agents harmless from and against any Losses that the may incur at any time by
reason of any Action brought by any Governmental Authority or other Third Party
arising out of (i) Purchaser's breach of this Agreement or of any warranty made
by Purchaser to Pfizer under this Agreement or (ii) the manufacture, sale,
marketing, use or distribution of the Products, except to the extent that Pfizer
is obligated to indemnify, protect and defend Purchaser and its directors,
officers, employees and agents for such Losses under Section 9.1.

                                       17
<PAGE>

         9.3      Notice of Claims. If any of the Persons to be indemnified
under this Article 9 (the "INDEMNIFIED PARTY") has suffered or incurred any
Loss, the Indemnified Party shall so notify the party from whom indemnification
is sought (the "INDEMNIFYING PARTY") promptly in writing describing such Loss,
the amount or estimated amount thereof, if known or reasonably capable of
estimation, and the method of computation of such Loss, all with reasonable
particularity and containing a reference to the provisions of this Agreement or
any other agreement or instrument delivered pursuant hereto in respect of which
such Loss shall have occurred. If any action at law or suit in equity is
instituted by or against a Third Party with respect to which the Indemnified
Party intends to claim any liability as a Loss under this Article 9, the
Indemnified Party shall promptly notify the Indemnifying Party of such action or
suit and tender to the Indemnifying Party the defense of such action or suit. A
failure by the Indemnified Party to give notice and to tender the defense of the
action or suit in a timely manner pursuant to this Section 9.3 shall not limit
the obligation of the Indemnifying Party under this Article 9, except (i) to the
extent such Indemnifying Party is materially prejudiced thereby and (ii) to the
extent expenses that are incurred during the period in which notice was not
provided shall not be deemed a Loss.

         9.4      Control of Claims.

         (a)      The Indemnifying Party under this Article 9 shall have the
right, but not the obligation, to conduct and control, through counsel of its
choosing, any claim, action, suit or proceeding for which indemnification is
sought pursuant to this Article 9 ("INDEMNIFIABLE CLAIM"), and the Indemnifying
Party may compromise or settle the same, provided that the Indemnifying Party
shall give the Indemnified Party advance notice of any proposed compromise or
settlement, provided further that the Indemnifying Party shall not compromise or
settle any Indemnifiable Claim without the approval of the Indemnified Party if
such compromise or settlement imposes any obligations on the Indemnified Party,
such approval not to be unreasonably withheld. No Indemnified Party may
compromise or settle any Indemnifiable Claim without the consent of the
Indemnifying Party. The Indemnifying Party shall permit the Indemnified Party to
participate in, but not control, the defense of any such Indemnifiable Claim
through counsel chosen by the Indemnified Party, provided that the fees and
expenses of such counsel shall be borne by the Indemnified Party. If the
Indemnifying Party elects not to control or conduct the defense or prosecution
of an Indemnifiable Claim, the Indemnifying Party nevertheless shall have the
right to participate in the defense or prosecution of any Indemnifiable Claim
and, at its own expense, to employ counsel of its own choosing for such purpose.

         (b)      The parties hereto shall cooperate in the defense or
prosecution of any Indemnifiable Claim, with such cooperation to include (i) the
retention of and the provision to the Indemnifying Party of records and
information that are reasonably relevant to such Indemnifiable Claim and (ii)
the making available of employees on a mutually convenient basis for providing
additional information and explanation of any material provided hereunder.

                                       18
<PAGE>

                                   ARTICLE 10

                                 CONFIDENTIALITY

         10.1     Pfizer's Obligation. Except for the proper exercise of any
rights granted or reserved under other provisions of this Agreement, Pfizer
agrees that it shall keep confidential, and shall cause its officers, employees,
directors and counsel to keep confidential and shall not publish or otherwise
divulge to a Third Party, other than any agents of Pfizer, or use for itself,
unless Purchaser shall have given its prior written approval, during the Term
and for a period of ten years after the end of the Term, any information of a
proprietary nature relating to Purchaser's business or operations, including
non-public information concerning Purchaser's products, processes, customers and
suppliers and the products and processes of Purchaser's customers and suppliers
furnished to Pfizer by Purchaser in connection with this Agreement (any of the
foregoing, "CONFIDENTIAL PURCHASER INFORMATION"); provided, however, that Pfizer
shall have the right to disclose any Confidential Purchaser Information provided
hereunder if, in the reasonable opinion of Pfizer's legal counsel, such
disclosure is necessary (a) in connection with the securing of any governmental
approval necessary for the performance by Pfizer of any of its obligations
hereunder or under any other agreement with Purchaser or (b) for the purpose of
complying with governmental regulations. Pfizer shall notify Purchaser of
Pfizer's intent to make such disclosure of Confidential Purchaser Information
pursuant to the proviso of the preceding sentence sufficiently prior to making
such disclosure so as to allow Purchaser adequate time to take whatever action
Purchaser may deem to be appropriate to protect the confidentiality of
Confidential Purchaser Information.

         10.2     Purchaser's Obligation. Except for the proper exercise of any
rights granted or reserved under other provisions of this Agreement, Purchaser
agrees that it shall keep confidential, and shall cause its officers, employees,
directors and counsel to keep confidential and shall not publish or otherwise
divulge to a Third Party, other than any agents of Purchaser, or use for itself,
unless Pfizer shall have given its prior written approval, during the Term and
for a period of ten years after the end of the Term, any information of a
proprietary nature relating to Pfizer's business or operations, including
non-public information concerning Pfizer's products, processes, customers and
suppliers and the products and processes of Pfizer's customers and suppliers,
furnished to Purchaser by Pfizer in connection with this Agreement (any of the
foregoing, "CONFIDENTIAL PFIZER INFORMATION"); provided, however, that Purchaser
shall have the right to disclose any Confidential Pfizer Information provided
hereunder if, in the reasonable opinion of Purchaser's legal counsel, such
disclosure is necessary (a) in connection with the securing of any governmental
approval necessary for the performance by Purchaser of any of its obligations
hereunder or under any other agreement with Pfizer or (b) for the purpose of
complying with government regulations. Purchaser shall notify Pfizer of
Purchaser's intent to make such disclosure of Confidential Pfizer Information
pursuant to the proviso of the preceding sentence sufficiently prior to making
such disclosure so as to allow Pfizer adequate time to take whatever action
Pfizer may deem to be appropriate to protect the confidentiality of Confidential
Pfizer Information.

                                       19
<PAGE>

         10.3     Permitted Disclosure or Use of Information. Nothing in this
Article 10 shall prevent disclosure or use of Confidential Purchaser Information
or Confidential Pfizer Information, as the case may be, that (a) is or has
become known to the public other than through a breach of this Agreement or (b)
lawfully was disclosed to the disclosing Party by a Third Party having the right
to disclose it.

         10.4     Use of Information to Perform Obligations Under this
Agreement. Within the limits set forth in this Article 10, each Party shall be
entitled at all times to use all Confidential Purchaser Information or
Confidential Pfizer Information, as the case may be, provided by the other Party
in order to perform its obligations under this Agreement.

                                   ARTICLE 11

                                  MISCELLANEOUS

         11.1     Force Majeure. No Party shall be liable to another for its
failure to perform any of its obligations hereunder caused by contingencies
beyond its control, including acts of God, fire, flood, wars, acts of terrorism,
sabotage, strike and government actions (other than actions prohibiting the sale
of the Products resulting from Pfizer's failure to supply Products in compliance
with the Specifications or cGMPs (i.e., failure to comply with 21 C.F.R. Parts
210 and 211) or otherwise resulting from Pfizer's failure to comply with any
applicable requirement of Law). Any Party asserting its inability to perform any
obligation hereunder for any such contingency shall promptly notify the other
Party of the existence of any such contingency and shall use its reasonably
diligent efforts to re-commence its performance of such obligation as soon as
commercially practicable.

         11.2     Assignment. None of the Parties may assign any of its rights
or obligations hereunder without the written approval of the other Party, such
approval not to be unreasonably withheld; provided, however, that the Parties
may assign any of their respective rights or obligations under this Agreement to
any of their respective Affiliates without the approval of the other Party, and
Pfizer may assign any of its rights and obligations under this Agreement to any
Third Party that purchases the Fajardo Plant without Purchaser's approval. This
Agreement shall be binding upon and inure to the benefit of the successors and
assigns of each of the Parties.

         11.3     Independent Contractor. The Parties shall each be an
independent contractor in the performance of their respective obligations
hereunder. No Third Party, including any employee of any Party, shall have, or
acquire, any rights by reason of this Agreement.

         11.4     Notices. All notices or other communications hereunder shall
be deemed to have been duly given and made if in writing and if served by
personal delivery upon the Party for whom it is intended, if delivered by
registered or certified mail, return receipt requested, or by a national courier
service, or if sent by facsimile, provided that the facsimile is promptly
confirmed by telephone confirmation thereof, to the Person at the address set
forth below, or such other address as may be designated in writing hereafter, in
the same manner, by such Person.

                                       20
<PAGE>

         If to Pfizer:

                  Pfizer Inc.
                  235 East 42nd Street
                  New York, New York 10017
                  Attention: President, Pfizer Global Manufacturing
                  Facsimile No. (212) 672-7517

         with a copy to:

                  Pfizer Inc.
                  235 East 42nd Street
                  New York, New York 10017
                  Attention: Jeffrey Kindler, Esq.
                  Senior Vice President and General Counsel
                  Telephone No. (212) 733-4935
                  Facsimile No. (212) 808-8924

         If to Purchaser:

                  Galen (Chemicals) Limited
                  4 Adelaide Street
                  Dun Laoghaire, Co. Dublin
                  Attention: Senior Vice President, Finance
                  Telephone No. 011 353 1 214 8474
                  Facsimile No. 011 353 1 214 8477

         with a copy to:

                  Galen Holdings PLC
                  100 Enterprise Drive
                  Rockaway, New Jersey  07866
                  Attention: Senior Vice President, Corporate Development,
                  General Counsel and Corporate Secretary
                  Telephone No. (973) 442-3371
                  Facsimile No. (973) 442-3316

         11.5     Governing Law. This Agreement shall be governed by and
construed in accordance with the Laws of the State of New York, regardless of
the Laws that might otherwise govern applicable principles of conflicts of Laws
thereof. With respect to any suit, action or proceeding relating to this
Agreement (each, a "PROCEEDING"), each Party irrevocably (i) agrees and consents
to be subject to the jurisdiction of the United States District Court for the
Southern District of New York or any New York State court sitting in New York
City and (ii) waives any objection which it may have at any time to the laying
of venue of any Proceeding brought in any such court, waives any claim that such
Proceeding

                                       21
<PAGE>

has been brought in an inconvenient forum and further waives the right to
object, with respect to such Proceeding, that such court does not have any
jurisdiction over such Party.

         11.6     Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, and all of which shall
constitute one and the same agreement.

         11.7     Headings. The heading references herein are for convenience
purposes only, do not constitute a part of this Agreement and shall not be
deemed to limit or affect any of the provisions hereof.

         11.8     Modifications. This Agreement contains the entire
understanding and agreement between the Parties as to the supply of the Products
hereunder. It may not be amended or modified, except by a written instrument
executed by the Parties.

         11.9     Cumulative Effect. The rights and obligations of the Parties
under this Agreement shall be cumulative to and not exclusive of the rights and
obligations of the Parties contained in the Purchase Agreement.

         11.10    Sales and Use Taxes. Purchaser shall be responsible for the
payment of any sales and use taxes on the Products delivered by Pfizer to
Purchaser.

         11.11    Severability. In the event that any one or more of the
provisions contained herein, or the application thereof in any circumstances, is
held invalid, illegal or unenforceable in any respect for any reason, the
Parties shall negotiate in good faith with a view to the substitution therefor
of a suitable and equitable solution in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid provision;
provided, however, that the validity, legality and enforceability of any such
provision in every other respect and of the remaining provisions contained
herein shall not be in any way impaired thereby, it being intended that all of
the rights and privileges of the Parties shall be enforceable to the fullest
extent permitted by Law.

                                       22
<PAGE>

         IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of
the day and year first above written.

                           PFIZER INC.,

                           By:______________________________________________
                              Name:
                              Title:

                           GALEN (CHEMICALS) LIMITED,

                           By:______________________________________________
                              Name:
                              Title:

                                       23<PAGE>

                                                                    EXHIBIT 4.34

                              COPROMOTION AGREEMENT

                  THIS AGREEMENT is made, effective as May 1, 2003, by and
between BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation ("BMS"), and GALEN
(CHEMICALS) LIMITED, a corporation of the Republic of Ireland ("Galen").
Capitalized terms not otherwise defined in the text of this Agreement shall have
the meanings set forth in Article 1 of this Agreement.

                              W I T N E S S E T H:

                  WHEREAS, BMS has received FDA clearance to market the Vitamin
D3 analog MC 903/calcipotriene under the trademark "Dovonex(R)"; and

                  WHEREAS, Galen is engaged in the business of marketing
pharmaceutical products to physicians; and

                  WHEREAS, BMS wishes to engage Galen to assist in the promotion
of Dovonex(R) to certain physicians, and Galen desires to have the right to
copromote said product to such physicians, upon the terms specified herein.

                  NOW, THEREFORE, in consideration of the mutual covenants
herein set forth, and intending to be legally bound hereby, the Parties hereto
agree as follows:

ARTICLE 1 - DEFINITIONS.

                  For purposes of this Agreement, the following terms shall have
the corresponding meanings set forth below:

                           "Actual Demand-Based Mail Order Net Sales" means, for
an applicable accounting period, the Demand-Based Mail Order Gross Sales for
such accounting period times the Gross to Net Factor for such accounting period.

                           "Actual Demand-Based Other Net Sales" means, for an
applicable accounting period, the Demand-Based Other Gross Sales for such
accounting period times the Gross to Net Factor for such accounting period.

                           "Actual Demand-Based Retail Net Sales" means, for an
applicable accounting period, the Demand-Based Retail Gross Sales for such
accounting period times the Gross to Net Factor for such accounting period.

                           "Actual Demand-Based Retail/MO Net Sales" means, for
an applicable accounting period, the sum of Actual Demand-Based Retail Net Sales
for such accounting period plus the Actual Demand-Based Mail Order Net Sales for
such accounting period.

<PAGE>

                           "Actual Net Sales from All Segments" means the sum of
Actual Demand-Based Retail/MO Net Sales and Actual Demand-Based Other Net Sales.

                           "Advertising and Promotional Costs" or "A&P Costs"
means those costs that are reasonably incident to the advertising and promotion
of the Product in the Territory, including without limitation, costs incurred:

                           (i)      to develop and distribute reasonable and
         customary selling and A&P Materials that have been approved by the JEC
         relating to the use of the Product, including without limitation field
         literature, Direct to Consumer (DTC) advertising campaigns, and
         media/journal advertising; provided, that any costs associated with the
         distribution of A&P Materials by a Party to its Sales Force Personnel
         shall be at such Party's own expense and shall not be included within
         Advertising and Promotion Costs; and

                           (ii)     to develop and implement symposia and
         medical educational programs and related materials, as well as Managed
         Care Organization (MCO) pull-through and promotional programs, relating
         to the Product; and

                           (iii)    to develop and copy training/motivation and
         communications materials relating to the Product; and

                           (iv)     to develop, conduct and obtain market
         research analyses and materials relating to the Product; and

                           (v)      to develop and coordinate public relations
         for the Product, including convention costs and promotional premiums;
         and

                           (vi)     to develop, publish, and disseminate
         publications relating to the Product; and

                           (vii)    to obtain Product samples and ship the same
         to a Party's central distribution facility (it being understood that
         any costs associated with the distribution of Product samples by a
         Party from its central distribution facility to its own Sales Force
         Personnel shall be at such Party's own expense and shall not be
         included within Advertising and Promotion Costs); and

                           (viii)   to develop and conduct micro-marketing
         programs (which are defined as customary dinner, lunch and other
         meeting programs conducted by Sales Force Personnel) implemented by
         Sales Force Personnel.

For purposes of subparts (i) - (vi) of this definition, the term "Advertising
and Promotional Costs" means the out-of-pocket costs and expenses paid by BMS,
Galen or their respective Affiliates to a Third Party, as the case may be (and a
reasonable charge for internal copying

                                       2
<PAGE>

expenses). For purposes of subpart (vii) of this definition, the cost to a Party
of obtaining Product samples shall be the Manufacturing Cost therefor incurred
by BMS or Galen in accordance with Section 3.4, as the case may be, and shall
include any sales/use taxes, if any, associated with the distribution or use of
the samples. For purposes of subpart (viii) of this definition, the term
"Advertising and Promotion Costs" means the out-of-pocket costs of
micro-marketing programs conducted by BMS or Galen. Except as set forth in the
definition of "Manufacturing Cost", for purposes of clarity, the Parties
acknowledge that "Advertising and Promotion Costs" do not include the costs and
overhead associated with Galen's Sales Force Personnel, BMS' Sales Force
Personnel or other employees of BMS and/or Galen responsible for performance of
this Agreement. The term "Advertising and Promotional Costs" or "A&P Costs" as
it relates to Galen shall include any such costs reimbursed to BMS by Galen.

                           "Affiliate" means, with respect to any Person, any
other Person which is controlled by, controlling or under common control with,
the specified Person, with "control" meaning direct or indirect beneficial
ownership or control of more than fifty percent (50%) of the voting stock of
such corporation or other business entity.

                           "Agreement" means this agreement, together with all
appendices, exhibits and schedules hereto, and as the same may be amended or
supplemented from time to time hereafter by a written agreement duly executed by
authorized representatives of each Party hereto.

                           "Agreement Quarter" means each three-month period
commencing on the first day of January, April, July, or October, as the case may
be, during the Copromotion Term; provided, that the first Agreement Quarter
shall commence on the Effective Date and end on June 30, 2003.

                           "Agreement Year" means each 12-month period
commencing on January 1 and each anniversary thereof during the Copromotion
Term; provided, that the first Agreement Year shall commence on the Effective
Date and end on December 31, 2003.

                           "AMP", as used in Exhibit 11.1.4, means the Average
Manufacturer's Price per topical gram (as finally calculated by BMS quarterly
for Medicaid processing) for a given presentation of the Product.

                           "A&P Material" has the meaning set forth in Section
3.2.2 hereof.

                           "Baseline Agreement Year Prescriptions"," Baseline
Semi-Annual Prescriptions", "Baseline Quarterly Prescriptions", "Baseline Mail
Order Prescriptions", and "Baseline Retail Prescriptions", shall have the
meaning set forth in Exhibit 11.1.5 hereof.

                           "Baseline Demand-Based Mail Order Gross Sales" for
any accounting period means the Weighted Average Mail Order Selling Price per
mail order prescription for such period times the Baseline Mail Order
Prescriptions for the Product for such period.

                                       3
<PAGE>

                           "Baseline Demand-Based Retail/MO Gross Sales" for any
accounting period means the sum of Baseline Demand-Based Retail Gross Sales and
Baseline Demand-Based Mail Order Gross Sales for such period.

                           "Baseline Demand-Based Retail Gross Sales" for any
accounting period means the Weighted Average Retail Selling Price per retail
prescription for such period times the Baseline Retail Prescriptions for the
Product for such period.

                           "Baseline Demand-Based Retail/MO Net Sales" means,
for an applicable accounting period, the Baseline Demand-Based Retail/MO Gross
Sales times the Gross to Net Factor for such accounting period.

                           "BMS Know-How" means all proprietary information that
is now or may hereafter during the term of this Agreement be controlled by BMS
or any of its Affiliates regarding the Compound or the Product.

                           "Call" means a face-to-face contact (including a live
video presentation or group presentations to Prescribing Professionals), between
a professional sales representative of the applicable Party during which a
Primary Position Detail or Secondary Position Detail is made to a Prescribing
Professional or other healthcare professionals or entities that have a
significant impact/influence on prescribing decisions including, but not limited
to Managed Health Care Organizations, in each case as measured by each Party's
internal recording of such activity; provided that such meeting is consistent
with and in accordance with the procedures customarily employed by such Party's
professional sales representatives responsible for performing such activities
for the majority of its other pharmaceutical products, consistently applied.
With respect to certain group or institutional Product presentations, Exhibit
1.1 sets forth how such presentations will be counted for determination of the
number of Details.

                           "Call List" means those Prescribing Professionals in
the Territory to whom Galen will be responsible for detailing the Product.

                           "Competing Product" has the meaning set forth in
Section 2.4 hereof.

                           "Compound" means the crystalline vitamin D3 analogue
MC 903 that is licensed to BMS under the LEO License Agreement.

                           "Combination Product" means any Product that contains
the Compound in combination with one or more other pharmaceutically active
ingredients, excluding Dovobet.

                           "Confidential Information" has the meaning set forth
in Article 15 hereof.

                           "Controlled by" means, with respect to any product,
information or intellectual property right, that the applicable Party or Person,
in whole or in part, owns or has a

                                       4
<PAGE>

license to such product, information or intellectual property right and has the
ability to grant access or a license (or a sublicense), as applicable, without
violating the terms of any agreement or other arrangements with any Third Party
existing at the time such Party or Person would be first required to grant such
access, license or sublicense.

                           "Copromotion Term" has the meaning set forth in
Section 13.1 hereof.

                           "Demand-Based Government Gross Sales" means the
demand-based gross sales reported by BMS based on internally recorded sales
figures for this segment for the Product for a given accounting period.

                           "Demand-Based Hospital/MHC Gross Sales" means the
demand-based gross sales reported by IMS Provider Perspective for Hospital and
IMS Provider Perspective for Managed Healthcare to these segments for the
Product for a given accounting period.

                           "Demand-Based Mail Order Gross Sales" means, for an
applicable accounting period, the total mail order prescriptions for the Product
reported by IMS National Prescription Audit for a given period, multiplied by
the Weighted Average Mail Order Selling Price for such period.

                           "Demand-Based Nursing Home Gross Sales" means the
demand-based gross sales reported by IMS Provider Perspective for Nursing Homes
to this segment for the Product for a given accounting period.

                           "Demand-Based Other Gross Sales" means, for an
applicable accounting period, the sum of Puerto Rico Gross Sales, plus
Demand-Based Government Gross Sales, plus Demand-Based Hospital/MHC Gross Sales,
plus Demand-Based Nursing Home Gross Sales.

                           "Demand-Based Retail Gross Sales" means, for an
applicable accounting period, the total retail prescriptions for the Product
reported by IMS National Prescription Audit for a given period, multiplied by
the Weighted Average Retail Selling Price for such period.

                           "Diligent Efforts" means the carrying out of
obligations or tasks in a manner consistent with the efforts a Party devotes to
its other products of similar market potential, profit potential or strategic
value resulting from its own internal research efforts, based on conditions then
prevailing.

                           "Dovobet" means a pharmaceutical preparation
containing both the Compound and the steroid betamethasone dipropionate, in all
dosage forms, formulations, presentations and line extensions.

                           "Dovobet(R) Product" means any prescription
pharmaceutical product which is a presentation of Dovobet(R).

                                       5
<PAGE>

                           "Effective Date" means May 1, 2003.

                           "Execution Date" means the date this Agreement is
signed by the last party to sign.

                           "ERISA" means the Employee Retirement Income Security
Act of 1974, as amended.

                           "FDA" means the U.S. Food and Drug Administration.

                           "FD&C Act" means the Federal Food, Drug and Cosmetic
Act, as amended, and all applicable regulations thereunder.

                           "Galen Improvements" means any inventions,
developments, modifications or improvements to the Product or the Compound which
are made by Galen or any of its Affiliates during the term of this Agreement (x)
as a result of research activities conducted by or for it or its Affiliates
relating to the Product or the Compound or (y) through the use of BMS Know-how,
whether patentable or registerable or not, except as any of the foregoing may
relate solely to Dovobet(R) and not any other Product or product.

                           "Galen Know-How" means all proprietary information
regarding the Compound or the Product that is now or may hereafter during the
Copromotion Term be controlled by Galen or any of its Affiliates, except as any
of the foregoing may relate solely to Dovobet(R) and not any other Product or
product.

                           "Governmental or Regulatory Authority" means any
court, tribunal, arbitrator, agency, commission, official or other
instrumentality of any federal, state, county, city or other political
subdivision, foreign or domestic.

                           "Gross to Net Factor", for a given accounting period,
means a fraction (x) the numerator of which is the sum of Demand-Based Retail
Gross Sales, plus Demand-Based Mail Order Gross Sales, plus Demand-Based Other
Gross Sales, less Total Discounts for such accounting period, and (y) the
denominator of which is the sum of Demand-Based Retail Gross Sales, plus
Demand-Based Mail Order Gross Sales, plus Demand-Based Other Gross Sales for
such accounting period.

                           "Gross Margin Percentage" for a given accounting
period, means a fraction, (A) the numerator of which represents (i) Actual Net
Sales from All Segments during such accounting period, less (ii) the
Manufacturing Cost of the Product represented by such Actual Net Sales from All
Segments for such accounting period, less (iii) the royalties due LEO on such
Actual Net Sales from All Segments during such accounting period, and (B) the
denominator of which represents Actual Net Sales from All Segments during such
accounting period. As of the Effective Date the Gross Margin Percentage equals
seventy percent (70%).

                                       6
<PAGE>

                           "IMS" means (x) IMS Health Incorporated and its
successors or (y) such other internationally recognized market research firm
(including, without limitation, NDC Health) to which Galen and BMS may mutually
agree to in writing.

                           "IND" means an Investigational New Drug Application,
as defined in the FD&C Act and applicable regulations promulgated thereunder as
amended from time to time, filed in the United States.

                           "Law" means all laws, statutes, rules, regulations,
ordinances and other pronouncements or orders having the effect of law of any
Governmental or Regulatory Authority.

                           "LEO" means LEO Pharmaceuticals Products, Ltd. A/S
(Lovens Kemiske Fabrik Produktionsaktieselskab), a corporation organized under
the laws of Denmark), and having an address at Industriparken 55, DK-2750
Ballerup, Denmark.

                           "LEO License Agreement" means the agreement between
E.R. Squibb & Sons, Inc. and LEO for the development and commercialization of
products containing the Compound in the Licensed Territory within the
dermatological field dated September 28, 1989, as heretofore amended by
amendments thereto dated as of July 6, 1992 and April 8, 1993, and as the same
may be amended or supplemented in the future, subject to Section 2.3.3.

                           "LEO Supply Agreement" means the agreement between
Bristol-Myers Squibb Company and LEO for the supply of finished and packaged
products containing the Compound in the Licensed Territory for use within the
dermatological field dated April 8, 1993, as amended heretofore, and as the same
may be amended or supplemented in the future, subject to Section 2.3.3.

                           "LEO Patents" means those pending patent applications
and issued patents owned by LEO having claims covering the Product and are
licensed to BMS under the LEO License Agreement.

                           "Manufacturing Cost" for Product samples, as well as
for any Product and any comparators (whether active or placebo) supplied for use
in any Phase IV and later clinical trial, means: (i) if and to the extent the
Product or comparator is manufactured, finished or packaged, in whole or in
part, by BMS and/or any of its Affiliates, the direct costs incurred in
manufacturing, finishing, and packaging same, plus BMS' fully-absorbed
allocation of indirect and overhead expenses connected therewith (including
without limitation manufacturing and charges in the nature of depreciation and
amortization of capitalized costs of manufacturing equipment and facilities and
reasonable allocation of idle capacity), as determined in accordance with U.S.
generally accepted accounting principles, consistently applied), (ii) if and to
the extent the Product or comparator is manufactured for BMS or any of its
Affiliates by a Third Party, in whole or in part, the costs (including
applicable royalties) actually charged by the Third Party to BMS or such
Affiliate for same.

                                       7
<PAGE>

                           "Minimum Annual PDE and Minimum Semi-Annual PDEs"
shall have the meaning under Section 3.5.1 of this Agreement.

                           "Minimum Quarterly PDEs" has the meaning set forth in
Section 3.5.1 hereof.

                           "NDA" means a New Drug Application, as defined in the
United States Federal Food, Drug and Cosmetic Act and applicable regulations
promulgated thereunder as amended from time to time, filed in the United States.

                           "NDA Approval" means the marketing clearance granted
by the FDA required for the marketing and promotion of the Product in the United
States.

                           "NDCHealth" means National Data Corporation, a
leading healthcare information services company.

                           "Net Weighted Average Mail Order Selling Price" per
mail order prescription for a given period means the Weighted Average Mail Order
Selling Price for a given accounting period, times the Gross to Net Factor for
such accounting period.

                           "Net Weighted Average Retail Selling Price" per
retail prescription for a given period means the Weighted Average Retail Selling
Price for a given accounting period, times the Gross to Net Factor for such
accounting period.

                           "Party" means Galen or BMS, as the case may be.

                           "Patents" means all patents and patent applications
in the Territory which are or become Controlled by BMS or any of its Affiliates
which patents generically or specifically claim the composition or use of any
Product in the Territory, including without limitation all continuations,
continuations-in-part, divisions, patents of addition, reissues, renewals,
substitutions, registrations, confirmations or extensions thereof.

                           "PDMA" means the Prescription Drug Marketing Act of
1987, as amended (as such may be subsequently modified and including any
applicable implementing regulations).

                           "Performance Compensation" has the meaning set forth
in Article 11 hereof.

                           "Person" means an individual, corporation,
partnership, limited liability company, trust, business trust, association,
joint stock company, joint venture, pool, syndicate, sole proprietorship,
unincorporated organization, Governmental or Regulatory Authority, or any other
form of legal entity not specifically listed herein.

                                       8
<PAGE>

                           "Phase IV Study" means (i) any Phase IV clinical
study (including without limitation opinion leader studies) pertaining to the
Product that are sponsored by BMS or any of its Affiliates in the Territory or
conducted by or through BMS in the Territory, or (ii) any pharmacoeconomic study
relating to the Product that are sponsored by BMS or any of its Affiliates in
the Territory or conducted by or through BMS in the Territory.

                           "Phase IV Study Costs" means all costs and other
payments for any Phase IV Study that are incurred by a Party or any of its
Affiliates in the Territory, plus the Manufacturing Cost of all Product and any
comparators (including active comparators and placebo) supplied in connection
with such Studies.

                           "Prescribing Professional" means (x) physicians and
osteopaths and (y) any nurse practitioners, physicians' assistants, and other
healthcare professionals where any of the foregoing in (y) have prescribing
authority under applicable Law.

                           "Primary Position Detail" means a promotional message
involving a full Product presentation delivered during a Call by a Party's
professional sales representatives in which key Product attributes are verbally
presented in the first position, consistent with the terms of this Agreement,
where such Product is given primary emphasis (i.e., an emphasis that is more
important than the emphasis given to any other product presented), and where no
more than three products are presented during such Call.

                           "Primary Detail Equivalent" or "PDE" means either one
Primary Position Detail or two Secondary Position Details.

                           "Product" means (x) all current pharmaceutical
preparations for human use in final topical dosage forms which contain the
Compound as a therapeutically active ingredient that have been approved for use
and sale in the Territory as of the Effective Date by any relevant Governmental
or Regulatory Authority in the Territory, and any line extensions thereof; and
(y) all future pharmaceutical preparations for human use in final dosage forms
which contain the Compound as a therapeutically active ingredient, but excluding
Dovobet(R), that are approved by any Governmental or Regulatory Authority in the
Territory during the Copromotion Term of this Agreement, and that (i) BMS is
able to promote, and has accepted to promote, under the LEO License Agreement
during the Copromotion Term and (ii) Galen has accepted in writing to co-promote
under this Agreement.

                           "Product Registration" has the meaning set forth in
Section 10.3 hereof.

                           "Promotion" means those activities normally
undertaken by a professional sales representative of a pharmaceutical company to
implement promotion plans for a particular prescription pharmaceutical product
aimed at encouraging the appropriate use of such product by a health care
professional with actual prescribing authority. When used as a verb, "Promote"
means to engage in such activities.

                                       9
<PAGE>

                           "Promotion Plan" means the then current plan for the
Promotion of the Product in the Territory and which is described in more detail
in Section 3.3.

                           "Puerto Rico Demand Based Gross Sales" means the
amount of factory gross sales of the Product reported by BMS' divisional
Affiliate in Puerto Rico.

                           "Regulatory Approvals" means the required approval of
the applicable Governmental or Regulatory Authority.

                           "Sales Force Personnel" means a Party's and/or its
Affiliates' sales force representatives and their managers (whether the same be
employees or, subject to the terms of Section 3.5.2 of this Agreement,
independent contractors of a Party) that are involved in the Promotion of the
Product in the Territory.

                           "Secondary Position Detail" means a promotional
message involving a Product that is delivered in the second position during a
Call by a Party's professional sales representatives, consistent with the terms
of this Agreement, where such Product is given significant emphasis (i.e., an
emphasis that is at least or more important than the emphasis given to any other
product presented (other than the product that is presented as the Primary
Position Detail)), and where no more than three products are presented during
such Call.

                           "Semi-Annual Periods" means the half-years comprising
(a) the first and second Agreement Quarter and (b) the third and fourth
Agreement Quarter of each Agreement Year.

                           "Serious Adverse Event" and "Non-Serious Adverse
Event" have the meanings set forth in Section 9.7 hereof.

                           "Territory" means the fifty (50) states of the United
States of America and the District of Columbia, and any U.S. possessions and
territories.

                           "Third Party(ies)" means any Person other than: (1)
Galen and BMS and (2) any Affiliates of Galen and BMS.

                           "Total Discounts" for an accounting period means the
following costs and expenses reasonably incurred by BMS with respect to the
Product, to the extent not reimbursed by a Third Party:

                  (i)      trade, quantity and cash discounts or rebates
                           actually and lawfully granted or given and any other
                           similar adjustments, including, without limitation,
                           those granted on account of price adjustments,
                           billing errors, rejected goods, and damaged goods;

                  (ii)     price reductions, credits, rebates, product returns,
                           charge-backs and prime

                                       10
<PAGE>

                           vendor rebates, fees, reimbursements or similar
                           payments or adjustments actually granted or given to
                           wholesalers and other distributors, buying groups,
                           health care insurance carriers, pharmacy benefit
                           management companies, health maintenance
                           organizations or other institutions or health care
                           organizations; and

                  (iii)    price reductions, credits, rebates, product returns,
                           charge-backs and prime vendor rebates, fees,
                           reimbursements or similar payments or adjustments
                           actually granted or given in connection with Product
                           sales to any Governmental or Regulatory Authority in
                           respect of any state or federal Medicare, Medicaid or
                           similar programs.

Notwithstanding the foregoing, in the event that the "Incentive Discounts"
granted in the aggregate for all presentations of Dovonex in the Territory for a
given Agreement Quarter exceed fifteen percent (15%) or more of the
corresponding gross sales (based on list price) of Dovonex in such Agreement
Quarter, then, for purposes of calculating the compensation due Galen under this
Agreement for such Agreement Quarter only, the aggregate amount of Incentive
Discounts that may be taken into account in determining Total Discounts for such
Agreement Quarter shall equal 15% of such gross sales (based on list price), and
the Total Discounts for such Agreement Quarter shall equal such 15% figure plus
such other amounts (e.g., product returns) as may be deducted under (i)-(iii).
For purposes of the preceding sentence, "Incentive Discounts" shall mean all
discounts granted under (i), (ii) and (iii) above and any price reductions below
the Dovonex list price for a given presentation as such list price for such
presentation exists on the Effective Date (or, for any new presentations
hereafter, as it is first priced for commercial sale), but excluding such
discounts, credits, or rebates that relate to matters such as product returns,
rejected or damaged goods, billing errors, and the like (which may still be
taken into account in determining Total Discounts for a given Agreement
Quarter); provided, that where the list price for a given presentation is
reduced by BMS below the list price for such presentation as of the Effective
Date, the 15% threshold shall be determined by reference to such list price as
of the Effective Date and not the then lower current list amount. For sake of
clarity and example, if the price for a given presentation of Dovonex is
$100/gram as of the Effective Date, then BMS is entitled as of the Effective
Date to grant $15 of Incentive Discounts before the excess above that figure
must be taken into account in determining whether BMS has exceeded the 15%
threshold in the aggregate for all presentations. If a year later: (A) the price
of the presentation has dropped to $90, then BMS would be entitled as of the
Effective Date to grant only an additional $5 of Incentive Discounts before the
excess above that figure must be taken into account in determining whether BMS
has exceeded the 15% threshold in the aggregate for all presentations, and (B)
the price of the presentation has increased to $110, then BMS would be entitled
as of the Effective Date to grant $16.50 of Incentive Discounts before the
excess above that figure must be taken into account in determining whether BMS
has exceeded the 15% threshold in the aggregate for all presentations.

An example calculation showing the determination of the maximum Incentive
Discounts is attached as Exhibit 11.1.6 hereto. The usual and customary
discounts and deductions described

                                       11
<PAGE>

above will be consistent with those used by BMS in determining net sales of its
pharmaceutical products for external reporting purposes.

                           "Trademark" means the Dovonex(R) trademark and any
other trademark or trade name (whether registered or unregistered) used on or
with the Product or in any A&P Material related to the Product in the Territory
during the Copromotion Term (other than the name and logo of BMS, Galen or any
of their respective Affiliates), subject to the terms of this Agreement.

                           "Valid Claim" means a composition of matter claim, or
method of use claim (or its equivalent) of an issued and unexpired Patent in the
Territory which is owned or controlled by BMS, which covers the Compound and/or
the Product, and which (i) has not been revoked or held unenforceable or invalid
by a decision of a Governmental or Regulatory Authority of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal; and
(ii) has not been abandoned, disclaimed, or admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise.

                           "Weighted Average Mail Order Selling Price" per mail
order prescription is calculated in the manner shown on Exhibit 11.1.4.

                           "Weighted Average Retail Selling Price" per retail
prescription is calculated in the manner shown on Exhibit 11.1.4.

ARTICLE 2 - GRANT OF RIGHTS TO GALEN; BMS RESERVED RIGHTS; NON-COMPETITION; LEO
            LICENSE AGREEMENT; RIGHT TO CROSS-REFERENCE.

         Section 2.1 Engagement of Galen to Promote. BMS hereby grants to Galen
the co-exclusive right (exclusive except as to BMS and its Affiliates), to
Promote the Product during the Copromotion Term, within the Territory, upon the
terms and conditions set forth in this Agreement. Galen's co-promotion rights
under this Agreement shall be exclusive as to any other Third Party within the
Territory, and BMS may not, without the prior written consent of Galen (not to
be unreasonably withheld) or except as provided in Section 3.5.2, enter into any
agreement with a Third Party to Promote or market the Product in the Territory,
during the Copromotion Term. Galen shall have the right to enter into any
written agreement with one or more of its Affiliates with respect to any right,
representation, warranty, or obligation of Galen under this Agreement; provided,
that Galen shall remain jointly and severally liable and responsible with such
Affiliate for the performance of any obligations, representations or warranties
delegated, contracted, assigned or otherwise transferred. Galen shall not
Promote or market the Product except in accordance with the rights expressly
granted to it under, and in accordance with the terms of, this Agreement.

         Section 2.2 BMS Reserved Rights. BMS reserves all rights not expressly
granted

                                       12
<PAGE>

under this Agreement. Galen agrees that it will not practice any rights reserved
by BMS that are not expressly granted to Galen under this Agreement.

         Section 2.3 Compliance with LEO License Agreement; Amendments.

                  2.3.1 Compliance with License Agreement. To the extent not
encompassed by the terms of this Agreement, Galen shall abide by all applicable
terms of the LEO License Agreement as are communicated to it by BMS in writing,
and any conflict between this Agreement and the LEO License Agreement shall be
governed by and subject to the terms in the LEO License Agreement.

                  2.3.2 Maintenance of License Agreement. BMS agrees that, with
respect to any rights or licenses granted to it under the LEO License Agreement,
BMS shall perform and observe in all material respects all of its duties and
obligations under the LEO License Agreement that are required to maintain in
effect such licenses or rights, and shall otherwise use commercially reasonable
efforts to maintain the LEO License Agreement; provided that the foregoing shall
not be construed to require that BMS maintain the LEO License Agreement if (x)
generic competition has entered the Territory for the Product, (y) LEO has
materially breached its obligations under the LEO License Agreement and BMS is
entitled under the terms of the LEO License Agreement to terminate such
agreement, or (z) LEO has materially breached its obligations under the LEO
Supply Agreement and BMS consequently is entitled to terminate the LEO License
Agreement pursuant to Article XIII(C) thereof.

                  2.3.3 Amendment of License Agreement. BMS agrees not to amend
the LEO License Agreement or the LEO Supply Agreement in a manner that would
materially adversely affect Galen rights and obligations under this Agreement
without Galen's prior written consent (not to be unreasonably withheld).

         Section 2.4 Noncompetition.

                  2.4.1 Subject to Section 2.5.1, during the Copromotion Term
         and for six (6) months thereafter, Galen and its Affiliates shall not
         market, Promote or sell within the Territory any other drug product
         that has received marketing clearance from the FDA for psoriasis
         treatment or prevention and which is either (x) a topical vitamin D(3)
         or vitamin D(3) analog or (y) a fixed combination of vitamin D(3) or
         any vitamin D(3) analog with a corticosteriod (a "Competing Product");
         provided, that

                           2.4.1.1 said six-month post-Copromotion Term
                  restriction shall be inapplicable if the Copromotion Term
                  shall have expired under Section 13.1.1, the term of this
                  Agreement has expired or otherwise been terminated pursuant to
                  Section 13.2.1, or this Agreement shall have been terminated
                  pursuant to any of Sections 11.6, 13.2.2, 13.2.3, 13.2.5,
                  13.3.1, 13.3.7 or 13.5 (where Galen is the terminating Party
                  due to BMS insolvency);

                                       13
<PAGE>

                           2.4.1.2 this Section 2.4 shall not apply to (i)
                  Dovobet, or (ii) or to any other product for which prior
                  written approval has been granted by a Vice-President (or
                  higher) within BMS; and

                           2.4.1.3 this Section 2.4 shall not apply in the event
                  that, and from and after the date that, Galen purchases the
                  NDA and Trademarks for the Product from BMS.

         For sake of clarity and avoidance of doubt, a corticosteroid shall not
be considered a Vitamin D(3) analog for purposes of the determination of whether
a product is a Competing Product. For sake of clarity and avoidance of doubt,
any breach by Galen and/or its Affiliates of the terms of this Section 2.4
shall, in addition to any remedies to which BMS may have hereunder or at law or
in equity, entitle BMS to terminate this Agreement upon thirty (30) days' prior
written notice to Galen, unless Galen, within such 30-day period, ceases the
breaching activity (or causes its Affiliate(s) to cease such breaching activity)
and provides reasonable assurances to BMS that it will not happen again during
the Copromotion Term. In the event that Galen or any of its Affiliates breaches
this provision a second time during the Copromotion Term, BMS shall be entitled
to terminate this Agreement upon thirty (30) days' prior written notice to
Galen, but without any opportunity on the part of Galen to cure such breach and
prevent such termination.

         The Parties further agree that the marketing, promotion and/or sale of
a Competing Product in the Territory by Galen and/or its Affiliates in breach of
this Section 2.4 may cause irreparable injury to BMS for which monetary damages
alone may not be an adequate remedy. In the event of such breach, BMS shall be
entitled to seek, upon petition to a court of competent jurisdiction and without
resort to any dispute resolution procedures as may be provided for in this
Agreement, equitable relief to prevent such breach, in addition to any remedies
it may have hereunder or at Law.

                  2.4.2 Subject to Section 2.5.2, during the Copromotion Term
BMS and its Affiliates shall not market, Promote, or sell within the Territory
any Competing Product.

         Section 2.5 Effect of Acquisition of Competing Product.

                  2.5.1 In the event that during the Copromotion Term:

                           2.5.1.1 a Person becomes an Affiliate of Galen, or

                           2.5.1.2 Galen or any of its Affiliates merges or
         consolidates with any Third Party,

(each of the foregoing, a "Triggering Event"), and such Person or Third Party
(or any Affiliate of such Person or Third Party) is then marketing a Competing
Product in the Territory, then, within thirty (30) days after the applicable
Triggering Event, Galen shall notify BMS in writing of such

                                       14
<PAGE>

circumstances and shall notify BMS in writing (the date that both such notices
are received by BMS is referred to as the "Notice Date") as to whether:

                           2.5.1.3 the Competing Product will be divested by
         Galen (or the applicable Galen Affiliate, or such Third Party or such
         Third Party's Affiliate) within the Territory; or

                           2.5.1.4 Galen elects to terminate this Agreement,
         which termination shall be effective on the later of one hundred eighty
         (180) days after the Notice Date and December 31, 2005, unless BMS
         notifies Galen within ninety (90) days after the Notice Date that the
         termination will be effective on an earlier date, provided that such
         date is not less than one hundred eighty (180) days after the Notice
         Date.

If no such written notice is timely received by BMS, then this Agreement shall
terminate on the later of two hundred forty (240) days after the Triggering
Event and December 31, 2005, unless BMS notifies Galen within one hundred twenty
(120) days after the Triggering Event either that the termination will be
effective on an earlier date, provided that such date is not less than two
hundred forty (240) days after the Triggering Event, or that BMS elects to waive
such termination, in which event, BMS shall not be entitled to terminate this
Agreement thereafter with respect to such Competing Product. If this Agreement
is to be terminated as a result of a Triggering Event, Galen and BMS shall each
continue to perform its duties under this Agreement in accordance with the terms
hereof until the actual termination date, provided, however, that the marketing
of a Competing Product by Galen or such Affiliate or Third Party during the
period extending from the Triggering Event until the actual termination date
shall not be considered a breach by Galen of its obligations under this
Agreement.

         If Galen informs BMS that such Competing Product will be divested, then
Galen (or such Third Party or Affiliate) shall use commercially reasonable and
diligent efforts to divest itself of such Competing Product in a manner
consistent with reasonable business judgment and to complete such divestiture of
the Competing Product as promptly as practicable following notification to BMS
of the decision to divest. Galen shall have until the date that is twelve (12)
months after the applicable Triggering Event to complete such divestiture (the
"Grace Period"); provided, that, so long as Galen demonstrates to BMS'
reasonable satisfaction that Galen used commercially reasonable and diligent
efforts to effect such divestiture within such 12-month Grace Period, but was
unable reasonably to effect such divestiture, then such 12-month Grace Period
shall be extended for such additional reasonable period thereafter as is
necessary to enable such Competing Product to be in fact divested. Galen (or
such Third Party or Affiliate) shall keep BMS reasonably informed of its efforts
and progress in effecting such divestiture until it is completed, and shall
provide a written summary of such efforts quarterly during such 12-month Grace
Period, and if applicable, monthly thereafter. Subject to the foregoing, the
marketing of a Competing Product by Galen or such Affiliate or Third Party
during the period extending from notification to BMS of the decision to divest
until the completion of the divestiture shall not be considered a breach by
Galen of its obligations under this Agreement.

                                       15
<PAGE>

                  2.5.2 In the event that during the Copromotion Term:

                           2.5.2.1 a Person becomes an Affiliate of BMS, or

                           2.5.2.2 BMS or any of its Affiliates merges or
         consolidates with any Third Party,

and such Person or Third Party (or any Affiliate of such Person or Third Party)
is then marketing a Competing Product in the Territory, then BMS (or the
applicable BMS Affiliate, or such Third Party or such Third Party's Affiliate)
may continue to market such Competing Product within the Territory thereafter
without BMS being deemed in violation of Section 2.4.2.

                  2.5.3 Nothing in this Section 2.5 is intended to affect
Galen's or BMS' obligations, covenants, warranties, representations set forth in
other sections of this Agreement.

ARTICLE 3 - PROMOTION, COMMERCIALIZATION AND DISTRIBUTION OF PRODUCT

         Section 3.1 General Diligence Obligation. Subject to the terms and
conditions of this Agreement, Galen will exercise Diligent Efforts to Promote
the Product in the Territory during the Copromotion Term in accordance with the
Promotion Plan, the Product labeling, the guidelines then approved by the Joint
Executive Committee, the terms of this Agreement, and applicable Law. All such
activity shall occur at Galen's sole expense except as may otherwise be
expressly provided by this Agreement.

         Section 3.2 Joint Executive Committee.

                  3.2.1 Joint Executive Committee.

                           3.2.1.1 Promptly after the Effective Date, the
         Parties shall form a Joint Executive Committee ("JEC") comprised of
         three (3) individuals, two (2) of which shall be appointed by BMS and
         one of which shall be appointed by Galen and all of whom shall be
         qualified to appropriately represent such Party. The JEC shall be
         chaired by one of the two (2) BMS representatives. Additional employees
         of either Party or its Affiliates may attend the JEC meeting as
         non-voting members on an ad hoc basis as deemed necessary or
         appropriate by such Party; consultants or contractors assisting a Party
         may attend only with the prior consent of the other Party's members of
         the JEC (such consent not to be unreasonably withheld). The chairperson
         of the JEC shall be responsible for preparation and distribution of the
         minutes of each JEC meeting. Such minutes shall memorialize decisions
         made by the JEC, but shall avoid details relating to discussions and
         general matters not involving decisions. Minutes of meetings shall be
         disseminated to committee members not later than ten (10) business days
         following any meeting of the JEC. All JEC meeting minutes shall,
         following review by the Parties and agreement of their contents, be
         countersigned on behalf of each Party as evidence of acceptance of the

                                       16
<PAGE>

         correctness of such minutes.

                           3.2.1.2  The JEC will be used as the forum for the
                                    Parties to provide input to each other, to
                                    enable the Parties to approve the Promotion
                                    Plan and monitor its progress and to enable
                                    the Parties to monitor each Party's
                                    compliance with its obligations under this
                                    Agreement, excluding those matters that are
                                    specifically reserved exclusively to the
                                    sole discretion of BMS or Galen under this
                                    Agreement. The JEC will focus on the overall
                                    business plan and positioning strategies for
                                    the Product, shall approve the Promotion
                                    Plan and material changes thereto. The JEC
                                    shall meet at least twice each year during
                                    the Copromotion Term (and more frequently if
                                    necessary), to discuss the actual results of
                                    the promotion of the Product in the
                                    Territory by the Parties as compared to the
                                    Promotion Plan, approve the Promotion Plan
                                    for the next succeeding Agreement Year and
                                    to discuss any other matters pertaining to a
                                    Party's performance of its Promotion
                                    obligations under this Agreement; provided,
                                    that it is understood that the first meeting
                                    of the JEC shall be held as soon as
                                    practical after the Execution Date. Meetings
                                    of the JEC shall be held alternately at a
                                    location designated by each Party or as the
                                    members of the JEC may agree. JEC meetings
                                    may not necessarily be face-to-face
                                    meetings, but upon unanimous agreement of
                                    the JEC, can be via other methods of
                                    communication, such as teleconferences
                                    and/or videoconferences. Subject to the
                                    terms and conditions of this Agreement,
                                    decisions of the JEC shall be by majority
                                    vote of a quorum of its members (with each
                                    of the three members having one vote), with
                                    a quorum constituting at least one voting
                                    representative of each Party. The majority
                                    vote provision under the preceding sentence
                                    shall not, however, apply: (A) where this
                                    Agreement specifically requires unanimous
                                    written consent of both Parties for a given
                                    matter to be decided by the JEC, (B) to
                                    matters involving a breach of this
                                    Agreement, and (C) as provided in Section
                                    3.2.4.2 hereof.

                           3.2.1.3  Each Party shall bear the costs of its
                                    representatives attending and participating
                                    in meetings of the JEC.

                  3.2.2 Regulatory Approvals. BMS shall have strategic
responsibility and sole authority and responsibility for obtaining and
maintaining all Regulatory Approvals that are related to the Product. and,
except where BMS has delegated this responsibility to Galen in writing, that are
related to the use of promotional and advertising materials or programs ("A&P
Materials") prepared or approved by the JEC. BMS hereby delegates to Galen the
authority and responsibility for obtaining all Regulatory Approvals that are
related to the use of promotional and advertising materials or programs
contained in the approved Promotion Plan. Galen shall

                                       17
<PAGE>

provide BMS with a copy of such A&P Materials at least fifteen (15) days prior
to first submission of the A&P Materials to FDA or first printing of same
(whichever is earlier). In the event that BMS has an objection to the content of
any such material or programs, BMS shall notify Galen within such fifteen (15)
day period. If BMS does not object within such fifteen (15) day period, Galen
shall be entitled to use such A&P Materials. Any reasonable changes recommended
by BMS must be incorporated into the A&P Materials. Galen will promptly notify
BMS of any warning/untitled letters received from DDMAC and provide BMS with
copies of all communications with FDA and information on resolution of the
matter.

                  3.2.3 Formulary Relationships. BMS shall retain sole
responsibility in its sole discretion for all contractual relationships for the
Product with formularies (including managed care and hospital), insurers, and
Governmental or Regulatory Authorities (including without limitation Medicare,
Medicaid, the Veterans Administration, and military entities). Galen will
consult with BMS with respect to strategy for obtaining and maintaining
contractual/formulary relationships for the Product with such entities, and will
consult with and assist BMS in obtaining entry into such entities for the sale
of the Product and subsequent pull-through of the Product.

                  3.2.4 No Adverse Change to Galen Rights Without Galen Consent.
Notwithstanding any term or condition of this Agreement that may state or imply
to the contrary:

                           3.2.4.1 Galen shall not be required to follow the
         Promotion Plan or any decision or guideline determined or promulgated
         by BMS or the JEC where Galen believes in good faith based on opinion
         of counsel that doing so would conflict in any material way with its
         obligations under applicable Law; and

                           3.2.4.2 No Promotion Plan, or any decision or
         guideline promulgated by BMS or the JEC, may materially adversely
         affect any of Galen's obligations, rights or benefits under this
         Agreement, or require Galen to spend any funds or reimburse or absorb
         any costs that are not expressly provided for under this Agreement,
         without Galen's prior written consent.

                  3.2.5 Cost and Control of Sales Forces. Except as otherwise
specifically provided in this Agreement, each Party shall be solely responsible
for the costs and expenses of establishing and maintaining its Sales Force
Personnel and conducting its other activities under this Agreement, and shall
have sole authority to control and direct the activities of the Sales Force
Personnel used by it to Promote the Product in the Territory in accordance with
its obligations hereunder and the terms of this Agreement.

                                       18
<PAGE>

         Section 3.3 Promotion Plan. Subject to Section 4.1:

                  3.3.1 Approval by JEC. All advertising, promotion, selling and
other commercialization activities contemplated for the Product for a given
Agreement Year (and each Agreement Quarter in such Agreement Year) shall be set
forth to the extent practical in the Promotion Plan for the Product. The
approved Promotion Plan for the first Agreement Year is attached hereto as
Exhibit 3.3.1. For each subsequent Agreement Year, Galen shall prepare the
Promotion Plan for such Agreement Year and deliver a copy thereof to BMS on or
before August 15 of the preceding Agreement Year. The Promotion Plan for any
Agreement Year, and all material changes or supplements thereto, must be
approved by the JEC before such Plan, change or supplement shall be deemed
effective; provided, that if Galen has delivered the Promotion Plan to BMS on or
before August 15 and the JEC has not approved the Promotion Plan by January 1 of
the Agreement Year covered by the Promotion Plan, and such failure is not due to
the unavailability of Galen representatives, then Galen shall be entitled to
rely on the Promotion Plan submitted in order to perform its promotion
obligations under this Agreement until such time as the JEC approves such
Promotion Plan or a modified Promotion Plan. JEC approval shall not be required
for implementation of the details of advertising, promotion, selling or other
commercialization activities where the activity and the overall budget for such
activity was approved by the JEC as part of the Promotion Plan; provided, that
if the JEC believes any activity was not authorized by the Promotion Plan or
that the implementation of an authorized activity is not appropriate in any way,
the JEC may specify the given activity and implementation details that should be
curtailed or modified.

                  3.3.2 Content of Promotion Plan. Subject to applicable terms
of this Agreement, the Promotion Plan will focus principally on the Promotion of
the Product by Galen in the Territory, and will include matters such as:

                           3.3.2.1 the Call plan, including total Calls and the
         target prescribers;

                           3.3.2.2 the breakdown of budgeted A&P Costs into the
         following categories: samples, A&P Materials and literature, medical
         education, market research, conventions, agency fees, and
         micro-marketing programs;

                           3.3.2.3 Product positioning and overall strategies
         and tactics, including promotional claims that may be made about the
         Product;

                           3.3.2.4 the quantity and timing of samples of
         Product(s) to be made available to Galen's sales forces for use in the
         Territory and the strategy/processes for the provision of same within
         the Territory; and

                           3.3.2.5 the level of marketing and other support for
         the Product, if any, to be provided directly by BMS.

                                       19
<PAGE>

In the event of any conflict between this Agreement and the terms of any
Promotion Plan, the terms of this Agreement shall control.

         Section 3.4 Product Samples. The following terms shall apply to the
manufacture, use and distribution of Product samples in the Territory during the
Copromotion Term:

                  3.4.1 Quantity. Galen shall determine a reasonable level of
samples to be provided to its Sales Force for use in the Territory. As samples
must be ordered by BMS from LEO, BMS will provide to Galen in writing such
forecasting, advance notice, and ordering requirements as BMS will require to
ensure timely manufacture of the samples by LEO and delivery of such samples to
Galen, which requirements BMS will provide to Galen in writing upon execution of
this Agreement and which may be amended by BMS upon reasonable notice from time
to time. Such requirements may be changed by BMS for future orders upon written
notice to Galen. Galen will order a sufficient number of samples for each
Agreement Year as are reasonably necessary to ensure that it meets its Diligent
Efforts obligations hereunder and that will provide adequate and effective
support for achievement of the Baselines in each Agreement Year. The number of
samples approved as part of the applicable Promotion Plan shall be deemed to be
adequate for purposes of this Section 3.4.1.

                  3.4.2 Title. Title to the samples shall remain with BMS, and
Galen shall be responsible for such sales/use taxes, if any, associated with the
distribution or use of the samples.

                  3.4.3 Distribution of Samples to Galen. BMS shall be
responsible for the delivery of Product samples to be provided to Galen under
the Promotion Plan to one central distribution point designated by Galen. The
storage of Product samples at the Galen central distribution point and the
distribution of samples to Galen Sales Force Personnel shall be at Galen's sole
expense.

                  3.4.4 Sample Cost. Galen shall pay BMS for all Product samples
provided by BMS to Galen at the Manufacturing Cost therefore, plus the cost of
shipping such samples to Galen's central distribution point, payment to be due
and payable within thirty (30) days after the later of (x) receipt by Galen of
an invoice therefor or (y) receipt of the samples.

                  3.4.5 Compliance with Prescription Drug Marketing Act. Each
party will ensure that its marketing and Promotion of the Product shall comply
with all requirements of applicable Law, including without limitation, the PDMA.
Such compliance shall include, without limitation, maintenance of written
procedures designed to ensure that its Sales Force Personnel marketing the
Product in the Territory comply with the PDMA; provided, that if both Parties so
agree in writing, the Parties will comply with any proposed implementing
regulation (or portion thereof) with respect to any Promotional activity under
this Agreement.

                  Each Party shall use Diligent Efforts to ensure that its Sales
Force Personnel comply with such written procedures. Each Party shall provide
the other Party with a copy of its procedures for review and comment, it being
understood that the content of a Party's procedures

                                       20
<PAGE>

shall be the sole responsibility of such Party. Such procedures shall include a
requirement that each Party shall be responsible for reporting directly to the
FDA any known thefts or significant losses of samples and other reportable
incidents as set forth in the PDMA, as the same is required by then applicable
Law during the Copromotion Term, and each Party shall promptly provide the other
written notice that a report has been made and a complete copy of any such
report. Furthermore, such procedures shall include a requirement that Galen will
notify BMS promptly after Galen learns that any samples shipped by BMS to Galen
have been lost or have not been received as scheduled or damaged in transit,
such that BMS will have a reasonable period of time to enable it to comply with
all applicable legal requirements with respect to such samples. Galen shall
promptly inform BMS of any violations of its written procedures or the PDMA by
its Sales Force Personnel.

                  BMS shall be entitled, at its expense and upon reasonable (but
not less than ten (10) business days) advance written notice to Galen, to
conduct an inspection and audit of Galen's compliance with this Section 3.4.5 at
any of its or its Affiliates' owned or controlled facilities in the Territory
where Product samples are stored. The purpose of such inspection and audit shall
be solely to ensure compliance by Galen with respect to the applicable
provisions of the PDMA as they apply to Galen's duties and obligations under
this Agreement and at Law, as well as to copy records relating to Product sample
receipt, storage and distribution.

         Section 3.5 Sales Force Deployment. The following terms shall apply to
promotion of Product(s) in the Territory by Galen and BMS under this Agreement:

                  3.5.1 Minimum PDEs.

                           3.5.1.1 During each Agreement Year, Galen shall
         provide at least Sixty-Five Thousand (65,000) internally reported PDEs
         within the Territory for the Product to the Prescribing Professionals
         indicated on the Call List (the "Minimum Annual PDEs"). Unless
         otherwise unanimously agreed upon by all members of the JEC, during
         each semi-annual period of each Agreement Year, Galen shall provide at
         least Thirty-two Thousand Five Hundred (32,500) internally reported
         PDEs within the Territory for the Product to the Prescribing
         Professionals indicated on the Call List (the "Minimum Semi-Annual
         PDEs"). Unless otherwise unanimously agreed upon by all members of the
         JEC, during each Agreement Quarter, Galen shall provide at least
         Sixteen Thousand Two Hundred Fifty (16,250) internally reported PDEs
         within the Territory for the Product to the Prescribing Professionals
         indicated on the Call List (the "Minimum Quarterly PDEs"). Where
         applicable, the foregoing figure shall be proportionately adjusted
         based on the actual number of days in the applicable period as a result
         of early termination of the Copromotion Term, of termination of the
         Copromotion Term other than at the end of an Agreement Year,
         Semi-Annual Period or Agreement Quarter, and/or for the initial
         Agreement Year being shorter than twelve months. At least seventy-five
         percent (75%) of Galen's Minimum Quarterly PDE requirements shall be
         delivered as Primary Position Details, with the balance delivered as
         Second Position Details. BMS shall not be entitled

                                       21
<PAGE>

         to terminate this Agreement for any Galen failure to miss the minimums
         except as set forth in Section 3.5.1.3.

                           3.5.1.2 It is understood that BMS does not have any
         minimum annual PDE obligations and may provide no PDEs in its
         discretion without affecting Galen's rights, benefits or obligations
         hereunder.

                           3.5.1.3 BMS may terminate this Agreement as set forth
                                   herein in the event that:

                                    3.5.1.3.1 In any Agreement Year, Galen does
                           not provide at least ninety percent (90%) of its
                           Minimum Annual PDEs; or

                                    3.5.1.3.2 In any two consecutive Agreement
                           Quarters, during the Copromotion Term, Galen does not
                           provide at least ninety percent (90%) of its Minimum
                           Quarterly PDEs; or

                                    3.5.1.3.3 If in any Agreement Year, at least
                           seventy-five percent (75%) of Galen's Minimum Annual
                           PDE requirements are not delivered as Primary
                           Position Details, with the balance delivered as
                           Second Position Details.

         For purposes of Sections 3.5.1.3.1 and 3.5.1.3.2 and for purposes of
         determining whether Galen has met its obligations under section
         3.5.1.1, (x) any PDEs that exceed one hundred ten percent (110%) of the
         Minimum Quarterly PDEs required for a given Agreement Quarter shall not
         be taken into account, and (y) any Calls made to Prescribing
         Professionals who are not part of the Call List shall not be taken into
         account.

         Any termination by BMS under this Section 3.5.1.3 with respect to a
         shortfall in a given Agreement Year or two consecutive Agreement
         Quarters must be made by BMS by written notice delivered to Galen
         within ninety (90) days after BMS is informed by Galen in writing of
         such shortfall or breach. The effective date of any such termination
         shall be specified by BMS in its written notice of termination but such
         date shall be not later than one hundred eighty (180) days after
         delivery of the written notice of termination to Galen, unless
         otherwise mutually agreed in writing. Any such termination shall also
         be subject to applicable provisions of Article 13. Galen shall continue
         to perform in accordance with the terms of this Agreement during the
         period between notice of termination and the actual termination date.

                           3.5.1.4 If, during any Semi-Annual period during any
         Agreement Year of the Copromotion Term, Galen delivers less than one
         hundred percent (100%) of the total Minimum PDEs required of it for
         such Semi-Annual period, the Performance Compensation due to Galen
         shall be adjusted as follows: the amount determined under Section
         11.1.1 for such Semi-Annual period shall be reduced by the percentage
         amount

                                       22
<PAGE>

         that such actual PDEs are deficient (e.g., if the Performance
         Compensation due Galen under Article 11 is Twenty Million U.S. dollars
         (U.S. $20,000,000), but only 92% of the Minimum Semi-Annual PDEs were
         performed in such Semi-Annual period, the Performance Compensation due
         Galen under Article 11 would be reduced by the deficient percentage,
         i.e., eight percent (8%), to Eighteen Million Four Hundred Thousand
         U.S. dollars (U.S. $18,400,000). This remedy shall be in addition to
         any termination of this Agreement that may be exercised by BMS pursuant
         to Sections 3.5.1.3, but otherwise this reduction shall be BMS' sole
         and exclusive remedy for damages incurred by it by reason of any such
         shortfall.

                  3.5.2 Use of Independent Contractors and Part-Time
         Representatives.

                           3.5.2.1 Galen agrees not to use any independent
         contractors to provide any of its Minimum Annual PDEs without the prior
         written consent of BMS or approval of the JEC. Galen will discuss its
         proposed independent contractor arrangements with the JEC. If the use
         of any independent contractors is approved by BMS or the JEC, Galen
         shall be jointly and severally liable with its Third Party contractee
         for any breach of this Agreement or failure to perform such delegated
         duties by such Third Party contractee (as well as for any breach by
         such Third Party contractee of its Agreement with Galen, as the case
         may be), and hereby unconditionally guarantees the performance by such
         Third Party contractee of, and shall cause such Third Party contractee
         to comply with the provisions of, this Agreement. All compensation,
         reimbursement of costs and other payments to be made for any Third
         Party contractee's services is solely a matter between Galen and such
         Third Party contractee.

                           3.5.2.2 For geographical reasons, as approved by the
         JEC, Galen's Sales Force(s) detailing the Product may retain part-time
         employees. The total number of these part-time individuals will be kept
         to a minimum, but in any event shall not exceed ten percent (10%) of
         the total number of Sales Force Personnel detailing the Product.

                  3.5.3 Disclosure of Internally Reported Calls; Auditing.

                           3.5.3.1 Disclosure of Internally Reported Calls.
         Galen shall report to BMS the actual number of Calls reported
         internally to Galen's management that are made by it within the
         Territory to Prescribing Professionals on its Call List during each
         month during the Copromotion Term, as well as the position (Primary or
         Secondary) of such Calls. Such internal reporting shall be determined
         in accordance with the procedures customarily employed by Galen for the
         majority of its other pharmaceutical products, consistently applied.
         Galen shall provide an interim report of the actual number of Calls
         made (and their position) in a given month to BMS within thirty (30)
         days after the end of such month and a final report within sixty (60)
         days after the end of the applicable month.

                           3.5.3.2 Audited Calls. BMS shall be entitled to
         obtain at its expense from IMS or other recognized service a report of
         the audited Calls provided by Galen under this

                                       23
<PAGE>

         Agreement. If permitted by such service, BMS shall promptly provide a
         copy of such report to Galen. BMS shall use reasonable efforts at its
         expense to secure IMS's or such other service's approval to providing
         the report to Galen. If the ratio of internally reported Calls to
         audited Calls is greater than 2:1 for any particular Agreement Quarter,
         then the JEC shall investigate the discrepancy and whether the
         internally reported calls are being accurately reported, and each Party
         shall cooperate with any such investigation and allow the other Party
         to review pertinent records.

                           3.5.3.3 Auditing of a Party's Internal Call Records.
         BMS may demand an audit of Galen's relevant books and records in order
         to verify its reports on its internally reported PDEs used in
         calculating whether Galen has met its obligations under Section 3.5.1.
         in accordance with the provisions of Section 11.5.

         Section 3.6 Provisions Applicable to All Galen Sales Force Personnel.

                  3.6.1 Noncompliance by Representative. In the event that
information comes to BMS' attention which gives BMS a reasonable basis for
believing that any Galen Sales Force Personnel may have (i) violated any
applicable Laws or an applicable Galen policy, or (ii) failed to provide
satisfactory service or comply with this Agreement, BMS shall have the right to
request Galen immediately to address the performance of such individual, in
addition to any other rights or remedies available to BMS under this Agreement,
at law or in equity. Galen shall promptly use commercially reasonable efforts to
evaluate and resolve such issue in accordance with Galen policies or as it may
otherwise deem appropriate. Galen shall keep BMS informed of the progress of,
and information learned during, its evaluation, and shall provide BMS with a
reasonably detailed written report summarizing any steps taken toward resolution
of the matter within thirty (30) days after same.

                  3.6.2 Equal Opportunity Employer. Unless exempted from such
compliance, Galen will comply with all applicable Laws in the hiring,
employment, and discharge of all Galen Sales Force Personnel. Galen represents
to BMS that Galen is an Equal Opportunity Employer and does not discriminate
against any person because of race, color, creed, age, sex, or national origin.

                  3.6.3 Compliance with Galen Policies. All Galen Sales Force
Personnel shall execute or shall previously have executed an agreement with
Galen, that includes, among other terms, appropriate language under which the
individual:

                           3.6.3.1 agrees to perform his or her obligations as
                  part of the Galen sales force and to use and account for
                  Product samples as required by Law including without
                  limitation, the PDMA and any applicable final FDA regulations,
                  and this Agreement; and

                           3.6.3.2 agrees to perform his/her duties in
                  accordance with Galen internal policies, a copy of which is
                  provided or made available by Galen to all its Sales

                                       24
<PAGE>

                  Force Personnel.

                  3.6.4 Worker's Compensation Insurance. Galen acknowledges and
agrees that BMS does not and will not maintain or procure any worker's
compensation insurance for or on behalf of Galen or its Sales Force Personnel,
all of which shall be Galen's sole responsibility.

                  3.6.5 Confidentiality and Inventions Agreement with Galen. All
Galen Sales Force Personnel and any other employee or contractor of Galen or its
Affiliates who comes into contact with any BMS Confidential Information shall
have first executed an appropriate agreement with Galen that includes
appropriate language under which the individual is bound to maintain
confidentiality of any Confidential Information disclosed by BMS on terms
consistent with Galen's obligations hereunder. All Galen Sales Force Personnel
and any other employee of Galen or its Affiliates who comes into contact with
any BMS Confidential Information (including BMS Know-how or LEO Know-how) shall
have first executed an appropriate agreement with Galen under which such
individual is bound to assign to Galen all his/her rights, title and interests
in any inventions made by such individual during the Copromotion Term relating
to any Galen Improvements described in Section 3.11; with respect to independent
contractors coming into contact with such BMS Confidential Information, Galen
shall use commercially reasonable efforts to obtain a corresponding assignment
of rights.

                  3.6.6 No Participation in BMS Benefit Plans. Galen
acknowledges and agrees that all Galen Sales Force Personnel are not, and are
not intended to be or be treated as, employees of BMS or any of its Affiliates,
and that such individuals are not, and are not intended to be, eligible to
participate in any benefits programs or in any "employee benefit plans", as such
term is defined in section 3(3) of ERISA, that are sponsored by BMS or any of
its Affiliates or that are offered from time to time by BMS or its Affiliates to
their own employees (the "BMS Benefit Plans"). All matters of compensation,
benefits and other terms of employment for any such personnel shall be solely a
matter between Galen and such individual. Galen shall be solely responsible and
liable for the payment of all compensation and benefits under any such employee
benefit plan to its Sales Force Personnel.

                           BMS shall not be responsible to Galen or to its Sales
Force Personnel used by it to Promote the Product for any compensation, expense
reimbursements or benefits (including, without limitation, vacation and holiday
remuneration, healthcare coverage or insurance, life insurance, pension or
profit-sharing benefits and disability benefits), payroll-related taxes or
withholdings, or any governmental charges or benefits (including without
limitation unemployment and disability insurance contributions or benefits and
workmen' compensation contributions or benefits) that may be imposed upon or be
related to the performance by Galen and its Sales Force Personnel of its
obligations under this Agreement, all of which shall be the sole responsibility
of Galen, even if it is subsequently determined by any court, the IRS or any
other Governmental or Regulatory Authority that such individual may be a common
law employee of BMS or any of its Affiliates.

                                       25
<PAGE>

                  3.6.7 Responsibility for Acts and Omissions of its Personnel.
Galen shall be solely responsible for its acts and omissions and for those acts
or omissions of its Sales Force Personnel while performing any of the services
to be provided by Galen under this Agreement.

                  3.6.8 Indemnification for Employee Reclassification.

                           3.6.8.1 Galen will indemnify, defend, and hold
         harmless BMS and its Affiliates, and its and their directors, employees
         and agents (collectively, the "BMS Indemnitees") from and against any
         damages, liability, loss and costs that may be paid or payable by any
         such BMS Indemnitee resulting from or in connection with any claim or
         other cause of action asserted by any Galen Sales Force Personnel, or
         by any Third Party (including without limitation Governmental or
         Regulatory Authorities) arising out of the execution and/or performance
         of this Agreement that is based on or with respect to:

                                    3.6.8.1.1 costs, damages and losses that BMS
                  or its Affiliates may incur resulting from any claims for
                  benefits that any Galen Sales Force Personnel may make under
                  or with respect to any BMS Benefit Plan; and

                                    3.6.8.1.2 any payment or obligation to make
                  a payment to any Galen Sales Force Personnel relating in any
                  way to any compensation, benefits of any type under any
                  employee benefit plan (as such term is defined in Section 3(3)
                  of ERISA), and any other bonus, stock option, stock purchase,
                  incentive, deferred compensation, supplemental retirement,
                  severance and other similar fringe or employee benefit plans,
                  programs or arrangements that may be sponsored at any time by
                  BMS or any of its Affiliates or by Galen or any of its
                  Affiliates, even if it is subsequently determined by any
                  court, the IRS or any other Governmental or Regulatory
                  Authority that any Galen Sales Force Personnel may be a common
                  law employee of BMS or any of its Affiliates; and

                                    3.6.8.1.3 the payment or withholding of any
                  contributions, payroll taxes, or any other payroll-related
                  item by or on behalf of Galen or any of its Sales Force
                  Personnel with respect to which Galen or any of its Sales
                  Force Personnel may be responsible hereunder or pursuant to
                  applicable Law to pay, make, collect, withhold or contribute,
                  even if it is subsequently determined by any court, the IRS or
                  by any other Governmental or Regulatory Authority that any
                  such Sales Force Personnel may be a common law employee of BMS
                  or any of its Affiliates; and

                                    3.6.8.1.4 failure of Galen to withhold or
                  pay required taxes or failure to file required forms with
                  regard to compensation paid to Galen by BMS and compensation
                  and benefits paid or extended by Galen to its Sales Force
                  Personnel.

                           3.6.8.2 Notwithstanding anything to the contrary in
         Section 3.6.8.1 above,

                                       26
<PAGE>

         Galen shall have no liability to any BMS Indemnitee to the extent
         attributable to any discriminatory, harassing or retaliatory acts of
         BMS or any BMS Indemnitee, or any tortious acts (including without
         limitation acts constituting assault, battery or defamation) by BMS or
         any BMS Indemnitee, with respect to any Galen Sales Force Personnel.

                           3.6.8.3 Nothing contained in this Section 3.6.8 is
         intended to affect or limit any Performance Compensation payable by BMS
         to Galen for the services rendered by Galen pursuant to this Agreement.

                  3.6.9 Galen Responsibility for Disciplinary Actions of Its
Employees. Galen shall be solely responsible and liable for all probationary and
termination actions taken by it, as well as for the formulation, content, and
for the dissemination (including content) of all employment policies and rules
(including written probationary and termination policies) applicable to its
employees and contractors.

                  3.6.10 Reassignment. Removal or reassignment of any Galen
Sales Force Personnel, including managers, to other Galen sales forces will be
made in a manner that does not disrupt or jeopardize Galen's ability to meet its
obligations under this Agreement.

         Section 3.7 Promotional and Advertising Responsibilities.

                  3.7.1 Overall Responsibility. Subject to Sections 3.2.2 and
3.3.1, all A&P Materials and literature to be used by Galen in the Territory in
connection with the promotion of the Product shall be subject to review and
approval of same by BMS prior to any use thereof. Galen shall submit samples of
such materials to BMS for its prior review and approval. BMS shall inform Galen
of its approval or rejection of such materials within fifteen (15) business days
of their receipt by BMS. If BMS does not approve or reject the materials within
such fifteen (15) business day period, then approval of such materials shall be
deemed granted by BMS, unless and until BMS subsequently notifies Galen in
writing that the materials may not be used. If BMS or the JEC requests that
Galen modify (or cease using) previously approved materials or literature or
modify (or not use) materials and literature submitted for review, Galen shall
promptly undertake to comply with same. BMS shall provide to Galen the rationale
under which BMS shall request that any materials or literature be modified or
cease being (or not be) used, and whether or not Galen agrees with BMS'
rationale, Galen shall promptly comply with BMS' request and not use any
materials and literature that have not been approved in writing (or been deemed
approved in writing) by BMS or the JEC. Galen shall be solely responsible for
all fees payable to any Governmental or Regulatory Authority in connection with
the review and approval of any such A&P Materials and literature and for all
costs incurred by either Party in connection with the development, preparation,
copying and dissemination of A&P Materials and literature, provided, that Galen
shall only be required to supply or bear the cost of one color reproduction of
any such A&P Materials and literature for BMS' review and that any additional
copies may be black and white photocopies. Notwithstanding the foregoing, in the
event that, subsequent to (i) the deemed approval of A&P Materials or literature
by BMS (or product positioning messages, pursuant to

                                       27
<PAGE>

Section 3.7.7), BMS notifies Galen that it may not use such A&P Materials and/or
literature (or product positioning messages) or (ii) the approval of A&P
Materials or literature (or product positioning messages) by BMS, BMS requests
that Galen modify or cease using previously approved A&P Materials or literature
(or product positioning message), BMS shall promptly reimburse Galen for its out
of pocket cost incurred in connection with changing and reproducing such A&P
Materials or literature (or product positioning message) and, with retrieving
such materials from the field; provided, that such reimbursement obligation
shall not apply if BMS' subsequent notification or request is required because
of a change in the package insert or NDA, by a change in applicable Law or a new
Law.

                  3.7.2 Galen Duties. During the Copromotion Term:

                           3.7.2.1 Galen agrees to instruct its Sales Force
         Personnel to use, and to use Diligent Efforts to monitor its Sales
         Force Personnel to ensure that such Sales Force Personnel use, only A&P
         Materials, Product samples, and literature approved by Galen and BMS
         under this Agreement for the promotion of the Product in the Territory;
         and

                           3.7.2.2 Any A&P Material, literature, and Product
         samples approved by BMS or supplied by BMS shall not be misbranded,
         changed, altered or adulterated prior to their distribution or use by
         Galen or its Sales Force Personnel; and

                           3.7.2.3 Galen will instruct its Sales Force Personnel
         to, and will use Diligent Efforts to monitor its Sales Force Personnel
         so that such personnel will:

                                    3.7.2.3.1 limit claims of efficacy and
                  safety for Product in the Territory to those that are
                  consistent with the promotional claims permitted by the
                  Promotion Plan and that are consistent in all material
                  respects with the FDA-approved prescribing information for the
                  Product in the Territory and with applicable Law;

                                    3.7.2.3.2 not add, delete or modify claims
                  of efficacy and safety in the Promotion of the Product under
                  this Agreement in any respect from those claims of efficacy
                  and safety that are contained in the Promotion Plan and in any
                  manner that would be inconsistent in any material respect with
                  the FDA-approved prescribing information and with applicable
                  Law;

                                    3.7.2.3.3 not make any changes in A&P
                  Materials and literature approved by BMS, except in accordance
                  with Section 3.7.1;

                                    3.7.2.3.4 use A&P Materials, literature, and
                  samples in the Territory in a manner that is consistent with
                  the Promotion Plan and only in furtherance of this Agreement;
                  and

                                       28
<PAGE>

                                    3.7.2.3.5 Promote the Product under this
                  Agreement in adherence in all material respects to the
                  Promotion Plan and to applicable legal requirements, as well
                  as the American Medical Association Gifts to Physicians From
                  Industry Guidelines.

                  3.7.2.4 Galen will be solely responsible and liable for any
         failure by its Sales Force Personnel to use only those A&P Materials,
         Product samples, and literature approved by Galen and BMS (or deemed
         approved by BMS) under this Agreement for the promotion of the Product
         in the Territory, for any misbranding, change, or alteration of any A&P
         Material or literature by Galen or its Sales Force Personnel that was
         not expressly approved in writing by BMS, for any alteration,
         misbranding or adulteration of any Product Samples by Galen or its
         Sales Force personnel, and for any failure of Galen or any of its Sale
         Force Personnel to comply with any of sections 3.7.2.3.1-3.7.2.3.5
         hereof.

                  3.7.3 Minimum Advertising and Promotional Spending.. During
the Copromotion Term, and subject to the terms of this Agreement, Galen agrees
to spend not less than Five Million dollars ($5,000,000) in each Agreement Year
on Advertising and Promotion Costs for the Product in accordance with the
Promotion Plan approved by the JEC; provided, that such $5,000,000 figure shall
be prorated for any Agreement Year that is less 365 days based on the number of
days in the actual Agreement Year divided by 365. If Galen breaches the
preceding sentence, then BMS may terminate this Agreement, unless the failure to
spend was attributable to the JEC's failure to approve such advertising and
promotion programs as would have enabled Galen to spend such $5,000,000 in such
preceding Agreement Year or, unless BMS and Galen shall have reached written
agreement on application of the underspend to a succeeding Year (with BMS being
under no obligation, express or implied, to agree to same).

                  3.7.4 Reimbursement by Galen of Advertising and Promotion.
Galen will reimburse BMS for any A&P Costs incurred by BMS after the Effective
Date where such Advertising and Promotion Costs incurred by BMS were requested
in writing by Galen or involve A&P Costs incurred by BMS that were approved in
advance by unanimous approval of all members of the JEC; provided, that the
foregoing shall not require JEC approval for individual budget line items or
implementation of the details of an advertising and promotion program as a
condition of reimbursement where the overall budget for such program was
unanimously approved by the JEC. Except for the foregoing, any other A&P Costs
incurred by BMS shall be the responsibility of BMS.

                  Any reimbursement amount due BMS shall be deducted on a
quarterly basis from the Performance Compensation payments due Galen under
Article 11 and shall be reconciled, or trued up, semi-annually. If there is not
sufficient Performance Compensation due Galen to cover such reimbursement of A&P
Costs to BMS, Galen shall make payment of the deficiency within thirty (30) days
after presentation by BMS of an invoice detailing the charges and deficiency.
BMS will provide a statement to Galen within sixty (60) days after the end of
each Agreement Quarter, identifying in reasonable detail the Advertising and
Promotion Costs incurred by BMS in

                                       29
<PAGE>

such Agreement Quarter subject to reimbursement by Galen under this Section
3.7.4. The calculation of such Advertising and Promotion Costs and the
reconciliation thereof shall be subject to audit and inspection in accordance
with Article 11 hereof.

                  The preceding two paragraphs of this section 3.7.4 shall not
apply to reimbursement of Samples costs, which shall be governed by section
3.4.4.

                  3.7.5 BMS Commitment. It is understood that BMS has no
obligation, express or implied, to incur any A&P Costs or to engage in any
advertising and promotion activities on its own, except where the advertising
and promotion activities shall have been approved by the JEC.

                  3.7.6 Compliance by Applicable Law. Each Party will use
commercially reasonable efforts to ensure that promotional and education
materials and literature developed, approved, or used by it or its Affiliates
for the Product in the Territory during the Copromotion Term, and all Product
advertising in the Territory during the Copromotion Term (whether in print,
radio, television, Internet, or otherwise) developed, approved, or used by it or
its Affiliates, comply in all material respects with the FDA-approved labeling
for the Product and with applicable Law. Galen will use Diligent Efforts to
ensure that it develops, implements, and uses promotional and educational
materials and literature and advertising programs that are of a nature,
quantity, and quality sufficient to ensure that the Minimum Baselines are
achieved each Agreement Year.

                  3.7.7 Approval of Product Positioning Messages. All written,
electronic and visual communications provided by Galen to a majority of its
Sales Force Personnel detailing the Product for use by such personnel regarding
Product strategy, positioning or selling messages shall be subject to prior
review and approval by BMS, or subject to modification or cessation upon request
by BMS, in the same manner as promotional and advertising materials and
literature are handled pursuant to Section 3.7.1.

         Section 3.8 Market Research Data. During the term of this Agreement,
each Party shall provide the other with access to all lawfully available primary
and secondary (audited and non-audited) market research data for the Product
reasonably promptly if and after the same are made available to it and so long
as it has the lawful right to provide same to the other Party; provided, that
the recipient Party shall hold such information in confidence until made
publicly available by the providing Party or by the Third Party source providing
same, and shall have executed such confidentiality agreement as may be requested
by such Third Party with respect to such disclosure of such information to it.

         Section 3.9 Medical Education Programs. Medical education programs for
the Product in the Territory may be approved by the JEC in the applicable
Promotion Plan or by the JEC on an ad hoc basis. Galen shall not be obligated to
conduct any medical education programs and symposia for the Product except as
set forth in the approved Promotion Plan or as approved by the JEC. All such
Medical Education Programs shall be conducted at Galen's sole expense, and Galen
shall reimburse BMS for any A&P Costs incurred by BMS as part of such medical

                                       30
<PAGE>

education programs in accordance with Section 3.7.4.

         Section 3.10 Clinical Trials. Except as set forth on Exhibit 3.10:

                  3.10.1 Control of Clinical Trials. Except as set forth in
Section 3.10.3, BMS shall have sole responsibility for the sponsorship, conduct
and termination of any clinical trials (including all Phase IV Studies) relating
to the Product. It is understood that BMS shall have no obligation, express or
implied, to Galen to incur any Phase I-IV study costs or to sponsor or conduct
any Phase I-IV studies for the Product and that Galen has no obligation, express
or implied, to propose any Phase IV Studies or to reimburse BMS for costs
incurred in connection with sponsoring and conducting any such Phase IV Study
other than those proposed or approved by Galen; provided, however, that:

                           3.10.1.1 BMS shall, through the JEC, provide Galen
         with a reasonable opportunity to design and present for BMS or JEC
         approval a program of Phase IV Studies relating to the Product that
         will be sponsored by BMS or its Affiliates in the Territory (it being
         understood that BMS, as the NDA holder, must remain responsible for
         sponsoring and conducting Phase IV Studies, although either BMS or
         Galen (as a CRO under contract with BMS) may monitor and supervise the
         studies). Galen shall be solely responsible for all fully-burdened
         costs incurred by Galen or BMS associated with sponsoring and
         conducting such Phase IV Studies proposed by Galen that are approved by
         BMS or the JEC, and will reimburse BMS for its fully-burdened costs
         incurred in sponsoring and conducting any such Phase IV Study.

                           3.10.1.2 BMS may also design and present Phase IV
         Studies for JEC approval as well. Galen shall have the opportunity to
         review and comment on the protocol for any such study. If the Galen
         members of the JEC approve the Phase IV Study proposed by BMS, then
         Galen shall reimburse BMS for its fully-burdened costs incurred in
         sponsoring and conducting any such Phase IV Study; if they do not so
         approve, BMS shall be responsible for its own costs incurred in
         sponsoring and conducting any such Phase IV Study.

                           3.10.1.3 Any reimbursement amount due BMS shall be
         deducted on a quarterly basis from the Performance Compensation
         payments due Galen under Article 11, and shall be reconciled, or trued
         up, semi-annually. If there is not sufficient Performance Compensation
         due Galen to cover such reimbursement of costs to BMS, Galen shall make
         payment of the deficiency within thirty (30) days after presentation by
         BMS of an invoice detailing the charges and deficiency. BMS will
         provide a statement to Galen within sixty (60) days after the end of
         each Agreement Quarter, identifying in reasonable detail the
         fully-burdened Phase I-IV Study Costs incurred by BMS in such Agreement
         Quarter subject to reimbursement by Galen under this Section 3.10.1.
         The calculation of such fully-burdened Phase I-IV Study Costs, and the
         reconciliation thereof, shall be subject to audit and inspection in
         accordance with Article 11 hereof.

                                       31
<PAGE>

                           3.10.1.4 Nothing in this Agreement shall limit or
         restrict BMS' ability to propose, sponsor or conduct any comparator
         studies in which the Product is compared to any other product or
         combination of products that is being developed or marketed by BMS.

                           3.10.1.5 As between BMS and Galen, notwithstanding
         the foregoing, Galen shall have no obligation or liability to BMS or
         any Third Party in connection with any sponsorship, conduct and
         termination of any clinical trials (including Phase IV Studies)
         relating to the Product, to the extent that (a) such study has
         commenced prior to the Effective Date, (b) BMS has executed an
         agreement with any Third Party in connection with such study prior to
         the Effective Date, or (c) BMS has awarded a grant to any Third Party
         in connection with any such study prior to the Effective Date.

                  3.10.2 Use of Data. During the term of this Agreement, without
the prior written consent of Galen (not to be unreasonably withheld), BMS shall
not use and disclose, and to permit others to use and disclose, for any purpose,
the data resulting from clinical studies relating to the Product conducted or
sponsored by either or both Parties (regardless of whether any of such costs are
reimbursed by Galen, in whole or in part), including, but not limited to, use in
the Product Registrations; provided, that, subject to BMS' obligations under
Article 15 hereof, the foregoing shall not apply to any study conducted after
the Effective Date that is sponsored or conducted by BMS or any of its
Affiliates in which the Product is compared to any other product or combination
of products being developed or marketed by BMS.

                  3.10.3 No Conduct of Studies of the Product or Combination
Product Without BMS Approval . Except as provided in Section 3.10.1, Galen will
not, and will cause its Affiliates not to, conduct any pre-clinical, clinical,
pharmacogenomic, or Phase IV Studies involving the Product or the Compound or
Combination Product using a Product or the Compound; provided, that the
foregoing shall not apply to any studies involving Dovobet. In the event that
Galen or its Affiliates wish to conduct or sponsor a clinical study comparing
Dovobet to Dovonex, whether singly or in combination with other products, Galen
shall provide BMS with a copy of the protocol and design for any such clinical
study in sufficient time prior to its submission to an IRB for approval so that
BMS shall have a reasonable opportunity to comment on the protocol and design
with respect to the scientific validity (e.g., in terms of safety or bias) and
applicable Law. Galen shall adopt such changes suggested by BMS as Galen may in
good faith believe to be necessary or desirable.

         Section 3.11 Improvements and Know-how.

                  3.11.1 In the event that Galen or any of its Affiliates make
any Galen Improvements during the Copromotion Term, such Galen Improvements
shall be promptly and fully advised to BMS in writing. Subject to Section
13.7.4, Galen hereby grants to BMS a non-exclusive, perpetual, irrevocable,
sublicensable, fully paid-up, right and license under Galen Know-How and Galen
Inventions to use same for any purpose anywhere in the world in connection with
the research, manufacture, use, sale, import, and offer for sale of the
Compound,

                                       32
<PAGE>

the Product, and any Combination Product, but no other products. Galen shall
not, and shall cause its Affiliates not to, register or permit to be registered
any industrial or intellectual property right embodying BMS' or LEO's
Improvements in any country without BMS' and LEO's prior written consent,
respectively. All rights, title and interests in any industrial or intellectual
property right applied for or obtained by Galen or its Affiliates in breach of
the preceding sentence shall be assigned gratis to BMS upon its request. From
time to time during the term of this Agreement (but not less frequently than
semi-annually), Galen shall furnish BMS with Galen Know-How that Galen or its
Affiliates acquires or develops.

         Section 3.12 Bonus Structure of Galen Sales Force Personnel. Galen's
target bonus incentives program for its Sales Force Personnel for the Product
during each Agreement Year will be based upon market performance similar to
Galen's then current other highest priority product and which is Promoted during
the same Agreement Year by any similar sales force within Galen, but not less
than the following: Each Galen sales representative detailing the Product in any
Agreement Year shall have at least forty percent (40%) of his/her dermatology
incentive compensation based on promotion of the Product, with at least fifty
percent (50%) of such Galen sales representatives having at least forty percent
of his/her entire incentive compensation based on Promotion of the Product. In
the event that BMS is concerned that Galen's target bonus incentives for the
Product do not meet the above guidelines, then the JEC will discuss the issue at
its next meeting in a good faith attempt to help resolve any of the perceived
inequities. If the JEC is unable to resolve any of such perceived inequities,
upon reasonable prior notice to Galen, BMS' independent public accountants shall
have access to the relevant books and records of Galen in order to conduct a
review or audit of Galen's sales force compensation practices to confirm whether
or not Galen is complying with the requirements set forth in this Section 3.12.
Such access shall be made available during normal business hours not more than
once in each Agreement Year. BMS shall provide a copy of its audit report to
Galen. Galen may designate competitively sensitive information which such
auditor may see and review but which it may not disclose to BMS; provided,
however, that such designation shall not encompass or restrict the auditor's
investigation or conclusions. BMS' independent public accountants shall enter
into a confidentiality agreement (in form and substance reasonably acceptable to
Galen) requiring such auditor to keep any information gathered from the
inspection of such records and books confidential. Subject to the foregoing,
Galen shall retain final control over all decisions relating to compensation and
bonus incentives for its Sales Force Personnel. Galen will utilize NDCHealth
data (or other mutually agreed upon service) to determine the actual performance
of its Sales Force Personnel for purposes of establishing compensation and
bonuses.

         Section 3.13 Management of Sales Force Personnel. During the
Copromotion Term, Galen shall ensure that the management of its Sales Force
Personnel shall use Diligent Efforts to Promote the Product in accordance with
Galen's obligations hereunder.

         Section 3.14 Response by Galen to Competitor. Upon being contacted by
any Third Party regarding an efficacy, safety, intellectual property rights,
supply or competition issue relating to the Product, Galen shall promptly notify
BMS of same. Galen will allow BMS to assume, if elected by BMS, exclusive
control over the timing and content of the response to any

                                       33
<PAGE>

such Third Party and Galen will not respond to such Third Party unless it has
first consulted with BMS and, subject to Section 10.1, received BMS' permission
to do so. BMS shall provide Galen with a copy of its response to such Third
Party inquiry where the issue involves a matter that, if adversely determined,
would materially adversely affect Galen's rights or obligations under this
Agreement (in which event BMS shall use reasonable efforts to consult with Galen
in connection therewith prior to the delivery of such response to such Third
Party).

         Section 3.15 Non-Solicitation. During the Copromotion Term a Party and
its Affiliates shall not solicit for employment the other Party's or its
Affiliates' sales or marketing personnel who are involved in the performance of
this Agreement. For purposes of the foregoing, "solicit" shall not be deemed to
mean (a) circumstances where a solicited employee initially contacts the other
Party or any of its Affiliates with regard to possible employment, or (b)
general solicitations of employment not specifically targeted at employees of a
Party or any of its Affiliates, including responses to general advertisements.

ARTICLE 4 - PRODUCT PRICING; REVENUE RECOGNITION; MANUFACTURING.

         Section 4.1 Product Pricing. BMS shall have the sole right and
responsibility for establishing and modifying the terms and conditions with
respect to the sale of Product in the Territory, including (a) any terms and
conditions relating to or affecting the price at which Product will be sold; (b)
any discount attributable to payments on receivables; (c) distribution of
Product; (d) credit, price adjustments, discounts and allowances to be granted
or refused; and (e) price increases or decreases and the timing thereof. BMS has
sole authority and discretion to implement pricing change. BMS shall notify
Galen in writing of such changes at the same time as BMS notifies its own sales
force representatives.

         Section 4.2 Revenue Recognition. BMS will book all sales of the Product
in the Territory. BMS shall be exclusively responsible for accepting and filling
purchase orders, billing, and returns with respect to Product. If Galen receives
an order for Product, it shall promptly transmit such order to BMS for
acceptance or rejection, which acceptance or rejection shall be at BMS' sole
discretion. BMS shall have the sole responsibility, at its sole cost and
expense, for Product shipping, distribution and warehousing in a timely manner,
for the invoicing and billing of purchasers of the Product, for order
confirmation (if any) in accordance with BMS' customary practices, and for the
collection of receivables resulting from sales of the Product.

         Section 4.3 Supply of Product.

                  4.3.1 BMS Responsibility. Pursuant to the LEO License
Agreement and LEO Supply Agreement, LEO is obligated to supply BMS, and BMS is
obligated to purchase, all of BMS' requirements for the Product, in finished and
packaged form, for use in the Territory. Subject to the terms of the LEO License
and Supply Agreements and to Sections 3.4 and 4.3 and to Article 8 of this
Agreement, and except as otherwise expressly provided herein, BMS shall use
commercially reasonable efforts to cause LEO to manufacture, finish, label,
package and supply,

                                       34
<PAGE>

at BMS' sole cost and expense, all of BMS's and Galen's (with respect to Product
samples only) requirements for the Product and Product samples in the Territory
during the Copromotion Term. BMS shall be solely responsible at its sole expense
for the distribution of Product in the Territory during the term of the
Agreement to Third Party purchasers (including without limitation distributors
and wholesalers) of the Product. BMS shall have no obligation to manufacture
Product itself.

                  4.3.2 Product Packaging; Manufacturing Representations and
Warranties. BMS represents and warrants to Galen that, under the LEO Supply
Agreement, LEO is obligated to ensure that all Product manufactured and/or sold
to BMS during the Copromotion Term and all samples of Product manufactured by or
for BMS during the Copromotion Term:

                           4.3.2.1 shall be manufactured, packaged and labeled,
         at the time of delivery to BMS (or to Galen for Product samples), in
         compliance in all material respects with current Good Manufacturing
         Practices (as may be promulgated by FDA and in effect from time to time
         during the Copromotion Term), with the CMC section of the Product's
         NDA, and with all applicable Laws; and

                           4.3.2.2 shall not be adulterated or misbranded in any
         material respect at the time of delivery to BMS (or to Galen for
         Product samples).

                  4.3.3 Quality Control. Under the LEO Supply Agreement, LEO
shall conduct quality control testing of Product prior to shipment to BMS in
accordance with the Product's NDA and all applicable Laws and in accordance with
prevailing industry standards and LEO's practices in effect on the Effective
Date, shall exercise not less than a reasonable standard of care in connection
with same, and shall prepare and retain records pertaining to such testing as
required by Law and LEO' standard operating procedures.

                  4.3.4 Change of Product Specifications and/or Source of
Supply. BMS shall have the right, at their respective sole discretion and
expense, to change the Product specifications from time to time at any time
during the term of this Agreement if required by LEO (where LEO is the
manufacturer) or if it is required to do so by any Governmental or Regulatory
Authority having jurisdiction over the Product or if BMS has undertaken
manufacturing or finishing of the Product. In the event of any such change, BMS
shall be responsible, at its sole cost and expense, for ensuring that any such
change is approved by each such applicable Governmental or Regulatory Authority.
If a change requires prior approval by the FDA, such change shall not be
implemented until such change has been so approved. As between BMS and Galen,
BMS shall determine in its sole discretion, and may from time to time change,
the source of supply of the Product without the consent of Galen; provided that
BMS shall give Galen prior written notice of its intention to do so, and that
BMS shall be responsible for securing all Regulatory Approvals at BMS' expense
that may be required to effect such change; and provided, further that Galen
understands that all Product is currently sourced by BMS directly from LEO and
that any such change would also need to be permitted by or consistent with the
terms of the LEO Supply Agreement and LEO License Agreement.

                                       35
<PAGE>

                  4.3.5 Product Returns. Any Product or Product-related items
returned to Galen shall be shipped by Galen to BMS' facility identified by BMS
as the point for receiving returned goods, with any reasonable or authorized
shipping or other documented direct cost to be paid or reimbursed by BMS to
Galen.

                  4.3.6 Timely Supply. BMS will use Diligent Efforts during the
Copromotion Term to cause LEO to supply Product to meet Galen's reasonable
projections of the requirements of Third Party purchasers in the Territory and
to supply the quantities of Product samples ordered by Galen to Promote the
Product; provided, that Galen has provided BMS with sufficient advance written
notice of such projections in accordance with this Agreement (so that BMS can
meet its forecasting and order obligations to LEO) and provided that LEO makes
timely delivery of conforming Product ordered to BMS. Galen acknowledges that it
has reviewed Section V (B) of LEO Supply Agreement and understands the ordering
and forecasting requirements imposed on BMS that are contained therein. Provided
that Galen shall have given BMS at least ten (10) days written notice of its
forecasting and order requirements consistent with BMS' obligations under the
LEO Supply Agreement, then, if BMS fails to provide LEO for a given quarter
timely written notice of BMS' orders and forecasts for Product and Product
samples, Galen shall have the right, upon ten (10) business days' prior notice
to BMS, to provide such orders and forecasts to LEO on BMS' behalf that Galen
had provided to BMS; provided, that Galen may not do so if BMS notifies Galen in
writing that doing so could result in BMS holding in excess of three (3) months'
of inventory of Product (including safety stock), based upon BMS' latest
estimates for projected sales. Nothing in this Section 4.3.6 is intended to
alter BMS' obligations and rights under the LEO Supply Agreement.

                  4.3.7 Excess Product and Inventory. The Parties will use good
faith commercially reasonable efforts to minimize the possibility that BMS will
be carrying inventory over and above the amount of Product that can reasonably
be sold in the ordinary course of business plus a reasonable amount of safety
stock.

                                       36
<PAGE>

ARTICLE 5 - TRADEMARKS AND COPYRIGHTS.

         Section 5.1 Determination of Trademark. The Dovonex(R) trademark shall
be used on the Product for marketing within the Territory. BMS shall own all
rights, title and interests, and be solely entitled to all goodwill developed,
in and to this trademark and any other Trademark.

         Section 5.2 Use of BMS and Galen Names on Labeling and Packaging. The
parties agree that, subject to the requirements of applicable Law and the
approval of FDA, BMS and Galen shall be given equal exposure and prominence on
all Product package inserts, packaging, samples and all A&P Materials used or
distributed in connection with the Product under this Agreement, provided, that
the Galen name and logo will not appear until the first re-printing of each of
the applicable components following the Effective Date. All Product labels, A&P
Materials, and commercial packs shall contain a reference to LEO as the licensor
and bulk manufacturer of the Product. Positioning of the Galen and LEO names and
logos shall be determined by the JEC in a manner consistent with applicable Law.
Regarding the Physicians Desk Reference ("PDR"), under Galen (or its permitted
designee's) listing in the PDR, there will be included the package inserts for
the Product included under BMS's listing in the PDR together with an appropriate
indication that the Product is manufactured by LEO and marketed by BMS and Galen
(or its permitted designee). All costs incurred by either Party with placing the
package insert in the PDR under Galen's name shall be borne solely by Galen.

         Section 5.3 Trademark Maintenance. BMS shall maintain a registration
for the Trademarks in the Territory at its expense. The Trademarks shall be
owned solely by BMS. Galen will not contest the ownership of the Trademarks,
their validity, or the validity of any registration therefor during the term of
this Agreement. This Agreement does not and is not intended to create a grant to
Galen of any property right or interest in any Trademark. All labeling, A&P
Materials and packaging for the Product in the Territory will clearly indicate
that the Trademarks are owned by BMS or its Affiliates.

         Section 5.4 Use of BMS Trademark by Galen. BMS consents to the use by
Galen of the Trademarks in connection with the performance of Galen's
obligations under this Agreement; provided, that except as provided in Sections
3.2.2 and 3.3.1, any such use is first approved in writing by BMS or the JEC in
advance. Galen agrees that all use of the Trademarks by Galen as provided in
this Agreement shall inure to the benefit of BMS and its Affiliates. Galen's
right to use the Trademarks with respect to a given Product shall terminate at
such time as Galen's rights to Promote such Product are terminated in accordance
with this Agreement.

         Section 5.5 Infringement of Trademark by Third Parties; Trademark
Indemnification. In the event that in-house legal counsel for either Party
becomes aware of actual or threatened infringement of a Trademark in the
Territory, such Party shall promptly notify the other Party in writing. Galen
shall render, at its expense (subject to reimbursement by BMS below), all
assistance reasonably requested in connection with any action taken by BMS or
its Affiliates to prevent such infringement. The control of such action,
including whether to initiate any legal proceeding and/or the settlement
thereof, shall solely be under the control of BMS or its

                                       37
<PAGE>

Affiliates; provided, that BMS and its Affiliates shall not, without Galen's
prior written consent, settle any such claim or proceeding in a manner that (a)
materially adversely affects Galen's rights, benefits (including compensation),
and obligations under this Agreement, and/or (b) admits liability on the part of
Galen, and/or (c) which results in any damages incurred by Galen or any monetary
payment by Galen not covered by BMS' indemnity obligation below; and provided,
further, that BMS shall indemnify and hold Galen and its Affiliates, and its and
their directors, employees, contractors, and agents, harmless from and against
any claims, damages, liabilities, costs and expenses that may be incurred by or
levied upon Galen or any of its Affiliates as a result of providing such
cooperation or of BMS using their respective name(s) in any such action or
related proceeding. BMS shall reimburse Galen for reasonable outside attorneys'
fees incurred by Galen at the specific written request, or with the prior
written consent, of BMS in any such action or related proceeding.

         Section 5.6 Copyrighted Works. All copyrighted works authored or
otherwise created or developed for use on or as A&P Materials, packaging and
labeling for the Product, whether singly or jointly, by Galen's or BMS'
employees, agents, or other persons acting under their authority in the conduct
of this Agreement, and all rights, title and interests therein, shall to the
extent directly related to the Product be owned by BMS ("BMS Works"). Galen
shall retain all rights to its sole works to the extent that they are not
directly related to the Product, and shall retain co-rights with BMS in any
joint works to the extent that they are not directly related to the Product.
Galen agrees to execute such instruments as may be reasonably requested by BMS
to confirm the assignment and/or ownership of BMS Works in BMS, free and clear
of liens, claims and encumbrances. BMS and its Affiliates shall be free to use
the BMS Works as BMS deems fit. Nothing herein shall be construed as giving
Galen any right or license to use any BMS Works for any purpose other than for
purposes of carrying out its obligations under this Agreement.

                  With respect to any of Galen's sole works that are not
directly related to the Product and that are provided by Galen for use with the
Product, BMS shall have a nonexclusive, worldwide, sublicensable, fully paid-up
right and license, both during and following the term of this Agreement, under
any intellectual property rights owned or controlled by Galen or its Affiliates
covering such sole works, to use same in connection with the use, sale,
marketing or Promotion of the Product, but not any other product .

ARTICLE 6 - [INTENTIONALLY OMITTED].

ARTICLE 7 - TRAINING OF SALES FORCES.

         Section 7.1 Initial Training. The Parties intend that BMS will provide
Galen's trainers for its Sales Force Personnel with the same or substantially
similar training with respect to promotion of the Product as has been given
traditionally to BMS' sales force in the Territory (it being understood that
such training shall be specific to the Product itself, as opposed to general
sales training). BMS and Galen will hold one such training session ("Initial
Training Session"), which shall be held on one mutually convenient date as soon
as practicable after the Execution Date, and which will be held at a location
mutually acceptable to BMS and Galen. BMS will

                                       38
<PAGE>

determine the content of such Initial Training Session, and shall review the
Product-related training materials and make recommendations for any revisions
and updates thereto as BMS may deem appropriate; provided, however, BMS shall
determine and be solely responsible for the content and development of all
training materials for the Initial Training Session.

         Section 7.2 Subsequent Training. Galen shall have the authority, and
shall be responsible at its cost and expense, for all training to be provided to
its Sales Force personnel following the Initial Training Session; provided, that
such training shall be consistent with the direction of BMS, the Promotion Plan,
and with the Product training materials and program developed by BMS for
training its own sales forces for the promotion of the Product in the Territory,
and that such training shall include training on the proper handling and
reporting of adverse drug experiences encountered for the Product and on timely
reporting of Product inquiries and other requests for information related to
Product.

         Section 7.3 Training Materials. BMS will determine the content of the
Product-specific training materials to be used for the Initial Training Session.
Promptly after the Execution Date, BMS will provide to Galen reasonable
quantities of training materials from its existing supplies to enable Galen to
provide the initial training of its Sales Force Personnel and Galen will
reimburse BMS for its out-of-pocket costs incurred to prepare and provide same.
Where available to BMS, BMS shall supply Galen with an electronic version of the
initial training materials (subject to any obligations BMS may have to any Third
Party that may have prepared the materials), so that Galen may use and reproduce
the materials, as needed, in accordance with the terms of this Agreement. BMS
shall use its commercially reasonable efforts, at its sole expense, to obtain
access to an electronic version of the initial training materials for Galen's
use pursuant to this Section 7.3 from any Third Party that prepared the
materials. The JEC may review the Product-related training materials from time
to time and make recommendations for any revisions and updates thereto as the
JEC may deem appropriate. Any Product-specific training materials developed by
Galen must be submitted to BMS for review and approval prior to any use by Galen
and may be used by BMS or LEO for the promotion of the Product. BMS shall inform
Galen of its approval or rejection of such materials within forty-five (45) days
of their receipt by BMS. Such approval by BMS shall be deemed granted, however,
in the absence of notice to the contrary by BMS within the forty-five (45) days
following receipt of such materials by BMS. All Product-specific training
materials may only be used by Galen for training in connection with the Product
and may not be used, copied or adapted for any other product or purpose. BMS
shall grant to Galen a limited, nonexclusive license under any copyrights
controlled by BMS with respect to any training materials provided by BMS solely
to use, copy and adapt the training materials for the above purpose, and Galen
covenants to use the license solely for the above purpose.

         Section 7.4 Cost. Galen shall bear the full cost and expense of all of
its trainers who attend the Initial Training Session, as well as all Sales Force
Personnel and management who attend a Product-related training program, without
contribution from BMS. BMS shall bear the costs and expenses of its personnel
provided for the Initial Training Session. It is understood and agreed that any
such initial and subsequent training costs under sections 7.1, 7.2 and 7.3 and

                                       39
<PAGE>

general training costs under section 7.5 that are incurred by either Party are
not A&P Costs.

         Section 7.5 General Training. Each of Galen and BMS shall be solely
responsible at its expense for general sales training of its Sales Force
Personnel.

ARTICLE 8 - FORCE MAJEURE.

         Section 8.1 Force Majeure. If the performance of any obligation under
this Agreement by either Party is prevented, restricted, interfered with or
delayed by reason of any cause beyond the reasonable control of the Party unable
to perform, not due to malfeasance and which could not, with the exercise of due
diligence, have been avoided (including without limitation, as a result of acts
of God, civil disorders or commotions, acts of aggression, fire, accident,
explosions, floods, drought, war, sabotage, embargo, utility failures, material
shortages, failure of supply of Product on the part of LEO, labor disturbances,
strike, riot, delay or errors by shipping companies, a change in Law, a national
health emergency, or appropriations of property), then, the Party so affected
shall not be excused from such performance, but shall merely suspend such
performance during the continuation of Force Majeure. The Party prevented from
performing its obligations or duties because of Force Majeure shall promptly
notify the other Party hereto of the occurrence and particulars of such Force
Majeure and shall provide the other Party, from time to time, with its best
estimate of the duration of such Force Majeure and with notice of the
termination thereof. The affected Party shall use all reasonable efforts to
avoid or remove such causes of non-performance and to ameliorate the effects of
such nonperformance as promptly as practicable thereafter and upon termination
of Force Majeure, the performance of any suspended obligation or duty shall
promptly recommence. Nothing contained herein shall require any Party to settle
on terms unsatisfactory to such Party any strike, lock-out or other labor
difficulty, any investigation or proceeding by any public authority, or any
litigation by any Third Party. When Force Majeure arises, the Parties shall
discuss what, if any, modification of the terms of this Agreement may be
required in order to arrive at an equitable solution. Neither Party shall be
liable to the other Party for any direct, indirect, consequential, incidental,
special, punitive, exemplary or other damages arising out of or relating to the
suspension or termination of any of its obligations or duties under this
Agreement by reason of the occurrence of Force Majeure.

ARTICLE 9 - CERTAIN REGULATORY MATTERS; PRODUCT RECALL.

         Section 9.1 General Control in BMS. Except as otherwise specifically
provided herein, all regulatory matters regarding the Product shall remain under
the exclusive control and responsibility of BMS, subject to the participation by
Galen through the JEC. BMS will have the sole responsibility, at its cost and
expense, to respond to Product and medical complaints and to handle all returns
and recalls of the Product. Subject to the terms of this Agreement, within three
(3) months of the Execution Date, BMS and Galen shall discuss and develop
mutually acceptable guidelines and procedures for the receipt, recordation,
communication (as between the Parties) and exchange of adverse event information
and the other matters covered in this Article 9; until such agreement is
executed, the terms of this Article 9 shall apply. It is anticipated that such
guidelines and procedures will include provisions for the direct reporting to
BMS of adverse

                                       40
<PAGE>

events by Galen Sales Force Personnel. The Parties shall bear their respective
costs incurred in connection with receiving, recording, reviewing,
communicating, and exchanging with each other regarding and, as applicable,
reporting and responding to adverse events.

         Section 9.2 Efficacy and Safety Information. BMS shall furnish Galen
with efficacy and safety information reasonably requested by Galen to assist it
in promoting the Product in the Territory, including, without limitation,
summaries of relevant clinical and safety data included in the NDA for the
Product and summaries of information related to the efficacy and safety profile
of the Product since its approval by the FDA. In connection therewith, except as
otherwise specifically provided in this Article 9, BMS will provide Galen in a
timely manner with copies of all Medwatch and or CIOMS-I reports submitted by
BMS with respect to the Product, (i.e., within seven (7) days of submission for
Serious Adverse Events and on a monthly basis for Non-Serious Adverse Events.)
Raw data or databases will not be made available to Galen.

         Section 9.3 Notification of Adverse Events; Reporting to Governmental
or Regulatory Authorities. Serious Adverse Events for the Product learned by
Galen shall be submitted to BMS in sufficient time to reasonably allow BMS to
comply with applicable regulations. Non-Serious Adverse Events for the Product
that are spontaneously reported to Galen shall be submitted to BMS no more than
one (1) month from the date received by Galen; provided, however, that medical
and scientific judgment should be exercised in deciding whether expedited
reporting is appropriate in other situations, such as important medical events
that may not be immediately life-threatening or result in death or
hospitalization but may jeopardize the patient or may require intervention to
prevent a Serious Adverse Event outcome.

                  BMS shall have the reporting responsibility for all adverse
events to applicable Governmental or Regulatory Authorities anywhere in the
world. BMS shall inform Galen of all adverse events reported by it to the FDA at
the same time as BMS reports same to the FDA.

                  Galen shall report all such adverse events involving the
Product learned by it to:

                  Vice President, Global Pharmacovigilance & Labeling
                  Bristol-Myers Squibb Pharmaceutical Research Institute
                  P.O. Box 5400
                  Mail Stop HW19-1.01
                  Princeton, New Jersey 08543-5400
                  U.S.A.
                  Facsimile No.: (609) 818-3804
                  Telephone No.: (609) 818-3737

A CIOMS-I form or a form that contains the data elements of a CIOMS-I form shall
be used.

                  Adverse events concerning the Product learned by BMS shall be
reported by BMS to Galen at the time that BMS reports such events to the FDA,
and shall be sent to:

                                       41

<PAGE>

                  Warner Chilcott, Inc.
                  100 Enterprise Drive
                  Rockaway, NJ 07866
                  Attention: Medical Director
                  Telephone No.: (973) 442-3343
                  Facsimile No.: (973) 442-3280

A Party may change its contact at any time for future notices upon written
notice given to the other.

         BMS shall create and maintain at its expense a master safety database
which shall cross-reference any adverse drug experience relating to the Product
occurring anywhere in the world.

         Section 9.4 Response by Galen to Regulatory Inquiries. Upon being
contacted by the FDA or any other applicable Governmental or Regulatory
Authority for any regulatory purpose directly related to this Agreement or to
the Product, Galen shall immediately notify BMS. To the extent permitted by
applicable Law, Galen will allow BMS to assume control over the timing and
content of the response to such Governmental or Regulatory Authority and will
not respond to the agency until consulting with BMS; provided, that the
foregoing shall not be construed to prevent Galen in any way from complying with
its obligations under applicable Law, including, without limitation, by
permitting unannounced FDA or similar inspections and responding to requests by
FDA inspectors in connection therewith.

         Section 9.5 Product Quality Complaint.

9.5.1 Galen shall inform BMS' Office of the Vice President, U.S. Safety &
Surveillance of any Product Quality Complaint received by it within three (3)
business days from the receipt date by Galen. "Product Quality Complaint" is
defined as any complaint that questions the purity, identity, potency or quality
of the Product, its packaging, or labeling, or any complaint that concerns any
incident that causes the drug product or its labeling to be mistaken for, or
applied to, another article or any bacteriological contamination, or any
significant chemical, physical, or other change or deterioration in the
distributed drug product, or any failure of one or more distributed batches of
the drug product to meet the specifications therefor in the NDA for the Product.
Such information shall be sent to the same address as set forth in Section 9.3
above. BMS shall be solely responsible for responding to any such Product
Quality Complaints.

                  9.5.2 BMS shall inform Galen of any Product Quality Complaint
received by it within three (3) business days from the receipt date by BMS. Such
information shall be sent to Galen as set forth below:

                           Galen Holdings PLC
                           100 Enterprise Drive
                           Rockaway, New Jersey  07866
                           Attention: Vice President- Regulatory Affairs

                                       42

<PAGE>

                           Facsimile No.: (973) 442-3280
                           Telephone No.: (973) 442-3233

         Section 9.6 Medical Inquiries. BMS Medical Communications Department
shall have sole responsibility for handling all medical inquiries concerning the
Product in accordance with its normal procedures therefor. Galen shall refer all
routine medical information requests by telephone or in writing to:

Medical Communications P24-17
Bristol-Myers Squibb Company
Worldwide Medicines Group
PO Box 4500
Princeton, NJ 08543-9911
Facsimile No.: 866-679-0077
Telephone No.: ____________________________

For urgent medical information requests, health care professionals shall be
referred by telephone to the Customer Contact Center at 800-321-1335.

A Party may change its contact at any time for future notices under this Section
upon written notice given to the other.

         BMS shall provide Galen with one copy of all medical documents,
including but not limited to medical responses, written, phone and person
contact inquiries and published literature which BMS believes is useful or
necessary in connection with the activities and duties contemplated of Galen
under this Agreement.

         Section 9.7 Definition of Adverse Event. A "Serious Adverse Event" for
the Product shall have the meaning set forth in 21 C.F.R. Section 314.80(a), as
amended from time to time and a "Non-Serious Adverse Event" is defined as an
untoward medical occurrence at any dose for the Product that is not a Serious
Adverse Event.

         Section 9.8 Product Recall.

                  9.8.1 In the event that either Party obtains information that
a Product or any portion thereof should be alleged or proven not to meet the
specifications, the labeling, or the NDA for such Product or to be otherwise
defective in the Territory, such Party shall notify the other Party immediately
and both Parties shall cooperate fully regarding the investigation and
disposition of any such matter. BMS and Galen shall each maintain such
traceability records as are sufficient and as may be necessary to permit a
recall, product withdrawal or field correction of any Product or Product
samples, as the case may be. In the event (i) any applicable Governmental or
Regulatory Authority should issue a request, directive or order that a Product
be recalled or withdrawn or (ii) BMS determines that any Product already in
interstate or international commerce in the Territory presents a risk of injury
or gross deception or is otherwise

                                       43

<PAGE>

defective and that a Recall of such Product is appropriate (each of (i) or (ii),
a "Recall"), each Party shall give telephonic notice (to be confirmed in
writing) to the other within 24 hours of the occurrence of such event.

                  9.8.2 Prior to making a decision to implement any such Recall,
BMS will, where it is reasonably able to do so, consult with Galen as to same,
but BMS shall have sole responsibility for determining all corrective action to
be taken and for carrying out the Recall. Galen will provide full cooperation
and assistance to BMS in connection therewith as may be requested by BMS,
including providing BMS within five (5) business days of receipt by Galen of
notice of the Recall a list of Prescribing Professionals who received any
Product samples subject to the Recall. BMS shall be responsible for all expenses
of effecting any such Recall (including any out-of-pocket expenses incurred by
Galen in connection with such cooperation), except to the extent such Recall is
attributable to a breach by Galen of its obligations hereunder (in which case
Galen shall be responsible for the expenses associated with any such Recall
attributable to such breach).

ARTICLE 10 - COMPLIANCE WITH LAW AND LABELING.

         Section 10.1 Compliance with Laws. Each Party shall comply in all
material respects with all Laws applicable to its activities under this
Agreement, including without limitation, any requirements of any product license
applicable to the Product in the Territory. The Parties will reasonably
cooperate with one another with the goal of ensuring full compliance with Laws.

         Section 10.2 Maintenance of Authorizations. Each Party shall maintain
in full force and effect at its expense all necessary licenses, permits,
approvals, consents, registrations, and other authorizations required by Law to
carry out its duties and obligations under this Agreement.

         Section 10.3 BMS Duties. During the Copromotion Term, BMS will use
Diligent Efforts to maintain at its expense, consistent with applicable legal
requirements, all necessary authorizations, permits, registrations, including
without limitation each IND, drug master file (DMF), and NDA for each Product,
and consents required of any applicable Governmental or Regulatory Authority or
Third Party that are needed to manufacture, package and store the Product
anywhere in the world, and to import, use, offer for sale, and sell the Product
in the Territory, including without limitation filing IND and NDA annual reports
and maintaining such records and filing such reports as may be required under
the FD&C Act, as well as applicable state and federal Laws (collectively,
"Product Registrations"). BMS shall retain all rights, title and interests in
and to such Product Registrations and to any benefits accruing thereto. BMS
shall use Diligent Efforts to make timely filing with applicable Governmental or
Regulatory Authorities in the Territory of all adverse drug experience reports
related to the Product. BMS shall notify Galen promptly in writing as to any
developments (including without limitation filings, notices and correspondence
received from or made by it with the FDA relating to safety or efficacy claims
of, or advertising or promotional claims for, the Product or that relate to
manufacturing problems) that would have a material adverse effect on the Product
Registrations.

                                       44

<PAGE>

                  Subject to the foregoing and the provisions of Article 9, all
such reports or filings made to the FDA and other Governmental or Regulatory
Authorities shall be the sole responsibility of BMS and shall be made at BMS'
discretion, and Galen shall cooperate with BMS with respect to obtaining and/or
maintaining the Product Registrations, shall execute, acknowledge and deliver
such further instruments at BMS' request and expense, and shall use commercially
reasonable efforts to do all such other acts, as promptly as possible, which may
be necessary or appropriate to assist BMS to obtain and maintain the Product
Registrations in the Territory; provided, that nothing herein shall be construed
as restricting Galen's ability to take action that it deems to be appropriate or
required of it under applicable Law. BMS shall have the final decision-making
authority in every case on whether and how to supplement, amend or otherwise
alter the Product Registrations and any other issues in connection with such
Product Registrations (including, but not limited to, decisions to Recall the
Product) and on whether and how to communicate with the FDA and other applicable
Governmental or Regulatory Authorities in connection therewith; provided, that
BMS will not, except where required by, or to fulfill its obligations under,
applicable Law or except where required by a Governmental or Regulatory
Authority acting within the scope of its authority, supplement, amend or
otherwise alter a Product Registration so as to materially adversely affect
Galen's rights, benefits and obligations under this Agreement that are derived
from such Product Registration.

                  BMS shall notify Galen in writing promptly of any information
that comes to the attention of Product management or its in-house counsel
regarding any threatened or pending action by the FDA or other Governmental or
Regulatory Authority that may materially adversely affect the safety or efficacy
claims of the Product, or the continued marketing of the Product in the
Territory, or the manufacture or supply of the Product for use in the Territory.
Galen shall provide BMS with reasonable assistance with respect to
communications to and from Governmental or Regulatory Authorities in the
Territory, it being understood that all such communications shall be the sole
responsibility of BMS; provided, that nothing herein shall be construed as
restricting Galen's ability to take action that it deems to be appropriate or
required of it under applicable Law.

         Section 10.4 No Misrepresentation. Galen shall make no representations
or warranties relative to the Product that conflict or are inconsistent with the
NDA, applicable Law, and the FDA-approved label for the Product. Galen shall be
responsible for any out-of-pocket costs incurred by BMS resulting from
statements made by Galen's sales representatives that relate to the safety or
efficacy of the Product that are not in compliance with applicable Law or have
not been authorized by BMS in advance in writing or as otherwise expressly
permitted in accordance with the terms of this Agreement.

ARTICLE 11 - COPROMOTION PERFORMANCE COMPENSATION.

         Section 11.1 Generally. Subject to Sections 11.6, and 13.6.2, as
compensation for Galen's performance of its Promotion obligations under this
Agreement, BMS shall pay Galen, with respect to each Semi-Annual Period,
compensation ("Performance Compensation") equal to the amount determined under
this Section 11.1, less any amount owed by Galen under Section

                                       45

<PAGE>

11.2:

                  11.1.1 For Each Semi-Annual Period in Agreement Year 1: The
sum of (a), plus (b), plus (c) below, multiplied by the Gross Margin Percentage
for such accounting period, where (a), (b) and (c) represent the following:

                           (a)      An amount determined by multiplying (1)
                                    Eighty Percent (80%), times (2) the Retail
                                    Net Sales Difference for such Semi-Annual
                                    Period; provided, that for purposes of this
                                    subsection (a) (but not for purposes of
                                    Section 11.1.1(c)), if the Retail Net Sales
                                    Difference is less than zero, this amount
                                    shall be deemed to be zero; plus

                           (b)      An amount determined by multiplying (1)
                                    Eighty Percent (80%), times (2) the Mail
                                    Order Net Sales Difference for such
                                    Semi-Annual Period; provided, that for
                                    purposes of this subsection (b) (but not for
                                    purposes of Section 11.1.1(c)), if the Mail
                                    Order Net Sales Difference is less than
                                    zero, this amount shall be deemed to be
                                    zero; plus,

                           (c)      If the Retail/MO Net Sales Difference is a
                                    positive number for such Semi-Annual Period,
                                    then an amount determined by multiplying (1)
                                    the Actual Demand-Based Other Net Sales for
                                    such Semi-Annual Period, times (2) a
                                    fraction, the numerator of which is the
                                    Retail/MO Net Sales Difference and the
                                    denominator of which is the total Actual
                                    Demand-Based Retail/MO Net Sales for the
                                    applicable Semi-Annual Period, times (3)
                                    Eighty Percent (80%).

As used in this Section 11.1:

         "Mail Order Net Sales Difference" means the sum of the Actual
Demand-Based Mail Order Net Sales less the Baseline Demand-Based Mail Order Net
Sales for the applicable accounting period.

         "Retail Net Sales Difference" means, the sum of the Actual Demand-Based
Retail Net Sales less the Baseline Demand Based Retail Net Sales for the
applicable accounting period.

         "Retail/MO Net Sales Difference" means the sum of the actual (whether
negative or positive) Retail Net Sales Difference plus the actual (whether
negative or positive) Mail Order Net Sales Difference.

                  11.1.2 For Each Semi-Annual Period Agreement Year 2: The sum
of (a), plus (b), plus (c) plus (d) below, multiplied by the Gross Margin
Percentage for such accounting period, where (a), (b), (c) and (d) represent the
following:

                                       46

<PAGE>

                           a)       Seven Percent (7%) of the Actual
                                    Demand-Based Retail/MO Net Sales for such
                                    Semi-Annual Period, plus seven percent (7%)
                                    of the Actual Demand-Based Other Net Sales
                                    for such Semi-Annual Period; plus

                           b)       An amount determined by multiplying (1)
                                    Sixty-three percent (63%), times (2) the
                                    Retail Net Sales Difference; provided, that
                                    for purposes of this subsection (b) ) (but
                                    not for purposes of Section 11.1.2(d)), if
                                    the Retail Net Sales Difference is less than
                                    zero, this amount shall be deemed to be
                                    zero; plus

                           c)       An amount determined by multiplying (1)
                                    Sixty-three percent (63%), times (2) the
                                    Mail Order Net Sales Difference; provided,
                                    that for purposes of this subsection (c)
                                    (but not for purposes of Section 11.1.2(d)),
                                    if the Mail Order Net Sales Difference is
                                    less than zero, this amount shall be deemed
                                    to be zero; plus,

                           d)       If the Retail/MO Net Sales Difference is a
                                    positive number for such Semi-Annual Period,
                                    then an amount determined by multiplying (1)
                                    the Actual Demand-Based Other Net Sales for
                                    such Semi-Annual Period, times (2) a
                                    fraction, the numerator of which is the
                                    Retail/MO Net Sales Difference and the
                                    denominator of which is the total Actual
                                    Demand-Based Retail/MO Net Sales for the
                                    applicable Semi-Annual Period, times (3)
                                    Sixty-three percent (63%).

                  11.1.3 For Each Semi-Annual Period in Agreement Years 3, 4 and
5: The sum of (a), plus (b), plus (c) plus (d) below, multiplied by the Gross
Margin Percentage for such accounting period, where (a), (b), (c) and (d)
represent the following:

                           a)       Twelve percent (12%) of the Actual
                                    Demand-Based Retail/MO Net Sales for such
                                    Semi-Annual Period, plus twelve percent
                                    (12%) of the Actual Demand-Based Other Net
                                    Sales for such Semi-Annual Period; plus

                           b)       An amount determined by multiplying (1)
                                    thirty-eight percent (38%), times (2) the
                                    Retail Net Sales Difference; provided, that
                                    for purposes of this subsection (b) (but not
                                    for purposes of Section 11.1.3(d)), if the
                                    Retail Net Sales Difference is less than
                                    zero, this amount shall be deemed to be
                                    zero; plus

                           c)       An amount determined by multiplying (1)
                                    thirty-eight percent (38%), times (2) the
                                    Mail Order Net Sales Difference; provided,

                                       47

<PAGE>

                                    that for purposes of this subsection (c)
                                    (but not for purposes of Section 11.1.3(d)),
                                    if the Mail Order Net Sales Difference is
                                    less than zero, this amount shall be deemed
                                    to be zero; plus,

                           d)       If the Retail/MO Net Sales Difference is a
                                    positive number for such Semi-Annual Period,
                                    then an amount determined by multiplying (1)
                                    the Actual Demand-Based Other Net Sales for
                                    such Semi-Annual Period, times (2) a
                                    fraction, the numerator of which is the
                                    Retail/MO Net Sales Difference and the
                                    denominator of which is the total Actual
                                    Demand-Based Retail/MO Net Sales for the
                                    applicable Semi-Annual Period, times (3)
                                    thirty-eight percent (38%).

                  11.1.4 An exhibit setting forth the Baseline Agreement Year
Prescriptions, the Baseline Semi-Annual Prescriptions and the Baseline Quarterly
Prescriptions for the mail order and retail segments for the Product is set
forth as Exhibit 11.1.5 hereto and an example of the Performance Fee calculation
is attached as Exhibit 11.1.4 hereto.

         Section 11.2 Offset. Any amount determined to be owed to Galen for a
given period pursuant to Section 11.1 shall be reduced by any amount determined
to be owing by Galen to BMS under Sections 3.4.4, 3.7.1, 3.7.4, 3.9, 3.10.1, 7.3
and 7.4 with respect to such period.

         Section 11.3 Currency; Bank Account; Tax Withholdings. All payments to
a Party under this Agreement shall be made by electronic funds transfer in legal
currency of the United States and shall be delivered to the account of such
Party designated by a Vice President of Finance in writing from time to time.
Any taxes, levies or other duties paid or required to be withheld by a Party on
account of monies payable to the other Party under this Agreement shall be
deducted from the amount of monies otherwise due such other Party under this
Agreement. In such event, paying Party shall secure and send to receiving Party
proof of any such taxes, levies or other duties withheld and paid by the paying
Party for the benefit of the receiving Party, and shall provide reasonable
cooperation to receiving Party in any effort to secure release or refund of
same.

         Section 11.4 Payment.

                  11.4.1 Quarterly Payments. In order for Galen to receive
Performance Compensation under this Article 11 on a quarterly basis during the
Copromotion Term, at the end of the first quarter in each Semi-Annual Period,
BMS will make a good faith calculation of the amount due to Galen for such
quarter and pay, less any amounts owed by Galen under Section 11.2, such balance
within 30 days following the end of such first quarter.

                  11.4.2 Semi-Annual Reconciliation. A preliminary semi-annual
reconciliation of the Performance Compensation due Galen under Section 11.1 with
respect to each Semi-Annual Period will be completed within sixty (60) days
after the end of such Semi-Annual Period (or, if later, as soon thereafter as
BMS has received all final IMS data required for BMS to compute any

                                       48

<PAGE>

adjustment to Performance Compensation calculated in accordance with Section
11.4.1) and reconciled against all amounts previously paid during such
Semi-Annual Period. If the reconciliation shows an amount due by either Party to
the other, the amount due shall be paid within thirty (30) days after the
receipt by Galen of such reconciliation report. The semi-annual reconciliation
report shall set forth the calculation of the Performance Compensation due Galen
for the applicable Semi-Annual Period within such Agreement Year, the
calculation of any amounts owed by Galen to BMS under Section 11.2 for such
Semi-Annual Period, and any reconciliations or adjustments made in accordance
with this Agreement with respect to such final payment for the applicable
Semi-Annual Period.

                  Since certain deductions required to calculate Performance
Compensation take more than sixty days after a Semi-Annual Period before being
confirmed with Third Parties (e.g., Medicare and Medicaid rebates), a final
reconciliation of the Performance Compensation due Galen under Section 11.1 with
respect to a Semi-Annual Period will be completed nine (9) months after the end
of such period and reconciled against all amounts previously paid with respect
to such Semi-Annual Period. The final semi-annual reconciliation report shall be
prepared in the same manner as the preliminary semi-annual reconciliation
report, and if the final semi-annual reconciliation shows an amount due by
either Party to the other, the amount due shall be paid within thirty (30) days
after the receipt by Galen of such final semi-annual reconciliation report.

         Section 11.5 Books and Records. BMS will maintain complete and accurate
books and records in sufficient detail to enable verification of Galen's
Performance Compensation, and Galen will maintain complete and accurate books
and records in sufficient detail to enable verification of its internally
reported PDEs. Not more than twice per Agreement Year, a Party may demand an
audit of the other Party's and its Affiliates' relevant books and records in
order to verify a Party's reports on the aforesaid matters, and vice-versa. Upon
reasonable prior notice (not less than ten (10) business days) to the other
Party and during the other Party's normal business hours, the auditing Party's
independent public accountants shall have access to the relevant books and
records of the other Party in order to conduct a review or audit thereof. Such
review and access shall be permitted only with respect to the two-year period
prior to the Agreement Quarter in which the audit occurs. Each Party may
designate competitively sensitive information which such auditor may see and
review but which it may not disclose to the other Party; provided, however, that
such designation shall not encompass or restrict the auditor's investigation or
conclusions. The accountants shall report its conclusions and calculations to
both Parties at the same time. The accountants shall execute an appropriate
confidentiality agreement (in form and substance reasonably acceptable to the
audited Party) prior to having access to any of its books and records requiring
such auditor to keep any information gathered from the inspection of such
records and books confidential.

                  The auditing Party shall bear the full cost of the performance
of any such audit except as hereinafter set forth. If, as a result of any
inspection of the books and records of the other Party, it is shown that a
Party's payments to the other under this Agreement were less than the amount
which should have been paid, then the Party owing the amount shall make all

                                       49

<PAGE>

payments required to be made to eliminate any discrepancy revealed by said
inspection within 30 days after written notification of same, plus interest on
the amount due from the date that the amount would otherwise have been paid as
part of the interim semi-annual reconciliation payment at an annual rate equal
to prime rate prevailing during such period plus one percent (1%). If the
Performance Compensation payments calculated under Section 11.1 were less than
the amount which should have been paid by an amount in excess of ten percent
(10%) of the payments actually made during the period in question, BMS shall
also reimburse Galen for its out-of-pocket costs of such audit and inspection.
If the A&P and Phase IV Study costs for which Galen claimed credit differed by
more than ten percent (10%) from the amounts which should actually have been
offset or credited during the period in question, Galen shall also reimburse BMS
for its out-of-pocket costs of such audit and inspection. For purposes of the
foregoing, the prime rate shall mean the rate in effect at Citibank in New York,
New York during the relevant period in question. If Galen understated its
internally reported PDEs for a given Agreement Year by five percent (5%) or
more, then Galen shall reimburse BMS for its out-of-pocket costs of such audit
and inspection.

         Section 11.6 Adjustment for Manufacturing Shortages. In the event that
supply problems have caused a material shortage in the supply of Product to
retail trade or managed care segments (with or without regard to the application
of Section 8.1) for more than four (4) weeks in any Semi-Annual Period, and so
long as Actual Demand-Based Retail/MO Gross Sales for such Semi-Annual Period
are less than one hundred ten percent (110%) of the Baseline Demand-Based
Retail/MO Gross Sales for such Semi-Annual Period, it shall notify BMS in
writing as promptly as practicable, and the Parties shall promptly meet to
consider an appropriate adjustment, if any, of Baseline Agreement Year
Prescriptions for Semi-Annual Period(s) affected by such material shortage. If
the Parties fail to reach mutual agreement on the appropriate adjustment under
this Section 11.6 within a reasonably period of time (not to exceed sixty (60)
days after BMS receives written notification from Galen to initiate such
negotiations after such an event has occurred), then Galen shall be entitled to
terminate the Copromotion Term upon one hundred eighty (180) days written notice
to BMS.

ARTICLE 12 - DISPUTE RESOLUTION.

         Section 12.1 Dispute Resolution. Except for matters for which unanimous
consent of all members of the JEC or of both Parties is specifically required
under this Agreement, in the event of any controversy, claim or dispute arising
out of or relating to this Agreement, the Parties shall try to settle their
differences amicably between themselves first, by referring the disputed matter
to JEC for resolution with assistance from each Party's Vice President for
Alliance Management (or similar executive). If not resolved by JEC, then the
disputed matter shall be referred to the President of BMS U.S. Primary Care and
the President, Pharmaceuticals of Galen, or their respective designees, for
resolution. Either Party may initiate such informal dispute resolution by
sending written notice of the dispute to the other Party requesting attempted
resolution by said executive officers, and, within twenty (20) days after such
notice, such representatives of the Parties shall meet for the purpose of
attempting in good faith to resolve such dispute. Neither Party shall be
precluded from using a court of competent jurisdiction to resolve any dispute

                                       50

<PAGE>

arising under this Agreement.

         Section 12.2 No Limitation. Notwithstanding the foregoing, nothing in
this Article 12 shall be construed as limiting in any way the right of a Party
to seek injunctive or other equitable relief from a court of competent
jurisdiction with respect to any actual or threatened breach of this Agreement
or to prevent infringement of its intellectual property rights.

ARTICLE 13 - COPROMOTION TERM AND TERMINATION.

         Section 13.1 Copromotion Term; Term of Agreement.

                  13.1.1 Copromotion Term. The Copromotion Term shall begin on
the Effective Date and shall continue until the earlier of: (i) the date that
all Valid Claims of any patents Controlled by BMS or any of its Affiliates
covering the composition or use of the Product in the Territory have terminated
or expired, (ii) the date that the LEO License Agreement terminates; (iii) the
date that the LEO Supply Agreement terminates and BMS has not been able to find
another source of supply within three (3) months thereafter; or (iv) December
31, 2007 (the "Copromotion Term"); provided, that the Copromotion Term is
subject to earlier termination in accordance with Section 2.3.2, 13.2, 13.3, or
13.5 below or by the Parties' mutual agreement.

                  13.1.2 Term of Agreement. Subject to Section 13.6 and 13.7,
this Agreement shall terminate upon the expiration or earlier termination of the
Copromotion Term.

         Section 13.2 Termination by Galen. Galen may terminate the Copromotion
Term upon the occurrence of any of the following:

                  13.2.1 immediately upon written notice to BMS, if BMS has
ceased marketing and/or LEO has permanently ceased manufacturing and marketing
the Product because of a significant safety problem related to the Product; or

                  13.2.2 immediately upon written notice of termination given to
BMS, if BMS has breached a material obligation, covenant, or duty under this
Agreement, unless, where such breach is curable, either BMS has cured such
default within sixty (60) days after Galen has advised BMS in writing of the
nature of the breach or default, or, if such breach is not curable within said
60-day period, BMS has taken substantial steps to remedy such breach and
continues to take diligent steps to cure same as promptly as reasonably
practicable thereafter; or

                  13.2.3 immediately upon written notice of termination given to
BMS, if any of BMS' representations and warranties set forth in Article 16 are
untrue in any material respect provided, that such notice of termination is
given not later than 180 days after Galen has learned of the circumstance(s)
giving rise to this right of termination; or

                  13.2.4 pursuant to Sections 11.6 or 13.5; or

                                       51

<PAGE>

                  13.2.5 upon sixty (60) days written notice to BMS in the event
that the FDA imposes a "black box" warning requirement on the labeling for the
Product in the Territory;

         Section 13.3 Termination by BMS. BMS may terminate the Copromotion Term
upon the occurrence of any of the following:

                  13.3.1 immediately upon written notice to Galen, if BMS has
ceased marketing and/or LEO has ceased manufacturing and marketing the Product
because of a significant safety problem related to the Product; or

                  13.3.2 immediately upon written notice of termination given to
Galen, if Galen has breached a material obligation, covenant, or duty under this
Agreement, unless, where such breach is curable, either Galen has cured such
default within sixty (60) days after BMS has advised Galen in writing of the
nature of the breach or default, or, if such breach is not curable within said
60-day period, Galen has taken substantial steps to remedy such breach and
continues to take diligent steps to cure same as promptly as reasonably
practicable thereafter; or

                  13.3.3 immediately upon written notice of termination given to
Galen, if any of Galen's representations and warranties set forth in Article 16
are untrue in any material respect, provided, that such notice of termination is
given not later than 180 days after BMS has learned of the circumstance(s)
giving rise to this right of termination; or

                  13.3.4 pursuant to Section 3.5.1.3; or

                  13.3.5 pursuant to Sections 2.4; or

                  13.3.6 pursuant to Section 2.5.1; or

                  13.3.7 pursuant to Sections 13.5 hereof; or

                  13.3.8 immediately upon written notice, if (i) Galen has acted
illegally in the manner in which it is Promoting a Product in the Territory or
has otherwise not complied in any material respect with applicable Law relating
to the Promotion of a Product, or (ii) Galen has materially breached or
persistently breached this Agreement in its Promotion of a Product, such that,
in any event or events falling within (i) or (ii), Galen materially jeopardizes
or harms BMS' NDA for, or materially harms the commercial value or the
commercial reputation of, the Product. The phrase "jeopardizes or harms" an NDA
includes, but is not limited to, the following serious types of issues:

                           13.3.8.1 a government seizure of Product;

                           13.3.8.2 a government injunction upon the sale of
         Product;

                           13.3.8.3 a government indictment of Galen or its
         employees based upon

                                       52

<PAGE>

         Promotion or other conduct of Galen or its employees involving Product;
         or

                           13.3.8.4 a consent decree or assurance of voluntary
         discontinuance or similar civil and/or criminal settlement agreement
         entered into between Galen and the federal or state government which
         involves the Product and relates to conduct of Galen or its employees
         which is not in compliance with or alleged by such government not to be
         in compliance with federal and/or state Laws impacting drug labeling,
         advertising and promotion including, without limitation the PDMA, the
         Antifraud and Abuse Amendments, the Omnibus Budget Reconciliation Act,
         and the Veteran's Administration Bill, and other similar Laws enacted
         in the future in the U.S.; or

                  13.3.9 pursuant to Section 3.7.3.

         Section 13.4 [Intentionally omitted].

         Section 13.5 Insolvency. Either Party may terminate this Agreement if,
at any time, the other Party shall file in any court or agency pursuant to any
statute or regulation of any state or country, a petition in bankruptcy or
insolvency or for reorganization or for an arrangement or for the appointment of
a receiver or trustee of the Party or of its assets, or if the other Party
proposes a written agreement of composition or extension of its debts, or if the
other Party shall be served with an involuntary petition against it, filed in
any insolvency proceeding, and such petition shall not be dismissed within sixty
(60) days after the filing thereof, or if the other Party shall propose or be a
party to any dissolution or liquidation, or if the other Party shall make an
assignment for the benefit of creditors. In the event that this Agreement is
terminated or rejected by a Party or its receiver or trustee under applicable
bankruptcy Laws due to such Party's bankruptcy, then all rights and licenses
granted under or pursuant to this Agreement by such Party to the other Party
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
Bankruptcy Code and any similar Law in any other country, licenses of rights to
"intellectual property" as defined under Section 101(52) of the Bankruptcy Code.
The Parties agree that all intellectual property rights licensed hereunder,
including, without limitation, any patents or patent applications in any country
of a Party covered by the license grants under this Agreement, are part of the
"intellectual property" as defined under Section 101(52) of the Bankruptcy Code
subject to the protections afforded the non-terminating Party under Section
365(n) of the Bankruptcy Code, and any similar Law in any other country.

         Section 13.6 Survival of Obligations.

                  13.6.1 The termination of this Agreement shall not release or
operate to discharge either Party from any liability or obligation that may have
accrued prior to such termination or constitute a waiver or relinquishment of
any cause of action or claim that a Party may have based on events, acts or
omissions occurring prior to such termination date. Any termination of the
Copromotion Term by a Party shall not be an exclusive remedy, but shall be in
addition to any legal or equitable remedies that may be available to a Party and
shall not affect a Party's rights to indemnification that are expressly set
forth in this Agreement. The mere termination of this

                                       53

<PAGE>

Agreement or the Copromotion Term in accordance with the terms hereof shall not,
in and of itself, give rise to any damages or liability on the part of the
terminating Party.

                  13.6.2 Upon termination of the Copromotion Term prior to the
completion of an Agreement Quarter, Galen shall be entitled to receive a pro
rata portion of the Performance Compensation which it would have been entitled
to receive under Article 11 had the Copromotion Term been in effect until the
end of said Quarter (based on the number of days that Galen was responsible for
promoting the Product in the Territory during such Agreement Quarter).

                  13.6.3 The following provisions shall survive any termination
of this Agreement: Sections 2.4, 3.2.5, 3.4.2, 3.4.4, 3.4.5 (unless Galen
purchases BMS' NDA for the Product), 3.5.3.3, 3.6.4, 3.6.6-3.6.9, 3.7.2.4,
3.7.4, 3.10.1.4, 3.10.1.5, 4.2, 4.3.2, 4.3.5 (unless Galen purchases BMS' NDA
for the Product), 8.1, 10.1, 13.6, 13.7 and Articles 5, 9, 11, 12, 14, 15, 17
and 18, as well as any other provisions, which, by their intent or meaning, are
intended to so survive, except that, if termination is triggered by reason of
the purchase by Galen of BMS' NDA for the Product, (i) BMS shall have no further
obligation with respect to claims alleged or arising after such termination date
with respect to Sections 14.5 and 14.6 and (ii) Sections 14.1 and 14.2 shall
only survive in respect of events, acts or omissions occurring prior to such
termination date.

         Section 13.7 Effect of Termination.

                  13.7.1 Upon the termination or expiration of the Copromotion
Term, unless otherwise agreed in writing by BMS and Galen, Galen shall promptly
(i) cease all of its promotion activities pursuant to this Agreement, (ii)
discontinue any use of the Trademark, (iii) return to BMS at BMS' expense all
sales training, A&P Material, literature, BMS call lists, BMS Confidential
Information (in accordance with Article 15 hereof), (iv) return to BMS at BMS'
expense any remaining Product samples then in Galen's possession, to a site
designated by BMS; and (v) enable BMS to Promote the Product to all physicians
in the Territory thereafter.

                  13.7.2 Subject to Section 13.7.4, Galen hereby grants to BMS,
effective upon the termination or expiration of the Copromotion Term, a
non-exclusive, perpetual, irrevocable, sublicensable, fully paid-up right and
license under Galen Know-How and Galen Inventions to use same for any purpose
anywhere in the world in connection with the research, manufacture, use, sale,
import, and offer for sale of the Compound, the Product, and any Combination
Product.

                  13.7.3 During any period after receipt of notice of
termination but preceding the effective date of termination, each Party shall
continue to diligently fulfill all obligations of this Agreement as apply to it
during such period in accordance with the provisions of this Agreement.

                  13.7.4 All licenses granted by Galen hereunder shall terminate
upon the earlier of the termination of the LEO License Agreement and the sale of
the Product by BMS to Galen; provided, that Galen shall have granted to LEO a
non-exclusive, perpetual, irrevocable, sublicensable, and fully paid-up right
and license under Galen Know-How and Galen Inventions to use same for any
purpose anywhere in the world in connection with the research, manufacture,

                                       54

<PAGE>

use, sale, import, and offer for sale of the Compound, the Product, and any
Combination Product, but no other products.

ARTICLE 14 - INDEMNIFICATION AND INSURANCE; INFRINGEMENT PROCEEDINGS.

         Section 14.1 Indemnification by BMS. Subject to Section 14.2, BMS shall
defend, indemnify and hold Galen, its Affiliates and their respective employees,
agents, officers and directors (collectively, the "Galen Indemnitees") harmless
from and against any and all losses, liabilities, obligations, claims, fees
(including, without limitation, reasonable attorneys fees and fees of other
professionals), expenses and lawsuits brought against or incurred by a Galen
Indemnitee that are claimed by any Third Party and that result from or arise in
connection with: (i) the breach of any covenant, obligation, representation or
warranty of BMS contained in this Agreement; (ii) any claim of patent,
copyright, trade secret or other intellectual property infringement arising out
of or in connection with any manufacture, use, sale, offer for sale,
importation, or use of the Product; (iii) any product liability claim arising
out of or in connection with the use of the Product by any Third Party; (iv)
injury to any person (including death) arising out of the use of the Product;
(v) negligence or willful misconduct by any employee, representative, contractor
(other than Galen or LEO) or agent of BMS and its Affiliates; and (vi) claims by
Third Parties arising out of any shortfall of the Product in the Territory.

         Section 14.2 Indemnification by Galen. Galen shall defend, indemnify
and hold BMS, its Affiliates and their respective employees, agents, officers
and directors (collectively, the "BMS Indemnitees") harmless from and against
any and all losses, liabilities, obligations, claims, fees (including, without
limitation, reasonable attorneys fees and fees of other professionals), expenses
and lawsuits brought against or incurred by an BMS Indemnitee by a Third Party
resulting from or arising in connection with: (i) the breach by Galen of any
covenant, obligation, representation or warranty of Galen contained in this
Agreement; (ii) negligence or willful misconduct by any employee,
representative, contractor (other than BMS) or agent of Galen and its
Affiliates; (iii) any failure of any A&P Materials (as defined in Section 3.2.2)
prepared or proposed by Galen to receive FDA Approval or to comply with the
Product labeling, applicable Law, or applicable FDA approvals received for same;
and/or (iv) any contamination, mislabeling, alteration, or adulteration of any
Product samples or A&P Materials to the extent caused by Galen while such
samples or materials are under the control of any Galen Indemnitee.

         Section 14.3 Indemnification Procedure. In order to receive the
benefits of the indemnity under Sections 3.10, 14.1, or 14.2, as applicable, a
Galen Indemnitee or BMS Indemnitee (either, an "Indemnitee") must:

         (i)      give the indemnifying Party (the "Indemnitor") written notice
                  of any claim or potential claim promptly after the Indemnitee
                  receives notice thereof; provided that failure of the
                  Indemnitee to provide such notice shall not constitute a
                  waiver of, or result in the loss of, such Party's right to
                  indemnification under this Agreement, except in the event that
                  the Indemnitor's rights, and/or its ability to

                                       55

<PAGE>

                  defend against or settle such claim or potential claim, are
                  materially prejudiced by such failure to notify;

         (ii)     allow the Indemnitor to assume the control of the defense and
                  settlement (including all decisions relating to litigation,
                  defense and appeal) of any such claim, provided, that: (a) the
                  Indemnitor has confirmed its indemnification obligation to the
                  Indemnitee under this Article 14, and (b) no such settlement
                  may materially adversely affect the rights or obligations of
                  the Indemnitee under this Agreement without the Indemnitee's
                  prior written consent; and

         (iii)    reasonably cooperate with the Indemnitor in its defense of the
                  claim (including, without limitation, making documents and
                  records available for review and copying and making persons
                  within the Indemnitee's control available for pertinent
                  interview and testimony), so long as such cooperation does not
                  vitiate any legal privilege to which such Indemnitee is
                  entitled.

If the Indemnitor defends the claim, the Indemnitee may at its expense and using
attorneys of its choice, participate in, but shall not have any control of, the
defense of such claim. An Indemnitor shall have no liability under this Article
14 as to any claim for which settlement or compromise of such claim, or an offer
of settlement or compromise of such claim, is made by an Indemnitee without the
prior written consent of the Indemnitor.

         Section 14.4 Insurance. Both BMS and Galen shall maintain an adequate
self-insurance and/or insurance program to protect against potential liabilities
and risk arising out of activities to be performed under this Agreement and upon
such terms (including coverages, deductible limits and self-insured retentions)
as are customary for the activities to be conducted by such Parties under this
Agreement and are appropriate to cover the Parties' respective indemnification
obligations hereunder. Each Party shall furnish to the other evidence of such
insurance and/or self insurance, upon request. Such insurance information shall
be kept in confidence in the same manner as any other confidential information
disclosed by one Party to the other hereunder.

         Section 14.5 Infringement Claimed by a Third Party. In the event of the
institution of any suit by a Third Party against Galen or its Affiliates for
patent, copyright or trademark infringement involving the manufacture, use,
sale, license or marketing of the Product in the Territory, Galen shall promptly
notify BMS in writing. BMS shall defend Galen in any such suit with counsel
reasonably satisfactory to Galen at BMS' own expense. BMS may settle any such
action in its sole and absolute discretion through the payment of damages,
royalties, milestones or other fees to such Third Party. Provided that BMS has
acknowledged its indemnification obligations to Galen under Section 14.3 in
writing, Galen shall render, at its expense all assistance reasonably requested
in connection with any action taken by BMS in such suit and permit BMS to use
its name in connection therewith, and the control of such action, including
whether to initiate any legal proceeding and/or the settlement thereof, shall
solely be under the control of BMS; provided, that BMS or its Affiliates shall
not, without Galen's prior written consent (not to be unreasonably withheld),
settle any such claim or proceeding in a manner that (a) materially adversely
affects Galen's rights, benefits or

                                       56

<PAGE>

obligations under this Agreement, or (b) admits liability on the part of Galen,
or (c) results in any damages payable by Galen that are not covered by BMS'
indemnification herein. BMS shall reimburse Galen for reasonable out-of-pocket
expenses (including attorney's fees and costs of litigation) incurred by Galen
in any such proceeding or at the specific written request of BMS. BMS shall
indemnify and hold Galen and its Affiliates harmless from and against any
claims, damages, liabilities, costs and expenses that may be incurred by or
levied upon Galen or any of its Affiliates as a result of providing such
cooperation or of using their respective name(s) in any such action or related
proceeding.

         Section 14.6 Infringement by Third Parties. In the event that in-house
legal counsel for BMS or any of its Affiliates or Galen or any of its Affiliates
becomes aware of actual or threatened infringement of a LEO Patent anywhere in
the Territory, that Party shall promptly notify the other Party in writing of
same. BMS shall have the exclusive right but not the obligation to bring, at its
own expense, an infringement action against any such Third Party, and to use the
name of Galen in connection therewith and to name Galen, as necessary, as a
party thereto; provided, that, BMS shall indemnify and hold Galen and its
Affiliates harmless from and against any claims, damages, liabilities, costs and
expenses that may be incurred by or levied upon Galen or any of its Affiliates
as a result of rendering cooperation to BMS in such action or proceeding or of
using their respective name(s) in any such action or related proceeding. Galen
shall render, at its expense (subject to reimbursement by BMS of Galen's
out-of-pocket costs and expenses incurred in connection therewith), all
assistance reasonably requested in connection with any action taken by BMS to
prevent such infringement. The control of such action, including whether to
initiate any legal proceeding and/or the settlement thereof, shall solely be
under the control of BMS; provided, that BMS may not, without Galen's prior
written consent, settle any such claim or proceeding in a manner that (a)
materially adversely affects Galen's rights, compensation, benefits, or
obligations under this Agreement, or (b) admits liability on the part of Galen,
or (c) which results in any damages payable by Galen, without Galen's consent.
All damages and monetary rewards received from such Third Party shall, after
payment of any amounts due to LEO under the LEO License Agreement, be divided
fifty percent (50%) to BMS and fifty percent (50%) to Galen.

ARTICLE 15 - CONFIDENTIALITY.

         Section 15.1 Confidential Information. Each Party acknowledges that it
may receive Confidential Information (as defined below) of the other Party in
the performance of or in furtherance of this Agreement. Each Party shall use
commercially reasonable efforts to hold confidential and not to, directly or
indirectly, disclose or publish to any Third Party or use for the benefit of a
Third Party or itself or its Affiliates, except in carrying out its duties
hereunder, any Confidential Information of the other Party, without first having
obtained the furnishing Party's written consent to such disclosure or use.
"Confidential Information" means know-how, scientific information, pre-clinical
and clinical data, adverse event information, formulas, methods and processes,
specifications, pricing information (including discounts, rebates and other
price adjustments) and other terms and conditions of sales, customer
information, business plans, and all other intellectual property which is not
publicly available and is owned or controlled by a

                                       57

<PAGE>

Party. These restrictions shall not apply to any Confidential Information which:

                  15.1.1 is known to the receiving Party or its Affiliates prior
to the time of disclosure to it; or

                  15.1.2 is independently developed by employees, agents, or
independent contractors of the receiving Party or its Affiliates without aid or
use of the disclosing Party's Confidential Information (and such independent
development can be demonstrated by the receiving Party); or

                  15.1.3 is disclosed, without restriction as to
confidentiality, to the receiving Party or its Affiliates by a Third Party that
has a right to make such disclosure; or

                  15.1.4 becomes part of the public domain through no breach by
the receiving Party of its obligations under this Agreement (including without
limitation information that is contained in any written A&P Material prepared by
BMS that is distributed for use in connection with the Product).

         Each receiving Party shall disclose Confidential Information of the
disclosing Party only to those employees and contractors of such Party and of
its Affiliates who have reason to know same in furtherance of a Party's duties
under this Agreement and who are bound by a written obligation of
confidentiality to the receiving Party (or its Affiliate) that is no less
stringent than the confidentiality obligations set forth in this Article 15.

         Section 15.2 Required Disclosures. The receiving Party shall also be
entitled to disclose the other Party's Confidential Information that is required
to be disclosed (i) to or by Governmental or Regulatory Authorities; (ii) to
comply with applicable Laws (including, without limitation, to comply with SEC,
NASDAQ or stock exchange disclosure requirements), (iii) to comply with judicial
process or an order of any Governmental or Regulatory Authority of competent
jurisdiction, or (iv) to defend or prosecute litigation; provided, however, that
in each case the Party required to disclose such Confidential Information shall
use reasonable efforts to notify the other Party in advance of such disclosure
and shall provide the disclosing Party with reasonable assistance to obtain a
protective order and/or confidential treatment of such Confidential Information,
to the extent available, and thereafter only discloses the minimum Confidential
Information required to be disclosed in order to ensure legal compliance.

         Section 15.3 Duration. This obligations set forth in this Article 15
shall survive the termination or expiration of this Agreement for ten (10)
years. Upon expiration or termination of this Agreement, a receiving Party shall
return to the disclosing Party or destroy all Confidential Information provided
to it by the disclosing Party, including all copies, notes and extracts thereof
or other written records containing such Confidential Information, except for
one (1) copy that it may keep in its archives for the sole purpose of verifying
its continuing confidentiality obligations hereunder.

                                       58

<PAGE>

         Section 15.4 Novation. The confidentiality obligations described above
shall supersede the Confidential Disclosure Agreement dated as of January 4,
2001 between the Parties with respect to the disclosure by either Party to the
other of any Confidential Information hereafter that may fall within the terms
of this Agreement and the terms of such Confidential Disclosure Agreement.
Further, said prior Confidential Disclosure Agreement is hereby amended to
incorporate the terms of Section 15.3 hereof.

ARTICLE 16 - REPRESENTATIONS AND WARRANTIES.

         Section 16.1 Mutual Representations and Warranties. Galen and BMS each
represent and warrant to the other Party that, as of the Execution Date:

                  16.1.1 Representations of Authority. It (as well as such
Party's Affiliates with which such Party may agree, contract or otherwise
arrange with to assume or perform any of such Party's rights, obligations,
representations, or warranties hereunder) has full corporate right, power and
authority to enter into this Agreement and to perform its respective obligations
under this Agreement and, subject to Section 16.1.2 hereof, that it has the
right to grant to the other the licenses granted pursuant to this Agreement.

                  16.1.2 Consents. All necessary consents, approvals and
authorizations of all Governmental or Regulatory Authorities and other persons
required to be obtained by it as of the Execution Date in connection with the
execution, delivery and performance of this Agreement have been or, if
reasonably capable of being obtained prior to the Execution Date, shall be
obtained.

                  16.1.3 No Conflict. Notwithstanding anything to the contrary
in this Agreement, the execution and delivery of this Agreement, the performance
of such Party's obligations in the conduct of this Agreement and the licenses
and sublicenses to be granted pursuant to this Agreement (a) do not and will not
conflict with or violate any requirement of applicable Laws existing as of the
Execution Date, and (b) do not and will not conflict with, violate, breach or
constitute a default or require any consent under, any contractual obligations
of such Party or any of its Affiliates existing as of the Execution Date, except
for such consents as shall have been obtained prior to the Execution Date.

                  16.1.4 Enforceability. This Agreement has been duly executed
by it, has been authorized by all necessary corporate action, and is a legal and
valid obligation binding upon it and is enforceable in accordance with its
terms.

ARTICLE 17 - NOTICES.

         Section 17.1 Notices. Unless otherwise explicitly set forth herein, any
notice required or permitted to be given hereunder shall be in writing and shall
be delivered personally by hand, or sent by reputable overnight courier,
signature required, to the addresses of each Party set forth below or to such
other address or addresses as shall be designated in writing in the same matter:

                                       59

<PAGE>

                  (a)      If to BMS:

                           Bristol-Myers Squibb U.S. Pharmaceutical Group
                           777 Scudders Mill Road
                           Plainsboro, NJ 08536
                           Attention: President - U.S. Pharmaceutical Group

with a copy to the attention of the "Vice President and Senior Counsel - USPG"
at the same address and a copy to the attention of the Vice President - Alliance
Management at Bristol-Myers Squibb Company, Route 206 at Province Line Road,
Princeton, New Jersey 08543-4000.

                  (b)      If to Galen:

                           Galen (Chemicals) Limited.
                           4 Adelaide Road
                           Dun Laoghaire, Co. Dublin
                           Attention: Senior Vice President - Finance

with a copy to the attention of the "Senior Vice President, Corporate
Development and General Counsel" at 100 Enterprise Drive, Rockaway, New Jersey
07866.

All notices shall be deemed given when received by the addressee.

                                       60

<PAGE>

ARTICLE 18 - MISCELLANEOUS PROVISIONS.

         Section 18.1 Assignment.

                           18.1.1 Neither Party shall assign or otherwise
transfer this Agreement or any interest herein or right hereunder without the
prior written consent of the other Party, and any such purported assignment,
transfer or attempt to assign or transfer any interest herein or right hereunder
shall be void and of no effect; except that each Party (i) may assign its rights
and obligations hereunder to an Affiliate without the prior consent of the other
Party (although, in such event, the assigning Party shall remain jointly and
severally responsible and liable with such Affiliate for the performance of all
of representations, warranties, obligations and agreements of the assigning
Party set forth herein) and (ii) may assign its rights and obligations to a
successor (whether by merger, consolidation, reorganization or other similar
event) or purchaser of all or substantially all of its business assets relating
to its pharmaceutical business; provided, that such successor or purchaser has
agreed in writing to assume all of such Party's rights and obligations hereunder
and a copy of such assumption is provided to the other Party hereunder.

                           18.1.2 BMS reserves the right to assign to an
Affiliate or to LEO all rights to the Product (including the IND and NDA), as
and upon such terms as BMS may elect and determine in its sole and absolute
discretion; provided, that such Affiliate or LEO shall have first agreed in
writing with Galen and with BMS that it shall be jointly and severally
responsible and liable with BMS with respect to the performance of BMS'
representations, warranties, covenants, and obligations under this Agreement.

         Section 18.2 Non-Waiver. Any failure on the part of a Party to enforce
at any time or for any period of time any of the provisions of this Agreement
shall not be deemed or construed to be a waiver of such provisions or of any
right of such Party thereafter to enforce each and every such provision on any
succeeding occasion or breach thereof.

         Section 18.3 Entirety of Agreement. This Agreement contains the entire
understanding of the Parties with respect to the subject matter hereof and
thereof and supersedes all previous and contemporaneous verbal and written
understandings, agreements, representations and warranties with respect to such
subject matter or on which the Parties may have relied. This Agreement (and any
provision or term hereof) may be released, waived, changed or supplemented only
by a written agreement signed by an officer or other authorized representative
of the Party against whom enforcement of any release, waiver, change or
supplement is sought. This Agreement shall not be strictly construed against
either Party hereto. Paragraph headings are for convenience only and shall not
be considered in interpreting this Agreement. Any provisions of this Agreement
that conflict with any subsequently executed agreement between BMS and Galen or
with the Option Agreement among LEO, BMS and Galen entered into concurrently
herewith shall be governed by and be subject to the terms of those agreements.

                                       61

<PAGE>

         Section 18.4 Public Announcements. The form and content of any public
announcement to be made by one Party regarding this Agreement, or the subject
matter contained herein, shall be subject to the prior written consent of the
other Party (which consent may not be unreasonably withheld), except as may be
required by applicable Law (including, without limitation, disclosure
requirements of the SEC, NASDAQ, or any other stock exchange) in which event the
other Party shall endeavor to give the other Party reasonable advance notice and
review of any such disclosure.

         Section 18.5 Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK
APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE,
WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES OF SUCH STATE OTHER THAN
SECTIONS 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW.

         Section 18.6 Relationship of the Parties. In making and performing this
Agreement, the Parties are acting, and intend to be treated, as independent
entities and nothing contained in this Agreement shall be construed or implied
to create an agency, partnership, joint venture, or employer and employee
relationship between BMS and Galen. Except as otherwise expressly provided
herein, neither Party may act on behalf of the other Party, and neither Party
may make (or has any authority to make) any representation, warranty or
commitment, whether express or implied, on behalf of the other Party or incur
any charges or expenses for or in the name of the other Party. No Party shall be
liable for the act of any other Party unless such act is expressly authorized in
writing by both Parties hereto. The relationship of the Parties under this
AGREEMENT is, and is intended to be, one of independent contractors hereunder.

                  Neither Party shall have any responsibility for the hiring,
firing, compensation or benefits of the other Party's employees, and all
compensation and benefits to be paid to any employee or representative of a
Party (including without limitation all Sales Force Personnel engaged by a
Party) shall be the responsibility of the Party engaging such individual.
Neither Party may create or impose any contractual or other liability on behalf
of the other Party without said Party's authorized prior written approval.

         Section 18.7 Counterparts. This Agreement shall become binding when any
one or more counterparts hereof, individually or taken together, shall bear the
signatures of each of the Parties hereto. This Agreement may be executed in any
number of counterparts, each of which shall be deemed an original as against the
Party whose signature appears thereon, but all of which taken together shall
constitute but one and the same instrument.

                          ****************************

                    [end of text - signature page to follow]

                                       62

<PAGE>

         IN WITNESS WHEREOF, the Parties hereto have duly executed this
Agreement as of the day and year first above written.

BRISTOL-MYERS SQUIBB                     GALEN (CHEMICALS) LIMITED
COMPANY

By: _____________________________        By: ___________________________________
Name:  Tamar D. Howson                   Name:  Roger M. Boissonneault
Title: Senior Vice President,            Title: Director
       Corporate Development

                                       63

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]